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Abstract 
The extracellular-related kinase 5 (ERK5) is a promising target for cancer therapy. A high-throughput screen was 
developed for ERK5, based on the IMAP FP Progressive Binding System, and used to identify hits from a library of 
57,617 compounds.  Four distinct chemical series were evident within the screening hits. Resynthesis and re-assay of 
the hits demonstrated that one series did not return active compounds, whereas three series returned active hits. 
Structure-activity studies demonstrated that the 4-benzoylpyrrole-2-carboxamide pharmacophore had excellent 
potential for further development. The minimum kinase binding pharmacophore was identified, and key examples 
demonstrated good selectivity for ERK5 over p38α kinase.  
INTRODUCTION 
The extracellular-related kinase 5 (ERK5), also known as Big Map Kinase (BMK1), is a 816 amino acid protein kinase 
that forms part of a non-canonical MAP kinase pathway in cells.1 Extracellular stimulation, in the form of growth 
factors, such as epidermal growth factor (EGF), nerve growth factor (NGF), vascular endothelium growth factor 
(VEGF), and fibroblast growth factor-2 (FGF-2), initiates a signalling cascade from the cell surface to nuclear 
transcription factors via ERK5.2 Unlike the linear canonical Ras/Raf/MEK/ERK pathway, the ERK5 signalling cascade 
occurs independently of Raf.3 ERK5 is activated specifically by MEK5, which is in turn activated by MEKK2/3.1a, 4 
ERK5 is structurally different from the other members of the ERK sub-families. A unique loop-12 structure and 
extended C-terminal domain (~400 amino acids) gives ERK5 its characteristic structure.2, 4 The C-terminal extension 
harbours nuclear localisation and export sequences, two proline-rich domains, a transcriptional activating domain, 
and MEF2 interacting region. The large C-terminal unique to ERK5 is auto-phosphorylated at multiple sites, resulting 
in an increase in transcriptional activity.5  
Phosphorylation of ERK5 results in activation of a number of transcription factors including MEF2, c-Myc, c-Jun, c-
Fos, Fra-1, and NFκB.6 ERK5 also phosphorylates and activates p90 RSK, also involved in signal transduction.7 An 
increasing body of mechanistic data indicates that ERK5 plays a key role in tumor biology, i.e. cell proliferation and 
survival, invasion and metastasis, and angiogenesis.8 
Expression of ERK5 is significantly up-regulated in advanced prostate cancer and has been identified as an 
independent prognostic biomarker for aggressive disease.9 ERK5 is over-expressed in 20% of breast cancer patients 
and its expression is an independent prognostic biomarker for reduced disease-free survival.10 In hepatocellular 
carcinoma (HCC), ERK5 overexpression has been reported, associated with gene amplification at the 17p11 
chromosome fragment, harboring the MAPK7 gene.11 High levels of ERK5 were found to correlate with more 
aggressive and metastatic stages in fresh samples from human clear cell renal cell carcinoma.12 
To date, three small-molecule inhibitors of the MEK5/ERK5 pathway have been described. The indolinone based 
inhibitors, BIX02188 (1a) and BIX02189 (1b), are dual inhibitors of the MEK5/ERK5 cascade. Both compounds inhibit 
MEK5 with nanomolar potency, whereas modest activity was reported for ERK5.13 Benzo[e]pyrimido-[5,4-
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b]diazepine-6(11H)-one (XMD8-92, 2) is a potent ERK5 inhibitor which exhibits anti-proliferative and anti-angiogenic 
effects on HeLa cells in mouse xenograft models.14 An X-ray crystal structure of 2 bound to ERK5 shows the inhibitor 
bound to the Met140 in the kinase hinge via a pair of hydrogen bonds from the aniline and pyrimidine nitrogens, and 
an additional water-bridged hydrogen bond from the diazepinone carbonyl to Asp200 and Glu102 in the DFG loop.15 
However, some of the in vivo activity of 2 has been attributed to off-target activities e.g. inhibition of doublecortin-
like kinase 1 (DCLK-1) in pancreatic cancer.16 Inhibition of ERK5 or siRNA knockdown has been shown to inhibit the 
growth of HCC cell lines, in vitro and in vivo.17 ERK5 signalling has been shown to be essential for chemically induced 
carcinogenesis in skin by erk5 gene deletion or ERK5 inhibition (with 2).18 The combination of doxorubicin and either 
erk5 gene deletion or ERK5 inhibition (with 2) was found to be additive in inflammation-driven tumour models.  
Thus, pharmacological inhibition of ERK5 may provide an opportunity for the treatment of inflammation-driven, 
invasive or metastatic cancers where ERK5 is deregulated. Given the strong link between ERK5 mediated signalling 
and malignancy, there remains a strong need to develop selective tool molecules to fully elucidate the effect of ERK5 
inhibition in vivo. For this reason, we sought to discover novel ERK5 inhibitory chemotypes through high-throughput 
screening as chemical tools and for development as therapeutic agents. 
In this paper, we describe the development of a high-throughput screening assay for ERK5 inhibition based on the 
IMAP FP format that was used to identify four discrete series of hit molecules. Validation of each series was 
attempted by resynthesis and retesting of selected members from each series. Preliminary structure activity studies 
were obtained resulting in the identification of one series for further optimisation. 
DEVELOPMENT AND EXECUTION OF ERK5 IMAP SCREEN 
Assay development 
The discovery of kinase inhibitors using high-thoughput screening is well established.19 In our case, expression of 
active ERK5 protein required co-expression of MEK5. The screen was developed using the IMAP format (Molecular 
Devices) that relies on the high specificity interaction of phospho groups on a fluorescently tagged peptide with M3+ 
containing nanoparticles. The IMAP format was chosen as a robust and efficient method of determining kinase 
activity using a ‘mix-and-measure’ format with a non-radioactive, fluorescence output.  
Preliminary experiments to determine a suitable peptide substrate for the IMAP FP assay used a commercial source 
of the enzyme and were based on sequence of the natural substrate of ERK5, and were augmented with a substrate 
finder kit. Five peptide sequences were designed based around the reported site of phosphorylation of MEF2C by 
ERK5, with the expected serine phosphorylation site highlighted in red (Table 1).1 The peptides were tested using the 
IMAP FP Progressive Binding System (Molecular Devices) in the absence and presence of ERK5 (Carna Biosciences). 
The IMAP FP substrate finder kit for serine/threonine kinases plate 2 (Molecular Devices) covering CMGC, CK1, STE, 
and TKL portions of the kinome was used to identify potential peptide substrates phosphorylated by ERK5. The FAM-
EGFR-derived peptide (LVEPLTPSGEAPNQK-5FAM-COOH) proved optimal. 
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Kinetic studies determined the ERK5 KMapp to be 300 µM. Ideally, kinase screens are run with the ATP concentration 
equal to the KM, however, in this case the IMAP format did not return acceptable results at a high ATP concentration 
(300 µM), presumably due to interference of ATP with the interaction of the phospho peptide with the metal 
nanoparticles.  For this reason, the HTS assay was run at the maximum acceptable ATP concentration (100 µM) to 
allow ‘mix-and-measure’ determinations.  
High-throughput Screening for ERK5 inhibitors 
To identify inhibitors of ERK5 the IMAP HTS assay  was set up and a library of 57,617 small molecules was screened 
(final DMSO concentration of 4% and a total reaction volume of 40 µL). The library was composed of a 48,479 
member diverse library and a 9136 member kinase focussed library, both libraries were sourced from commercial 
vendors. Z’ factors for each plate were calculated using Equation 2, and were typically 0.6-0.8. Plates with Z’ factors 
below 0.4 were re-screened (Supporting Information).  
HTS Results 
The HTS assay returned 245 active compounds (0.5 % hit rate), i.e. >50% inh at 30 M, from the 57,617 member 
library. Active compounds (245) showing >50% inhibition in the screen were resupplied from stock or commercial 
vendors and retested at 30, 10 and 3.3 M. 71 active compounds, giving >30% mean inhibition, were treated as 
confirmed hits (0.10% overall hit-rate) and assayed over a full IC50 range. IC50 determinations required a two stage 
process whereby the reaction occurred initially in the absence of the IMAP reagent, followed by subsequent addition 
of the IMAP reagent, to allow the KM concentration of ATP to be used. 
The hit compounds produced inhibition curves with IC50 values ranging from 0.6 to 76 µM (1 compound >120 µM). 
Confirmed hits were clustered according to common structures, revealing four promising chemical series. SAR 
around the hits was expanded by assaying related in-house compounds and close analogues from commercial 
suppliers.  From these results, four compound series were selected for validation by resynthesis prior to progressing 
to hit-to-lead studies: 2-amino-N,N-alkylbenzo[d]thiazole-6-sulfonamides (Table 2, 3a-c); 4-substituted-2-
(substitutedthio)-6-phenylnicotinonitriles (Table 3, 4a,b); 4-amino-2-(arylamino)pyrimidine-5-carbonitriles (Table 5, 
5a-c); and 4-aroyl-N-alkyl-1H-pyrrole-2-carboxamides (Table 6, 6a-e). 
SYNTHESIS 
Benzothiazole Series 3 
Numerous methods have been described for the synthesis of benzothiazoles.20 For the synthesis of compounds 3a,b 
and analogues, we used the reported reaction of anilines with potassium thiocyanate-copper(II) sulfate (Scheme 1).21 
The required 4-aminophenylsulfonamides (7a-c) were prepared by reduction of the corresponding nitro compounds 
(8a-c). The nitro precursors were obtained by coupling the relevant amine with 4-nitrobenzenesulfonyl chloride. The 
5-sulfonamide isomer 9a, was prepared via the same method (Scheme 2). Thus, 3-nitrobenzenesulfonyl chloride was 
reacted with pyrrolidine or N-methylethylamine, and the resulting sulfonamides 10a,b were reduced to the 
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respective anilines 11a,b (Scheme 2). Reactions of 11a,b with with potassium thiocyanate-copper(II) sulfate gave in 
each case, besides the desired 5-substituted benzothiazole 9a,b, a significant quantity of a thiocyanatobenzene 
(12a,b).     
Nicotinonitrile Series 4 
The first synthetic approach considered for the synthesis of 3-cyanopyridines was based on the route reported by 
Shestopalov et al.22 For example, 4-fluorochalcone 13a, prepared via Claisen-Schmidt condensation of acetophenone 
with 4-fluorobenzaldehyde, was treated with elemental sulfur and morpholine in ethanol at reflux, followed by 
malononitrile, to give pyridinethione 14a in moderate yield (Method A, Scheme 3). Isolation of the intermediate 
pyridinethiones 14 required extensive purification, attributed to the propensity of this intermediate to tautomerise, 
and its readiness to oxidise under atmospheric conditions.  
Consideration of the likely mechanism of the one-pot sequence of the cyclisation reaction prompted the 
replacement of the sulfur and malononitrile with 2-cyanothioacetamide for the Michael addition in an alternative 
route (Method B, Scheme 3). Reactions were performed under nitrogen to avoid oxidative side-reactions. The crude 
intermediate 14 was used directly in the alkylation step, to avoid a lengthy purification, giving cyanopyridines 15a-k.  
Method B allowed isolation of 15a in an improved 54% yield over 2 steps. Deprotection with TFA gave acids 4a-k in 
near quantitative yield (99%). The carboxamide 17 was prepared from 4a by a HBTU-mediated coupling with p-
methoxybenzylamine giving amide 16, which was deprotected with TFA.  
Further variations to the thioether group were introduced via alkylation of 14a (Schemes 4-7). The acetamide 
derivatives 31 and 32 were prepared by the alkylation of 14a and 14g, respectively, with bromoacetamide 30 which 
was obtained by reaction of aminoacetone hydrochloride 29 with bromoacetylchloride (Scheme 8).23  
Cyanopyrimidine Series 5 
A small series of 4-amino-2-anilinopyrimidine-5-carbonitriles (5a-c) were prepared by the reaction of the appropriate 
aniline with chloropyrimidine (33) at 100 oC in DMF (Scheme 9).24 
4-Benzoylpyrrole-2-carboxamide Series 6 
A selection of 4-benzoylpyrrole-2-carboxamides were prepared by Friedel-Crafts acylation of methyl 1H-pyrrole-2-
carboxylate (34) with a substituted benzoyl chloride giving pyrrole (35). Hydrolysis of the methyl ester with lithium 
hydroxide gave carboxylic acid 36 that was coupled with the appropriate amine using CDI to give the desired 
carboxamides (6a-r)(Scheme 10). The N-methyl derivative 6m was prepared by methylation of ester 35a, followed by 
hydrolysis and coupling with 3-pyridylmethylamine (Scheme 11).  
2-Substituted-4-benzoylpyrrole derivatives  
The alkene derivative 40 was prepared by aldol condensation of ketone 39 and isonicotinaldehyde (Scheme 12). 
Selective reduction was achieved by refluxing alkene 40 in aqueous ethanol with indium metal and ammonium 
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chloride giving alkane 41 in moderate yield. 25  The cyclopropyl analogue 42 was prepared by a Corey Chaykovsky 
reaction.26 Thus, alkene 40 was reacted with trimethylsulfoxonium iodide and potassium tert-butoxide giving 42 in 
12% yield.27 Diketone 44 was prepared via a Claisen condensation between 1-(1H-pyrrol-2-yl)ethanone and methyl 
isonicotinate diketone 43 (Scheme 13). Friedel-Crafts acylation with 2,3-dichlorobenzoyl chloride gave 44. 
DISCUSSION 
Selected examples of the HTS hits in the benzothiazole series (3a, 3b, 3i) were synthesised and re-assayed. The ERK5 
inhibitory activity for the resynthesized benzothiazoles were 1000-fold lower than for the library material (Table 2). 
Comparision of the 1H-NMR and LCMS spectra of the resynthesized and screened samples of 3a suggested that the 
library material was the 5-sulfonamide 9a, so authentic samples of isomers 9a and 9b were prepared. In order to 
eliminate the possibility of mis-identification of the compounds by spectroscopic methods, the identity of 
isothiocyanate 12a and benzothiazoles 3a and 3i were elucidated by small-molecule X-ray crystallography (Figures 1-
3). 
The assay results for these isomers also failed to replicate the initial IC50 values from the screening samples. 
Interestingly, the isothiocyanate side-product 12a showed 10-fold greater potency than the benzothiazole, although 
this result was not replicated for the analogue 12b. Time-dependent enzyme inactivation by isothiocyanates, via 
their reaction with lysine residues, has been reported.28 Further investigations into the mechanism of action of 12a 
were not conducted.  Some aminothiazoles have recently been identified as frequent hitters from a fragment 
screening set and dubbed promiscuous 2-aminothiazoles (PrATs).29 The reason for the discrepancy between the 
activity of the HTS sample and the resynthesized material is not clear. Numerous mechanisms for false positives in 
HTS are possible, including the presence of trace impurities or protein aggregation, and further effort was not 
expended eliminating these possibilities.30  
Three HTS hits in the nicotinonitrile series (4a, 19, and 31) were synthesised and reassayed (Tables 3 and 4). The 
results for the glycine derivative 4a and proline methyl ester derivative 19 were in good agreement with the HTS IC50 
values. In contrast, the propan-2-one derivative 31 was 50-fold less active than the HTS result. On this basis, a 
limited series of compounds was prepared to establish preliminary SARs and to determine the minimum inhibitory 
pharmacophore. The SARs for the 4- and 6-substitutents were delineated keeping the 2-thio substituent as the 
glycine amide (Table 3). The 4,6-diphenyl, 4-phenyl-6-methyl and 4,6-dimethyl compounds (4d, 4j and 4k, 
respectively) were each devoid of activity. The 4-(2-fluorophenyl) derivative 4c was  7-fold less active than the 4-(4-
fluorophenyl) derivative 4a, whereas the 4-(3-fluorophenyl) derivative 4b lacked measurable potency. The 
combination of 2-fluoro and 4-fluoro substituents (4f) was not additive and resulted in a 15-fold loss of potency 
compared with 4a. The 4-(4-pyridyl) derivative 4g exhibited a 13-fold loss in potency compared to 4a, despite the 
similar electronic properties of the rings.  Substitution of the 4-phenyl group with 4-trifluoromethyl 4e, or 4-methoxy 
4h resulted in loss of activity. 
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The SARs for the thioether side-chain were investigated (Table 4). The pyridine thiol 14a lacking the amide side-chain 
showed a 20-fold loss in potency compared to 4a. The glycine ethyl ester 15l showed similar activity to the proline 
methyl ester derivative 19, and was 4-fold less potent than the corresponding glycine derivative 4a. In contrast, the 
glycine amide 17 lacked measurable activity. The shorter, unsubstituted amide 20 showed weak activity, whereas 
the corresponding ester 21 was inactive. Two thioalkyl carboxylic acids 23a and 23b were inactive, as was the 
corresponding amine 28, demonstrating the requirement for the amide group in the sidechain for potency. 
Comparison of the 4-fluorophenyl propan-2-one derivative 31 with the 4-pyridyl derivative 32 showed a 5-fold loss in 
potency consistent with the results in the glycine amide series (4a and 4g). 
Overall, each of the changes made to the hit compounds in the nicotinonitrile series (4a, 19, and 31) resulted in loss 
of potency. Modifications to the aromatic and side-chain substituents revealed a highly constrained pharmacophore 
and limited SAR. As a result, no further optimisation of this series was attempted. Interestingly, 3-cyano-4,6-
diphenyl-pyridines have been identified recently as inhibitors of the PA-PB1 protein-protein interaction for 
influenza.31 
The cyanopyrimidines 5a-c showed reasonable activity against ERK5, with IC50 values in the 12-88 M range (Table 
5), and generally consistent with the HTS values. The activity against ERK5 in this series was promising, but the series 
had also been selected for development against another target internally. For this reason, no further analogues were 
prepared. Kinase inhibitors incorporating a 5-cyanopyrimidine core have been reported, e.g. Wee1 inhibitors32, and 
CDK2 inhibitors33. 
Five 4-benzoylpyrrole-2-carboxamides (6a-e) gave good potency in the HTS. Upon resynthesis and retesting, the 2,3-
dichlorobenzoyl-N-(4-fluorobenzyl) substitued analogue 6a maintained significant activity (IC50 = 3.7 μM) despite a 5-
fold loss in potency compared to the HTS result (Table 6). Similarly, the 2-trifluoromethylbenzoyl-N-methyl 
substituted analogue 6d gave a two-fold drop in activity (IC50 = 9.6 μM) compared to the HTS result, and the benzoyl-
N-methyl-3-pyridyl derivative 6e gave a 3-fold drop in activity (IC50 = 26 μM). In contrast, the resynthesized 2,4-
dichlorobenzoyl analogues 6b and 6c bearing either the N,N-dimethylamide or N-phenethylamide substituents, 
respectively, showed no activity.  
Encouraged by these results, a small series of aroylpyrroles was prepared. Compounds were designed to establish 
the minimum kinase binding pharmacophore, and to explore possibilities to gain potency and selectivity by variation 
of the amide substituent.  The benzoyl substituent was fixed as most potent 2,3-dichlorophenyl for all these 
examples.  
Series (6f-n) was prepared to explore simple variations to the amide moiety (Table 7). Monomethyl amide 6f was 
equipotent with the parent 4-fluorobenzyl amide 6a, whereas the dimethyl amide 6g was 7-fold less potent. 
Introduction of the 3-pyridylmethyl amide from 6e or the 4-pyridylmethyl amide 6h, retained potency, whereas the 
benzyl derivative 6k and 2-pyridyl derivative 6j were less potent, and phenylethyl amide 6l was inactive. Similar to 
6g, N-methyl-(3-pyridylmethyl) amide derivative 6n was 7-fold less potent than primary amide 6i. Importantly, 
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methylation of the pyrrole NH (6m) completely abolished ERK5 activity, indicating an essential interaction with the 
kinase at this position. In contrast, the relatively small drop in activity for the secondary amides 6g and 6n suggested 
the amide NH was not forming a critical interaction, and that the drop in potency could be related to the 
conformational preference of the amide group. With this in mind, a limited number of conformationally restricted, 5- 
and 6-membered cyclic secondary amides were investigated (Table 8). The 3,4-dihydro-2,6-naphthyridinyl and 
isoindolinyl derivatives (6o and 6q) were inactive. In contrast, 3,4-dihydroisoquinolinyl 6p was 5-fold less potent than 
6h, a comparable to the loss in potency seen for the N-methyl analogues, whereas the pyrrolidinopyridinyl 6r was 
equipotent with 6h. Selected examples in this series were assayed in an orthogonal LANCE™ assay format (see 
supporting information), based on time-resolved fluorescence resonance energy transfer (FRET), to eliminate the 
possibility of false positives. In all cases, the LANCE results were comparable with those obtained using the IMAP 
assay. 
In order to establish the minimum kinase binding pharmacophore, systematic isosteric replacements to the amide 
group were made. The acetyl derivative 39 and the 1,3-diketone 44 were inactive (Table 9). In contrast, the 
unsaturated ketone 40 and the cyclopropyl ketone 42 retained similar activity to the parent 6a, whereas the 
saturated ketone 41 was 10-fold less active. These results confirm that the amide NH is not required for activity, and 
that conformational rigidity at this position is favourable. The loss of activity for diketone 44 was explained by the 
preferred enol tautomer lacking an essential H-bond to the kinase via the ketone adjacent to the pyrrole.     
The most potent pyrrole inhibitor 6h was submitted for a kinase selectivity screen and gave a promising selectivity 
profile. Of the 20 kinases, screened only one kinase (SAPK2a or p38 MAP kinase) was inhibited at >50% inhibition 
(10 µM).  Subsequent to our identification of pyrrole-2-carboxamides as ERK5 inhibitors, similar compounds, e.g. 45, 
have been independently identified as p38 MAP kinase inhibitors with micromolar activity.34 The X-ray structure of 
45 shows it bound to the hinge of the kinase via hydrogen bonds from the pyrrole NH and the carboxamide carbonyl, 
with the aryl portion occupying the lipophilic region close to the gatekeeper, and the furan binding in the outer 
lipophilic region. ERK5 shares 48% sequence homology with p38 MAP kinase, and 58% homology in the kinase 
domain. In addition, the gatekeeper residues of the kinases are similar, with leucine in ERK5 and threonine in p38 
MAP kinase. The ERK5 SAR for our series is consistent with a similar binding mode to ERK5 as seen in the p38 X-ray 
structure, in particular the donor/acceptor doublet of H-bonds from the pyrrole NH and amide carbonyl to the 
kinase.  
At this point, given the similarity between the published p38 MAP kinase inhibitors and our hit series, we needed 
to establish selectivity vs p38 MAP kinase to provide useful ERK5 tool compounds or therapeutic agents.34-35 Thus, 
selected compounds were counterscreened against p38 MAP kinase using a LANCE assay. As anticipated, the 2-
pyridyl derivatives 6j and 3,4-dihydroisoquinolinyl derivative 6p were equipotent for both p38 MAP kinase and 
ERK5. Importantly, the pyrrolidinopyridinyl derivative 6r was inactive in the p38 assay. The ability to eliminate p38 
MAP kinase activity whilst maintaining ERK5 activity by variation of the amide side chain was not readily predicted 
9 
 
from the published p38 X-ray structure and points to differing structural requirements around the amide side-chain 
that may be exploited in further development of the series.  
CONCLUSIONS 
The IMAP FP high-throughput screen for ERK5 returned four distinct chemical series as hits. Synthesis of the hits and 
selected close analogues demonstrated that the HTS activity of the benzothiazoles 3 was not reproducable, activity 
for the cyanopyridine hits (4a, 19) was reproducable, but the limited scope to develop the SAR ruled this series out, 
and two series with confirmed active hits. The lack of activity of these hits was disappointing but not atypical in 
screening campaigns. The cyanopyrimidine hits 5a-c were not pursued for reasons of competition. The remaining 
series, the pyrrole carboxamides 6a-e, demonstrated consistent ERK5 activity, with SARs consistent with a kinase 
hinge binder. Selectivity against the close homologue p38 MAP kinase was achieved without loss of ERK5 activity 
through minor structural modification, and a representative example 6h showed an acceptable kinase selectivity 
profile in a panel. At this stage the pyrrole carboxamides demonstrated tractable synthesis, intelligible preliminary 
SARs, and promising selectivity. The relatively modest kinase inhibitory activity achieved at this stage did not give 
any concern as the pharmacophore established presented opportunities to optimise potency at both the benzoyl 
and amide portions, indepenently. Having demonstrated the necessary requirements to progress to the hit-to-lead 
optimisation stage, further SAR studies were undertaken, with an initial focus on improving potency, which will be 
reported seperately.36 
EXPERIMENTAL SECTION  
IMAP Substrate mapping 
Non-phosphorylated and phosphorylated versions of each ERK5 sequence (Table 1) were obtained from the CRUK 
Peptide Synthesis Research Services group. The substrate finder kit was used according to the manufacturer’s 
instructions. Reaction buffer (10 µL) containing ATP (100 µM) was added to wells of the plate to reconstitute 5-FAM 
labeled substrates. Reaction buffer (10 µL) with or without ERK5 (6.4 ng/µL) was added to appropriate wells of the 
plate, to generate background controls and positive controls. The reaction was incubated for 1 hour at ambient 
temperature after which IMAP Binding Solution (60 µL) was added. After a further 1 hour of incubation the 
fluorescence polarisation was measured. The results were analysed using the IMAP Substrate Mapper provided with 
the kit. 
Kinetic characterisation of ERK5 
Reactions were carried out with varying concentrations of ATP at constant substrate and enzyme concentrations. 
Due to limitations of the IMAP FP assay with respect to ATP concentrations, we utilised a transfer method to 
increase the maximum concentration of ATP that can be used. Reactions were conducted as normal in 10 µL reaction 
volume. After either 1, 2, 3 or 4 hour incubation period at 37°C, 4 µL of the reaction was transferred to 196 µL of 
reaction buffer followed by a subsequent transfer of  10 µL of this solution to 30 µL of IMAP Binding Solution. Rates 
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of reaction at 1 hour reaction time at the range of substrate concentrations were determined, and kinetic 
parameters were determined by non-linear regression fitting of the data to the Michaelis-Menten equation 
(Equation 1) ; curve fitting was performed using GraphPad Prism software.37 
ERK5 High-throughput Screen 
Compounds were assayed in a 10 µL reaction mixture per well containing: 1 in 700 dilution of ERK5 stock from CRT, 
100 nM peptide R7129 and 100 µM of ATP. The reactions were performed with 10 mM Tris-HCl (pH 7.2), 10 mM 
MgCl2, 0.05% NaN3 and 0.01% Tween-20. Reactions were incubated for 3 hours at 37°C, followed by addition of 30 
µL of IMAP binding solution (1 in 600 dilution of IMAP binding reagent in 60% Binding Buffer A and 40% Binding 
Buffer B) and a further incubation for 2 hours at ambient temperature. Plates were read on an Analyst HT microplate 
reader and the data analysed using ActivityBase. 
 ERK5 IC50 Determination (IMAP) 
The enzyme reaction was run as described for the HTS but using 300 µM ATP, 250 nM peptide and a reduced 
incubation time of 2 hours at 37°C. 1 µL of this reaction was then transferred to a new assay plate and 9 µL of 
reaction buffer was added followed by 30 µL of IMAP binding solution.  
X-ray crystallography 
Data were collected on an Oxford Diffraction Gemini A Ultra diffractometer for 3i, using MoK radiation ( = 0.71073 
Å) at 150K, and on a Bruker Apex2 diffractometer for 3a and 12a, using synchrotron radiation ( = 0.6946 Å; SRS 
station 9.8, Daresbury Laboratory) at 120 K because of the very small size of crystals available.  Corrections were 
made for synchrotron beam decay and for absorption and other systematic effects on the basis of repeated and 
equivalent data.  The structures were solved by direct methods and refined on all unique F2 values with anisotropic 
non-hydrogen atoms, with freely refined isotropic H atoms bonded to N, and with a riding model for H atoms 
bonded to C.  All four structures are fully ordered; 3i have two independent molecules in the asymmetric unit, and 
the non-centrosymmetric but achiral crystal structure of 3i displays inversion twinning with essentially equal 
components.  Full crystallographic details are given in the Supporting information.  Programs were standard Oxford 
Diffraction CrysAlisPro38 and Bruker Apex239 for data collection and processing, and SHELXTL40 and SHELXL-
2014_ENREF_52_ENREF_5341 for structure solution and refinement.  CCDC references: 1410001, 141003, and 
1410004. 
ASSOCIATED CONTENT 
Supporting Information 
Additional screening and synthesis information, X-ray crystal structure data for compounds 12a, 3a, and 3i, synthetic 
procedures, ERK5 and p38 LANCE assay protocols, kinase selectivity data for 6h. 
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EQUATIONS 
Equation 1 
𝑣
[𝐸]
 =
𝑘𝑐𝑎𝑡[𝑆]
(𝐾𝑚 + [𝑆])
 
Equation 2 
𝑍′ =  1 −  
3𝜎𝑐+ +  3𝜎𝑐−
|µ𝑐+ − µ𝑐−|
 
Where σ and µ represent the standard deviation and mean of the positive (c+) and negative (c-) plate controls, 
respectively.  
 
TABLES 
Table 1 
Number Sequence 
166 5-FAM-AGRSPVD 
168 5-FAM-EAGRSPVDS 
170 5-FAM-HEAGRSPVDSL 
172 5-FAM-RHEAGRSPVDSLS 
174 5-FAM-TRHEAGRSPVDSLSS 
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Table 2 
               
Compound Structure R1 R2 
ERK5 IC50 (μM) 
HTS Resynthesizeda 
3a A -(CH2)4- 0.057 51 ± 5.0 
3b A Et Me 0.087 85 ± 5.0 
3c A Me H 0.087 - 
3d A Et H 0.11 - 
3e A CH2=CHCH2- H 0.13 - 
3f A s-Bu H 0.13 - 
3g A -(CH2)5- 0.46 - 
3h A i-Pr H 0.60 - 
3i A n-Pr H 0.89 >120b 
3j A Et Et 0.93 - 
3k A -(CH2)2O(CH2)2- 5.13 - 
9a B -(CH2)4- - 29 ± 1.3 
9b B Et Me - 21 ± 1.5 
12a C -(CH2)4- - 2.3 ± 1.5 
12b C Et Me - >120b 
a) Values are the mean of at least 3 determinations ± SD; b) n = 2 
17 
 
Table 3: ERK5 inhibitory activity of nicotinonitrile series 4a-k.  
 
Compd R1 R2 
ERK5 IC50 (µM) 
HTS Resynthesizeda 
4a 4-F-Ph Ph 1.6 4.9 ± 0.3 
4b 3-F-Ph Ph - >120b 
4c 2-F-Ph Ph - 34.3 ± 6.4 
4d Ph Ph - >120b 
4e 4-(CF3)-Ph Ph - >120b 
4f 2,4-di-F-Ph Ph - 72.9 ± 26.1 
4g 4-Py Ph - 65.1 ± 12.4 
4h 4-MeOPh Ph - >120b 
4i Ph 4-MeOPh - >120b 
4j Ph CH3 - >120b 
4k CH3 CH3 - >120b 
a) Values are the mean of at least 3 determinations ± SD; b) n = 2 
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Table 4: ERK5 inhibitory activity of nicotinonitrile series 14a,15l, 17,19-21, 23, 28 and 31-32.  
 
Compound R R1 R2 
ERK5 IC50 (µM) 
HTS Resynthesizeda 
14a H Ph 4-F-Ph - 111 ± 6.5 
15l 
 
Ph 4-F-Ph - 20.9 ± 1.6
c 
17 
 
Ph 4-F-Ph  - >120 
19 
 
Ph 4-F-Ph 31 29.4 ± 3.7
c 
20 
 
Ph 4-F-Ph - 117 ± 18 
21 
 
Ph 4-F-Ph - >120 
23a 
 
Ph 4-F-Ph - >120
d 
23b 
 
Ph 4-F-Ph - >120
d 
28 
 
Ph 4-F-Ph  - >120 
31 
 
Ph 4-F-Ph 0.4 20.5 ± 1.3 
32 
 
Ph 4-Py - 104.9 ± 6.5 
a) Values are the mean of at least 3 determinations ± SD b) n = 1; c) n = 2; d)precipitation observed at 1.2 mM in 
40% DMSO; 
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Table 5: ERK5 inhibitory activity of pyrimidine series 5a-c.  
 
Compound R 
ERK5 IC50 (µM) 
HTS Resynthesizeda 
5a 2-CH3 26 88 ± 3 
5b 3-OCH3 11 23 ± 7 
5c 4-F 6.5 12 ± 3 
a) Values are the mean of at least 3 determinations ± SD 
Table 6 : ERK5 inhibitory activity of pyrrole carboxamides (6a-e) 
 
Compound Ar R1 R2 
ERK5 IC50 (µM) 
HTS Resynthesizeda 
6a 
  
H 0.66 3.7  
6b 
 
CH3 CH3 1.89 >120b 
6c 
  
H 3.50 >120b 
6d 
 
CH3 H 4.32 9.6 ± 3.9 
6e 
 
  
H 8.0 26.0 ± 1.2 
a) Values are the mean of at least 3 determinations ± SD; b) n = 2 
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Table 7. ERK5 SAR for pyrrole carboxamides (6f-n) 
 
Compound R1 R2 R3 
ERK5 IC50 (µM) 
IMAPa LANCEa 
6f H H CH3 3.3 ± 1.0b 3.6 ± 1.0 
6g H CH3 CH3 24 ± 27c 44 ± 24 
6h H H 
 
2.0 ± 2.0d - 
6i H H 
 
3.8 ± 3.7c 1.1 ± 0.4c 
6j H H 
 
7.2 ± 0.02 3.9 ± 0.8 
6k H H 
 
21e - 
6l H H 
 
>120 
- 
 
6m CH3 H 
 
>120 - 
6n H CH3 
 
25 ± 1.3 13 ± 1.9 
a) determinations ± standard deviation (mean of n = 2 unless otherwise stated); b) IC50 mean of n = 4; c) IC50 mean of n = 6; d) 
IC50 mean of n = 10; e) IC50 n = 1. 
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Table 8. SAR for cyclic pyrrole carboxamides (6j, 6o-r) against ERK5 and p38.  
 
Compound ID R 
ERK5 IC50 (µM)a p38 LANCE  
IC50 (µM)a IMAP LANCE 
6j  
 
7.2 ± 0.03  4.3 ± 1.2b 
6o 
 
>120 -  
6p 
 
11 ± 2.3b 25 ± 1.8 28 ± 20 
6q 
 
>120 -  
6r 
 
2.7 ± 0.4 
- 
 
> 120 
a) determinations ± standard deviation (mean of n = 2 unless otherwise stated); b) IC50 mean of n = 4. 
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Table 9. ERK5 SAR for pyrroles (39-42, 44). 
 
Compound ID R 
ERK5 IC50 (µM)a 
IMAP LANCE 
39 CH3 >120 - 
40 
 
3.1 ± 0.1b - 
41 
 
23 ± 4.4 24 ± 2.2 
42 
 
6.8 ± 2.0 16 ± 5.7c 
44 
 
>120 - 
a) determinations ± standard deviation (mean of n = 2 unless otherwise stated); b) mean of n = 4; c) mean of n = 6 
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FIGURES 
Figure 1: Crystal structure of 3-(pyrrolidin-1-ylsulfonyl)-4-thiocyanatobenzenamine 12a. 
  
Figure 2: Crystal structure of 6-(pyrrolidine-1-sulfonyl)-benzothiazol-2-ylamine 3a. 
 
Figure 3: Crystal structure of 2-amino-N-propylbenzo[d]thiazole-6-sulfonamide 3i. 
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STRUCTURES 
      
1a R = H, 1b R = Me       2        45 
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SCHEMES 
Scheme 1. 
 
Reagents and conditions: a) pyrrolidine or N-methylethylamine or propylamine, Et3N, DCM; b) Pd/C, H2, EtOAc; c) 
KSCN, Cu(II)SO4, MeOH.  
 Scheme 2. 
 
Reagents and conditions: a) pyrrolidine or N-methylethylamine, Et3N, DCM; b) Pd/C, H2, EtOAc; c) KSCN, Cu(II)SO4, 
MeOH. 
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Scheme 3 
  
Reagents and Conditions: a) KOH, EtOH, RT; b) Method A, S8, morpholine, EtOH, 80 oC 30 min then malononitrile; or 
Method B, 2-cyanothioacetamide, 1.6 M NaOMe in MeOH, 80 oC; c) tert-butyl or ethyl 2-(2-
bromoacetamido)acetate, K2CO3 or KOH, DMF, 100 oC; d) TFA, RT; e) p-methoxybenzylamine, HBTU, DIPEA, DMF, 60 
oC; f) TFA, 70 oC. NB: No base was required in step c after step b (Method B), as an excess of NaOMe was used in step 
b 
Scheme 4 
 
Reagents and Conditions: a) bromoacetyl chloride, CaCO3, CHCl3, H2O, 0 oC; b) 14a, KOH, DMF, reflux. 
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Scheme 5 
 
Reagents and Conditions: a) methyl bromoacetate, KOH, DMF, reflux, or chloroacetamide, NaOAc.3H2O, ethanol, 
reflux.  
Scheme 6 
 
Reagents and Conditions: a) RBr, K2CO3, THF, 100 oC; b) TFA, RT. 
Scheme 7 
 
Reagents and Conditions: a) ethanolamine, RT; b) Boc2O, Et3N, DCM, 0 oC-RT; c) MsCl, Et3N, DCM, 0 oC-RT; d) 14a, 
DMF, 100 oC; e) TFA, RT. 
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Scheme 8 
 
Reagents and Conditions: a)i) Ac2O, pyridine, reflux; ii) HCl, H2O, reflux; b) bromoacetyl chloride, CaCO3, DCM, reflux; 
c)  14a or 14g, K2CO3,  DMF, 100 oC 
Scheme 9 
 
Reagents and Conditions: a) DMF, 100 oC. 
Scheme 10 
 
Reagents and Conditions: a) ArCOCl, AlCl3, DCM, 0 oC-RT; b) LiOH, THF, H2O, 60 oC; c) i) CDI, THF, 70 oC; ii) R1R2NH, 50 
oC - RT. 
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Scheme 11 
 
Reagents and Conditions: a) NaH, DMF, MeI; b) LiOH, THF, H2O, 60 oC; c) i) CDI, THF, 70 oC; ii) 3-pyridylmethylamine, 
50 oC - RT. 
Scheme 12 
 
Reagents and Conditions: a) AlCl3, 2,3-dichlorobenzoyl chloride, DCM, 0 oC-RT, 18 h.; b) Isonicotinaldehyde, KOH, 
EtOH, H2O, 0 oC–RT, 18 h.; c) Indium powder, NH4Cl, EtOH, H2O, reflux, 8 h; d) (CH3)2SO+I-, KOtBu, DMSO, RT, 24 h.   
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Scheme 13
 
Reagents and Conditions: a) KOtBu, THF, RT, 6 h. b) AlCl3, 2,3-dichlorobenzoyl chloride, DCM, 0 °C-RT, 18 h. 
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SUPPORTING INFORMATION 
High-throughput screening and hit validation of extracellular-
related kinase 5 (ERK5) inhibitors. 
Stephanie M. Myers, Ruth H. Bawn, Louise C. Bisset, Timothy J. Blackburn, Betty Cottyn, Lauren Molyneux, 
Ai-Ching Wong, Celine Cano, William Clegg, Ross. W. Harrington, Hing Leung, Laurent Rigoreau, Sandrine 
Vidot, Bernard T. Golding, Roger J. Griffin, Tim Hammonds, David R. Newell, Ian R. Hardcastle* 
Screening 
Z’ factors for each plate were calculated using Equation 2, and were typically 0.6-0.8. Plates with Z’ factors below 0.4 
were re-screened. 
A: B:   
Figure S1: A) Z’ factors for diversity library; b) Z’ factors for kinase focussed library 
 
Figure S2: ERK5 retest data 
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Plates were read on a Pherastar microplate reader (BMG Labtech).  
5 x Assay buffer was prepared freshly: 250 mM Tris pH 7.5, 25 mM MgCl2, 2.5 mM EGTA, 10 mM DTT, 0.05% Triton x 
100. ERK5 (In-house preparation, co-expressed with MEK5) 2.3 uM. Substrate- Perkin Elmer, Ulight-MBP Peptide, 
product number TRF0109, 5 nmoles (stock concentration of 5 uM). Antibody- Perkin Elmer, Europium-anti-phospho-
MBP antibody. Stock concentration of 0.625 uM. Lance Detection Buffer- 10 x stock concentration. Used at 1 x final 
concentration. Adenosine 5’-triphosphate disodium salt. EDTA. 
Assay buffer concentrations were 50 mM Tris pH 7.5, 5 mM MgCl2, 0.5 mM EGTA, 2 mM DTT, 0.01% Triton x 100. 
Enzyme and Substrate/ATP reaction mix was made up in equivalent of 1 x buffer. ERK5 working solution  1.44 uM, 15 
nM. Made up to 2 x working stock concentration of 30 nM. Prepared in 1 x Assay Buffer. For 1 plate, added 52 l of 
ERK5, 500 l of 5 x Assay Buffer and 1948 l of H2O and 0.5 ml of No Protein negative control- 100 μl Assay Buffer, 
400 μl H2O. Substrate/ATP working solution: Km for ATP is 350 uM. Substrate final concentration 50 nM. 2.5 x 
working stock solution of ATP and Substrate mix - 875 M ATP working solution and 125 nM Substrate. For 1 plate, 
added 17.5 l of 100 mM ATP stock + 50 l of Substrate + 400 l of 5 x Assay Buffer + 1532.5 l of H2O. 
EDTA/Antibody Detection Reagent: Prepared a 2 x working stock of EDTA/Antibody mix, final concentrations in assay 
of 2 nM antibody and 5 mM EDTA. Stock concentrations of 0.625 uM and 0.5 M for Antibody and EDTA respectively. 
Diluted detection reagent in LANCE detection buffer at a working stock concentration of 1 x from 10 x. For 1 plate, 
added 84 μl of EDTA + 27 l of Antibody + 420 l of LANCE Detection Buffer + 3669 l of H2O.  
Dry spotted 1 l of compound in 20% DMSO to test wells, or 20% DMSO to blanks and controls into the assay plate 
using a MATRIX PlateMate Plus. Added 5 l of ERK5 working solution to test and control wells and 5 l of no 
protein negative control solution to blanks using a Thermo Multidrop Combi or Matrix multichannel pipette. Added 4 
l of Substrate/ATP working solution to all wells using a Thermo Multidrop Combi or Matrix multichannel pipette. 
Incubated for 2 hours at 37 oC. Added 10 l of EDTA/Antibody to all wells using a Thermo Multidrop Combi or Matrix 
multichannel pipette. Incubated for 2 hours at room temperature in the dark then read on the Pherastar plate 
reader. 
p38 alpha IC50 Determination (LANCE) 
The p38 LANCE assay protocol was carried out as described for the ERK5 LANCE assay protocol using the same 
quantities and concentrations unless stated below. Km for ATP is 350 µM, as was determined for ERK5. 
p38/SAPK2a, active N-terminal GST-tagged recombinant full length protein (Millipore, Product # 14-251). Supplied 
at 10 µg/4 µl was diluted down to 10 µg/40 µl by addition of 156 µl of 50 mM Tris/HCL pH 7.5, 150 mM NaCl, 0.1 mM 
EGTA, 0.03% Brij-35, 50% glycerol and 0.1% 2-mercaptoethanol. 
Synthesis 
Benzothiazole Series 3 
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Reactions of 11a,b with with potassium thiocyanate-copper(II) sulfate gave in each case, besides the desired 5-
substituted benzothiazole 9a,b, a significant quantity of a thiocyanatobenzene (12a,b). This can be rationalised by 
postulating the formation of the electrophilic species +SCN from KSCN-CuSO4, which attacks the aniline primarily at 
available ortho and para positions. The former leads, by cyclisation of an intermediate thiocyanatobenzene, to a 
benzothiazole, whereas the latter mode of attack is arrested at the thiocyanatobenzene.      
The sequence described above is well exemplified by 3-(pyrrolidin-1-ylsulfonyl)benzenamine 11a, which gave 3-
(pyrrolidin-1-ylsulfonyl)-4-thiocyanatobenzenamine (12a) and (pyrrolidin-1-ylsulfonyl)benzo[d]thiazol-2-amine (9a). 
Structural identification by 1H NMR was initially ambiguous because both compounds are 1,2,4-trisubstituted 
benzenes and have a similar set of coupling constants. However, the structural assignment to 12a could be secured 
by crystal structure analysis (Supporting information: Figure S1). Further, the infrared spectrum of 12a showed max 
2155 cm-1, whereas the accompanying compound was silent in the absorption region for the SCN group and is 
therefore 9a. The structures of the benzothiazoles 3a and 3i were also validated by X-ray analysis (Supporting 
information: Figures S2 and S3). The reactions leading to 3a-c only afforded benzothiazoles because there was only 
one intermediate thiocyanate in each case, i.e. with the SCN group ortho to the initial amino function.  
Nicotinonitrile Series 4 
Alkylation of 14a with tert-butyl 2-(2-bromoacetamido)acetate gave 15a, leading to 4a after deprotection using TFA. 
Similarly, reaction of 14a with ethyl 2-(2-bromoacetamido)acetate gave the ethyl ester 15l. For 4g, 4-pyridylchalcone 
13g was prepared via Wittig reaction of 4-pyridine carboxaldehyde with (benzoylmethylene)triphenylphosphorane, 
following failure of the Claisen-Schmidt condensation (Scheme not shown).   
The proline derivative 19 was prepared by reaction of proline methyl ester with bromoacetyl chloride giving 18, 
which was reacted with 14a as previously described (Scheme 4). 
Further variations to the thioether group were introduced via alkylation of 14a. The shorter carboxamides 20 and 21 
were prepared by alkylation of 14a with chloroacetamide and methyl-2-bromoacetate, respectively (Scheme 5). 
Alkylation of 14a with either t-butyl 4-bromobutanoate or t-butyl 5-bromopentanoate, followed by treatment with 
TFA gave the simplified alkylcarboxylic acid derivatives 23a and b, respectively (Scheme 6). Similarly, the aminoacid 
derivative 28 resulted from the alkylation of 14a with the protected mesylate of N-(2-hydroxyethyl)glycine 26 giving 
27, followed by deprotection to 28. Mesylate 26 was obtained by reaction of t-butyl bromoacetate with 
ethanolamine giving 24, followed by sequential Boc protection and mesylation (Scheme 7).   
The acetamide derivatives 31 and 32 were prepared by the alkylation of 14a and 14g, respectively, with 
bromoacetamide 30 which was obtained by reaction of aminoacetone hydrochloride 29 with bromoacetylchloride 
(Scheme 8).1  
4-Benzoylpyrrole-2-carboxamide Series 6 
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To prepare derivative 6p pyridyl amines 45 prepared as reported (Scheme S1).2 Starting from 3-
bromoisonicotinaldehyde 47, a Sonagashira reaction with ethynyltrimethylsilane afforded  3-
((trimethylsilyl)ethynyl)isonicotinaldehyde 48 in 98% yield. Cyclisation of 48 in the presence of ammonia afforded 
2,6-naphthyridine 49. Selective reduction using platinum dioxide and calcium oxide in 2-methoxyethanol afforded 
amine 45 in 67% yield. CDI mediated amide coupling between carboxylic acid 36a and amine 45 gave the target 
compound 6p in 55% yield. 
                                 
Scheme S1. (i) PdCl2(PPh3)2, DABCO, CuI, THF, RT, 24 h. (ii) 2.0 M NH3 in EtOH, 80 °C, 2 h. (iii) PtO2, CaO2, H2,  2-
methoxyethanol, RT, 16 h. 
Crystal Structures 
The principal aim of the crystallographic studies was a definitive identification of the compounds.  The detailed 
molecular structures and crystallographic features require only brief comments, as bond lengths, angles and 
conformations are all normal and full results are provided.  12a has only one molecule in the asymmetric unit; there 
are no - ring stacking interactions, and intermolecular NH…OS hydrogen bonds generate sheets of molecules 
(Figure S4). 3a and 3i are both benzothiazoles with the ring system substituted by an NH2 group and by a sulfonyl 
group bearing either a secondary (pyrrolidine, 3a) or a primary (n-propylamine, 3i) amine substituent.  3a has one 
molecule in the asymmetric unit, from which centrosymmetric -stacked dimers are formed; centrosymmetric dimer 
assembly also occurs through pairs of NH…N(thiazole) intermolecular hydrogen bonds (Figure S5), while NH…OS 
hydrogen bonds involving just one of the two sulfonyl O atoms link these dimers together in approximately planar 
ribbons from which pyrrolidine substituents protrude on both sides.  3i has two molecules with very similar 
conformations in the asymmetric unit, and there is no -stacking at all in this structure; it contains the same type of 
hydrogen-bonded dimers as 3a (Figure S6), though here they are formed by pairs of crystallographically independent 
molecules and there is no precise inversion symmetry (it is only approximate), and the availability of an extra 
(sulfonamide) NH group means that all O atoms act as hydrogen bond acceptors in a complex three-dimensional 
network. 
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Figure S4.  A hydrogen-bonded sheet of molecules of 3-(pyrrolidin-1-ylsulfonyl)-4-thiocyanatobenzenamine 12a.  C-
bound H atoms have been omitted for clarity.  Here and in other Figures atoms are shown as 40% probability 
displacement ellipsoids. 
 
Figure S5.  A hydrogen-bonded centrosymmetric dimer of 6-(pyrrolidine-1-sulfonyl)-benzothiazol-2-ylamine 3a. 
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Figure S6.  The approximately centrosymmetric  hydrogen-bonded dimer of 2-amino-N-propylbenzo[d]thiazole-6-
sulfonamide 3i.  
Experimental Section  
General Methods 
Reagents were purchased from fine chemicals vendors, and used as received unless otherwise stated. Solvents were 
purified and stored according to standard procedures. Petrol refers to that fraction in the boiling range 40-60 °C. THF 
refers to anhydrous tetrahydrofuran, either by distillaton from sodium benzophenone, or from commercial sources. 
Melting points were obtained on a Stuart Scientific SMP3 apparatus and are uncorrected. Thin layer chromatography 
was performed using silica gel plates (Kieselgel 60F254; 0.2 mm), and visualized with UV light or potassium 
permanganate. Chromatography was conducted under medium pressure in glass columns or using a Biotage SP4 
instrument in prepacked columns (FLASH+ Silica columns (40-63 µm, 60 Å). Proton (1H) and carbon (13C) nuclear 
magnetic resonance (NMR) spectra were recorded on a  Bruker Spectrospin AC 300E (1H at 300 MHz, 13C at 75 MHz), 
a Jeol JNM-LA500 spectrometer (1H at 500 MHz, 13C at 125 MHz), or a Bruker Avance II 500 (1H at 500 MHz, 13C at 125 
MHz) employing the solvent as internal standard. IR spectra were recorded on a Bio-Rad FTS 3000MX diamond ATR. 
Liquid Chromatography-Mass Spectrometry (MS) was carried out on a Micromass Platform instrument operating in 
positive and negative ion electrospray mode, employing a 50 x 4.6 mm C18 column (Waters Symmetry or Waters 
Atlantis) 5 or 12 min gradient elution with 0.05% formic acid in methanol (10-90%). Elemental analyses were 
performed by The School of Pharmacy, Analytical Facility, University of London, WC1N 1AX. Accurate masses were 
measured using a Finnigan MAR 95 XP or a Finnigan MAR 900 XLT at the EPSRC National Mass Spectrometry Service 
Centre (Chemistry Department, University of Wales, Swansea, Wales, SA2 8PP). 
6-(Pyrrolidin-1-ylsulfonyl)benzo[d]thiazol-2-amine (3a)3 
A suspension of 4-(pyrrolidin-1-ylsulfonyl)aniline (410 mg, 1.8 mmol), KSCN (4.43 g, 45 mmol) and anhydrous 
Cu(II)SO4 (3.53 g, 23 mmol) in MeOH (9 mL) was heated at reflux for 3 h, then cooled and filtered. The filtrate was 
diluted with water (5 mL/mmol) and heated to reflux and EtOH (11 mL/mmol) added. The reaction mixture was 
cooled, filtered and concentrated in vacuo. The residue was diluted with water (5 mL/mmol), basified to pH 11 with 
aq. conc. ammonia and the product dissolved into EtOAc (5  10 mL/mmol). The combined organic layers were 
washed with aq. NH4Cl (2  25 mL/mmol), followed by brine (25 mL/mmol), dried (MgSO4) and concentrated in 
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vacuo. Chromatography (silica gel, 1:1 EtOAc:petrol) gave 3a as an off white solid (480 mg, 94%): Rf = 0.40 (EtOAc); 
mp: 248-249 oC; λmax (EtOH/nm) 229, 283; IR (cm-1) 3398 (N-H), 3290 (N-H), 1524 (thiazole-C=N), 1329 (S=O), 1309 
(S=O), 1145 (S=O); δH (300 MHz, DMSO-d6): 1.61-1.65 (4H, m, 2 × NCH2CH2), 3.10-3.14 (4H, m, 2 × NCH2), 7.45 (1H, d, 
J = 8.5 Hz, ArH), 7.60 (1H, dd, J = 2.0 and 8.5 Hz, ArH), 7.96 (2H, s, NH2), 8.17 (1H, d, J = 2.0 Hz, ArH); δC (75 MHz, 
DMSO-d6): 25.0 (NCH2CH2), 48.0 (NCH2CH2), 117.7 (ArC), 121.1 (ArC), 125.4 (ArC), 132.1 (ArC), 156.7 (ArC), 170.3 
(ArC); LC-MS (ES+) m/z = 284.19 [M+H]+; HRMS calcd. for C11H14N3O2S2 [M+H]+ 284.0522, found 284.0518. 
General procedure A – Synthesis of Nitrophenylsulfonamides 
To a stirred solution of the amine (1 mol equiv.) and triethylamine (1.5 equiv.) in dichloromethane (2 mL/mmol 
amine) at 0-5 ˚C was added the nitrobenzenesulfonyl chloride (0.5 equiv.) in small portions. The resulting yellow 
solution was stirred at room temperature for 3 h. The reaction mixture was diluted with dichloromethane (5 
mL/mmol amine), washed with aqueous sulfuric acid (1.0 M), followed by saturated aqueous sodium bicarbonate 
and brine (each 5 mL/mmol amine). The organic phase was dried over MgSO4, filtered and concentrated. The crude 
product was purified by recrystallisation from ethyl acetate/petrol. 
1-((4-Nitrophenyl)sulfonyl)pyrrolidine (8a)4 
General procedure A: p-nitrobenzenesulfonylchloride (0.71 g, 3.2 mmol), pyrrolidine (0.68 g, 0.80 mL, 9.6 mmol) and 
triethylamine (0.97 g, 1.33 mL, 9.6 mmol) in DCM (6 mL). Recrystallisation from EtOAc gave 6a as an off white solid 
(800 mg, 98%): Rf = 0.48 (1:1 EtOAc:petrol); mp: 159-160 ˚C; λmax (EtOH/nm) 273; IR (cm-1) 1472 (N=O), 1347 (S=O), 
1300 (S=O); δH (300 MHz, CDCl3): 1.77-1.85 (4H, m, 2 × NCH2CH2), 3.27-3.31 (4H, m, 2 × NCH2), 7.99-8.04 (2H, m, 2 × 
ArH), 8.36-8.40 (2H, m, 2 × ArH); δC (75 MHz, CDCl3): 25.7 (NCH2CH2), 48.3 (NCH2CH2), 124.5 (ArCH), 128.8 (ArCH), 
144.2 (ArC), 150.6 (ArC); LC-MS (ES+) m/z = 256.15 [M+H]+. 
N-Ethyl-N-methyl-4-nitrobenzenesulfonamide (8b) 
General procedure A. (0.35 g, 72%); mp 122-123 ˚C; δH (300 MHz, CDCl3) 1.10 (3H, t, J = 7.2 Hz, CH3CH2), 2.74 (3H, s, 
CH3N), 3.09 (2H, q, J = 7.2 Hz, CH3CH2), 7.89-7.93 (2H, m, 2  H-Ar), 8.29-8.33 (2H, m, 2  H-Ar); δC (75.5 MHz, CDCl3) 
11.6, 32.5, 43.6, 122.8, 126.9, 143.4, 148.8; MS  (ES+) m/z = 243.20  [M-H]-. 
4-Nitro-N-propylbenzenesulfonamide (8c) 
General procedure A. (0.41 g, 85%); mp 88-89˚C; δH (300 MHz, CDCl3) 0.82 (3H, t, J = 7.5 Hz, CH3CH2), 1.39-1.52 (2H, 
m, CH3CH2), 2.89-2.96 (2H, m, CH2NH), 4.61 (1H, t, J = 6.0 Hz, NH), 7.96-8.02 (2H, m, 2  H-Ar), 8.28-8.33 (2H, m, 2  
H-Ar); δC (75.5 MHz, CDCl3) 11.2, 23.5, 45.6, 124.6, 128.6, 146.9; MS (ES+) m/z = 243.16  [M-H]-  
1-(3-Nitrophenylsulfonyl)pyrrolidine (10a) 
General procedure A. (1.52 g, 89%); mp 103-104 ˚C (lit mp 99-100˚C);17 δH (300 MHz, CDCl3) 1.74-1.80 (4H, m, 2  
NCH2CH2), 3.22-3.26 (4H, m, 2  NCH2), 7.70 (1H, dd, J = 8.0, 8.0 Hz, H-Ar), 8.08-8.12 (1H, m, H-Ar), 8.37-8.41 (1H, m, 
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H-Ar), 8.60 (1H, dd, J = 1.8, 1.8 Hz, H-Ar); δC (75.5 MHz, CDCl3) 25.7, 48.4, 122.7, 127.1, 130.6, 133.0, 140.9, 149.0; 
MS (ES+) m/z = 256.43 [M+H]+. 
N-Ethyl-N-methyl-3-nitrobenzenesulfonamide (10b) 
General procedure A. (0.97 g, 89%); mp 57-58 ˚C; δH (300 MHz, CDCl3) 1.11 (3H, t, J = 7.0 Hz, CH3CH2), 2.75 (3H, s, 
CH3N), 3.12 (2H, q, J = 7.0 Hz, CH3CH2), 7.69 (1H, dd, J = 8.0, 8.0 Hz, H-Ar), 8.06 (1H, d, J = 8.0 Hz, H-Ar), 8.37 (1H, d, J 
= 8.0 Hz, H-Ar), 8.56 (1H, d, J = 1.5 Hz, H-Ar); δC (75.5 MHz, CDCl3) 13.4, 34.3, 45.4, 122.6, 127.1, 130.6, 132.9, 141.6, 
149.0; MS (ES+) m/z = 243.81 [M-H]-. 
General procedure B – Synthesis of Aminophenylsulfonamides 
To the nitrophenylsulfonamide (1 mol equiv.) in ethyl acetate (12 mL/mmol), was cautiously added palladium, 10 
wt% on activated carbon (0.1 equiv.) and the reaction was stirred under H2 for 18 h. The resulting mixture was 
filtered through Celite and concentrated in vacuo to yield the product. 
4-(Pyrrolidin-1-ylsulfonyl)benzenamine (7a) 
General procedure B. (0.32 g, 91%); mp 167-168 ˚C (lit mp 167.5-168˚C);15 δH (300 MHz, CDCl3) 1.65-1.70 (4H, m, 2  
NCH2CH2), 3.11-3.15 (4H, m, 2  NCH2), 4.04 (2H, br s, NH2), 6.61-6.65 (2H, m, 2  H-Ar), 7.53-7.56 (2H, m, 2  H-Ar); 
δC (75.5 MHz, CDCl3) 25.5, 48.1, 114.4, 129.8, 130.0, 150.2; MS (ES+) m/z = 227.25 [M+H]+. 
4-Amino-N-ethyl-N-methylbenzenesulfonamide (7b) 
General procedure B. (0.24 g, 94%); mp 81-82 ˚C; δH (300 MHz, CDCl3) 1.05 (3H, t, J = 7.2 Hz, CH3CH2), 2.62 (3H, s, 
CH3N), 2.98 (2H, q, J = 7.2 Hz, CH2CH3), 4.06 (2H, br s, NH2), 6.60-6.64 (2H, m, 2  H-Ar), 7.46-7.51 (2H, m, 2  H-Ar); 
δC (75.5 MHz, CDCl3) ppm 13.3, 34.2, 45.1, 114.4, 129.8, 150.8; MS (ES+) m/z = 215.25 [M+H]+; 
4-Amino-N-propylbenzenesulfonamide (7c) 
General procedure B. (0.28 g, 95%); mp 83-84 ˚C (lit mp 85˚C);16 δH (300 MHz, CDCl3) 0.80 (3H, t, J = 7.2 Hz, CH3CH2), 
1.35-1.47 (2H, m, CH3CH2), 2.77-2.84 (2H, m,  CH2NH), 4.05 (2H, br s, NH2), 4.23 (1H, t, J = 6.0 Hz, NH), 6.59-6.64 (2H, 
m, 2  H-Ar), 7.54-7.59 (2H, m, 2  H-Ar); δC (75.5 MHz, CDCl3) 11.3, 23.3, 45.3, 114.5, 129.6, 150.7; MS (ES+) m/z = 
215.24 [M+H]+;  
3-(Pyrrolidin-1-ylsulfonyl)benzenamine (11a) 
General procedure B. (1.26 g, 93%); mp 157-158˚C (lit mp 155-156˚C);17 δH (300 MHz, CDCl3) 1.67-1.71 (4H, m, 2  
NCH2CH2), 3.16-3.20 (4H, m, 2  NCH2), 3.84 (2H, br s, NH2), 6.79 (1H, ddd, J = 1.2, 2.1, 7.8 Hz, H-Ar), 7.06 (1H, dd, J = 
1.8, 2.1 Hz, H-Ar), 7.09-7.12 (1H, m, H-Ar), 7.21 (1H, dd, J = 7.8, 7.8 Hz, H-Ar); δC (75.5 MHz, CDCl3) 25.6, 48.2, 113.8, 
117.6, 119.0, 130.1, 138.9, 147.5; MS (ES+) m/z = 227.18 [M+H]+. 
3-Amino-N-ethyl-N-methylbenzenesulfonamide (11b) 
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General procedure B. (0.80 g, 89%); mp 55-56 ˚C; δH (300 MHz, CDCl3) 1.07 (3H, t, J = 7.2 Hz, CH3CH2), 2.67 (3H, s, 
CH3N), 3.03 (2H, q, J = 7.2 Hz, CH3CH2), 3.84 (2H, br s, NH2), 6.75-6.79 (1H, m, H-Ar), 7.00 (1H, dd, J = 1.9, 2.0 Hz, H-
Ar), 7.04-7.07 (1H, m, H-Ar), 7.21 (1H, dd, J = 7.8, 7.8 Hz, H-Ar); δC (75.5 MHz, CDCl3) 13.4, 34.3, 45.2, 113.6, 117.4, 
118.9, 130.1, 147.5; MS (ES+) m/z = 215.25 [M+H]+. 
General procedure C – Benzothiazole Formation5 
To the aminophenylsulfonamide (1 mol equiv.), KSCN (25 equiv.) and anhydrous Cu(II)SO4 (12 equiv.), was added 
anhydrous methanol (5 mL/mmol amine) with stirring. After boiling at reflux for 3 h the reaction mixture was cooled 
and filtered. The filtrate was diluted with water (5 mL/mmol amine) and heated to reflux. After addition of ethanol 
(11 mL/mmol), the reaction mixture was cooled and filtered. The filtrate was concentrated and diluted with water (5 
mL/mmol) and basified (pH 11) with aqueous ammonia. After extraction with ethyl acetate (5  10 mL/mmol), the 
combined organic layers were washed with saturated aqueous ammonium chloride (2  25 mL/mmol), brine (25 
mL/mmol) and dried over MgSO4. The mixture was filtered and concentrated in vacuo. The crude product was 
purified by recrystallisation from ethyl acetate-petrol or by medium pressure chromatography. 
2-Amino-N-ethyl-N-methylbenzo[d]thiazole-6-sulfonamide (3b) 
General procedure C. (0.02 g, 25%); mp 179-180˚C; δH (300 MHz, DMSO) 1.03 (3H, t, J = 7.0 Hz, CH3CH2), 2.63 (3H, s, 
CH3N) 2.97 (2H, q, J = 7.0 Hz, CH2CH3), 7.44 (1H, d, J = 8.4 Hz, H-Ar), 7.56 (1H, dd, J =1.9, 8.4 Hz, H-Ar), 7.96 (2H, br s, 
NH2), 8.13 (1H, s, H-Ar); δC (75.5 MHz, DMSO) 13.2, 34.3, 44.8, 117.7, 120.9, 125.2, 156.6, 170.2; MS (ES+) m/z = 
272.15 [M+H]+; HRMS [M+H]+ m/z Calc. for C10H14N3O2S2: 272.0522 Found 272.0524; υmax (film)/cm-1 3400.2, 3311.6; 
UV λmax 229, 283 nm (EtOH). 
2-Amino-N-propylbenzo[d]thiazole-6-sulfonamide (3i) 
General procedure C. (0.28 g, 95%); mp 215-216 oC; δH (300 MHz, DMSO) 0.78 (3H, t, J = 7.0 Hz, CH3CH2), 1.32-1.40 
(2H, m, CH2CH3),  2.63-2.70 (2H, m, CH2NH), 7.40-7.45 (2H, m, NH, H-Ar), 7.58-7.61 (1H, m, H-Ar), 7.92 (2H, br s, NH2), 
8.10 (1H, s, H-Ar); δC (75MHz, DMSO) 11.4, 22.8, 44.8, 117.7, 120.3, 124.7, 131.7, 133.1, 156.1, 169.9; MS (ES+) m/z = 
272.13 [M+H]+; HRMS [M+NH4]+ m/z Calc. for C10H17N4O2S2: 289.0787 Found 289.0784; υmax (film)/cm-1 3375.3, 
3302.1; UV λmax 228, 282 nm (EtOH).  
3-(Pyrrolidin-1-ylsulfonyl)-4-thiocyanatobenzenamine (12a) 
General procedure C. (0.31 g, 50%); mp 99-100 ˚C; δH (300 MHz, DMSO) 1.82-1.87 (4H, m, 2  NCH2CH2), 3.24-3.28 
(4H, m, 2  NCH2), 6.21 (2H, br s, NH2), 6.88 (1H, dd, J = 2.7, 8.4 Hz, H-Ar), 7.19 (1H, d, J = 2.7 Hz, H-Ar), 7.55 (1H, d, J 
= 8.4 Hz, H-Ar); δC (75.5 MHz, DMSO) 25.1, 48.1, 116.1, 119.5, 121.8, 136.6, 153.4, 168.7; MS (ES+) m/z = 284.53 
[M+H]+; HRMS [M+H]+ m/z Calc.for C11H14N3S2O2: 284.0522 Found 284.0523; υmax (film)/cm-1 3435.2, 3356.1, 2154.5; 
UV λmax 273 nm (EtOH). 
5-Amino-N-ethyl-N-methyl-2-thiocyanatobenzenesulfonamide (12b) 
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General procedure C. (0.25 g, 49%); mp 59-60 ˚C; δH (300 MHz, DMSO) 1.10 (3H, t, J = 7.0 Hz, CH3CH2), 2.80 (3H, s, 
CH3N), 3.22 (2H, q, J = 7.0 Hz, CH3CH2), 6.23 (2H, br s, NH2), 6.87 (1H, dd, J = 8.5, 2.4 Hz, H-Ar), 7.19 (1H, d, J = 2.4 Hz, 
H-Ar), 7.54 (1H, d, J = 8.5, H-Ar); δC (75.5 MHz, DMSO) 13.3, 33.8, 44.5, 104.0, 112.1, 115.6, 118.4, 135.6, 140.3, 
151.5; MS (ES+) m/z = 272.05 [M+H]+; HRMS [M+H]+ m/z Calc.for C10H14N3S2O2: 272.0522 Found 272.0522; υmax 
(film)/cm-1 3466.9, 3373.5, 2149.4; UV λmax 273 nm (EtOH). 
5-(Pyrrolidin-1-ylsulfonyl)benzo[d]thiazol-2-amine (9a) 
General procedure C. (0.09 g, 14%); mp 262-263 ˚C; δH (300 MHz, DMSO) 1.15-1.20 (4H, m, 2  NCH2CH2), 3.11-3.18 
(4H, m, 2  NCH2), 7.36 (1H, dd, J = 1.8, 8.1 Hz, H-Ar), 7.58 (1H, d, J = 1.8 Hz, H-Ar), 7.86 (2H, br s, NH2), 7.89 (1H, d, J 
= 8.1, H-Ar); δC (75.5 MHz, DMSO) 25.3, 47.9, 115.6, 118.7, 135.2, 151.2; MS (ES+) m/z = 284.25 [M+H]+; HRMS 
[M+H]+ m/z Calc.for C11H14N3S2O2: 284.0522 Found 284.0522; υmax (film)/cm-1 3346.5; UV λmax 273 nm (EtOH). 
2-Amino-N-ethyl-N-methylbenzo[d]thiazole-5-sulfonamide (9b) 
General procedure C. (0.08 g, 16%); mp 232-233 ˚C; δH (300 MHz, DMSO) 1.03 (3H, t, J = 7.0 Hz, CH3CH2), 2.65 (3H, s, 
CH3N), 3.00 (2H, q, J = 7.0 Hz, CH3CH2), 7.36 (1H, dd, J = 1.8, 8.4 Hz, H-Ar), 7.58 (1H, d, J = 1.8 Hz, H-Ar), 7.86 (2H, br s, 
NH2), 7.90 (1H, d, J = 8.4 Hz, H-Ar); δC (75.5 MHz, DMSO) 13.2, 34.3, 44.9, 115.9, 119.3, 121.9, 153.4, 168.7; MS (ES+) 
m/z = 272.18 [M+H]+; HRMS [M+H]+ m/z Calc.for C10H14N3S2O2: 272.0522 Found 272.0525; υmax (film)/cm-1 3385.1, 
3249.1; UV λmax 237 nm (EtOH). 
General procedure D6 
To a solution of the required 2-thioxo-1,2-dihydropyridine-3-carbonitrile (1.0 eq) and the suitable α-halogen 
compound (1.0 eq) in dimethylformamide (20 ml) was added potassium hydroxide (1.2 eq) at 0 oC. The reaction 
mixture was heated under reflux for 24 h, allowed to cool and diluted with water. The precipitate was collected by 
filtration and either recrystallization (THF) or chromatography (silica; 20-100% EtOAc/petrol) gave the desired 2-
pyridyl sulfide. 
2-[3-Cyano-4-(4-methoxyphenyl)-6-phenylpyridin-2-ylsulfanyl]acetylamino} acetic acid tert-butyl ester,15h 
General procedure D: 4-(4-methoxyphenyl)-2-mercapto-6-phenylnicotinonitrile, 14h (0.200 g, 0.6 mmol), tert-butyl 
2-(2-bromoacetamido)acetate (0.230 g, 0.52 mmol), KOH (0.034 g, 0.6 mmol), DMF (20 mL). Yellow solid (0.057 g, 
20%); m.p. 111.3˚C; λmax (EtOH/nm) 276, 339; IR υmax/cm-1 2212, 1738, 1660;  1H-NMR (300 MHz, CDCl3) δ ppm 1.38 
(9H, s, (CH3)3), 2.07 (3H, s, O-CH3), 3.91 (3H, s, O-CH3), 4.11 (2H, s, CH2S), 7.06 (2H, m, H-Ar), 7.25 (1H, br s, NH), 7.27 
(2H, m, H-Ar), 7.40 (1H, m, H-Ar), 7.50 (1H, m, CH-pyridine), 7.61 (2H, m, H-Ar), 7.99 (3H, m, H-Ar and NH); 13C-NMR 
(75 MHz, CDCl3) δ ppm 28.3, 34.3, 42.0, 55.8, 115.1, 127.8, 129.2, 129.4, 130.2, 131.0, 82.5, 104.3, 117.2, 137.5, 
154.9, 159.3, 161.9, 162.1, 168.4, 168.7; MS (ES+) m/z =  490.2 [M+H]+. 
[2-(3-Cyano-4,6-diphenylpyridin-2-ylsulfanyl)acetylamino]acetic acid tert-butyl ester, 15d  
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General procedure D: 4,6-diphenyl-2-mercaptonicotinonitrile (0.200 g, 0.68 mmol), tert-butyl 2-(2-
bromoacetamido)acetate (0.262 g, 0.1 mmol), KOH (0.04 g, 0.68 mmol), DMF (20 mL). Yellow solid (0.073 g, 23%); 
mp 70.1˚C; λmax (EtOH/nm) 270, 333; IR υmax/cm-1 2158, 1735, 1652; 1H-NMR (300 MHz, CDCl3) δ ppm 1.51 (9H, s, 
(CH3)3), 3.99 (2H, d, CH2), 4.10 (2H, s, CH2), 7.10-7.65 (9H, m, H-Ar and CH-pyridine), 7.98 (2H, m, H-Ar); 13C-NMR (75 
MHz, CDCl3) δ ppm 28.4, 42.7, 117.1, 127.9, 128.7, 129.4, 130.5, 131.1, 132.5, 60.1, 83.7, 148.5, 159.0, 167.6, 183.3, 
189.0, 189.6, 192.6; MS: (ES+) m/z =  460.2 [M+H]+. 
{2-[3-Cyano-6-(4-methoxyphenyl)-4-phenylpyridin-2-ylsulfanyl]acetylamino}acetic acid tert-butyl ester, 15i  
General procedure D: 6-(4-methoxyphenyl)-2-mercapto-4-phenylnicotinonitrile 14i (0.100 g, 0.31 mmol), tert-butyl 
2-(2-bromoacetamido)acetate (0.118 g, 0.47 mmol), KOH (0.034 g, 0.6 mmol), DMF (20 mL). Yellow solid (0.154 g, 
61%); 1H-NMR (300 MHz, CDCl3) δ ppm 1.39 (9H, s, (CH3)3), 3.89 (3H, s, CH3), 3.90 (2H, m, CH2), 4.08 (2H, s, CH2), 7.02 
(2H, d, J = 8.7 Hz, H-Ar), 7.27 (4H, m, NH and H-Ar), 7.52 (1H, s, CH-pyridine), 7.62 (2H, m, H-Ar), 8.04 (2H, d, J = 8.7 
Hz, H-Ar). 
[2-(3-Cyano-6-methyl-4-phenylpyridin-2-ylsulfanyl)acetylamino]acetic acid tert-butyl ester, 15j 
General procedure D: 6-phenyl-2-mercapto-4-methylnicotinonitrile (0.100 g, 0.44 mmol), tert-butyl 2-(2-
bromoacetamido)acetate (0.167 g, 0.66 mmol), KOH (0.024 g, 0.43 mmol), DMF (5 mL). Yellow solid (0.143 g, 82%); 
m.p. 126.1˚C; λmax (EtOH/nm) 262; IR υmax/cm-1 3297, 2218, 1731, 1682; 1H-NMR (300 MHz, DMSO-d6) δ ppm 1.40 
(9H, s, (CH3)3), 3.76 (2H, d, J = 0.6 Hz, CH2NH), 4.07 (2H, s, CH2), 7.29 (1H, m, H-Ar), 7.58 (5H, m, H-Ar), 8.51 (1H, br s, 
NH); 13C-NMR (75 MHz, DMSO-d6) δ ppm 24.7, 28.1, 33.9, 42.3, 120.0, 128.7, 129.2, 130.3; MS (ES+) m/z =  398.1 
[M+H]+. 
 [2-(3-Cyano-4,6-dimethylpyridin-2-ylsulfanyl)acetylamino]acetic acid tert-butyl ester, 15k 
General procedure D: 4,6-dimethyl-2-mercaptonicotinonitrile (0.100 g, 0.6 mmol), tert-butyl 2-(2-
bromoacetamido)acetate (0.226 g, 9.1 mmol), KOH (0.034 g, 0.6 mmol), DMF (20 mL). Yellow solid (0.122 g, 61%); 
m.p. 132.4˚C; λmax (EtOH/nm) 221, 266, 302; IR υmax/cm-1 2218, 1737, 1652;1H-NMR (300 MHz, CDCl3) δ ppm 1.44 (9H, 
s, (CH3)3), 2.48 (3H, s, CH3), 2.59 (3H, s, CH3), 3.92 (4H, s, CH2), 6.89 (1H, s, CH-pyridine), 7.55 (1H, s, NH); 13C-NMR (75 
MHz, CDCl3) δ ppm 20.4, 24.8, 28.4, 33.8, 42.9, 121.1, 82.5, 100.0, 105.8, 114.7, 152.8, 162.2, 168.9, 168.9; MS (ES+) 
m/z =  336.1 [M+H]+; Anal. Calcd for C16H21N3O3S: C, 57.29; H, 6.31; N, 12.53. Found.C, 57.48; H, 6.08; N, 11.99. 
2-Bromo-N-(2-oxopropyl)acetamide, 30 
A mixture of glycine (10.0 g, 0.13 mol), pyridine (65 mL, 0.80 mol) and acetic anhydride (143 mL, 1.52 mol) was 
refluxed 6 h, then allowed to cool and poured onto ice/water (500 mL). The mixture was extracted with DCM (3 x 
100 mL). The organic extracts were washed with water (3 x 100 mL), dried (MgSO4), and concentrated in vacuo giving 
acetamidoacetone (4.22 g, 56%) which was used without further purification. 
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A mixture of conc. hydrochloric acid (6 mL), water (6 mL) and acetamidoacetone (2 g, 17.4 mmol) and the mixture 
was refluxed under N2 for 6 h, then concentrated in vacuo giving 1-aminopropan-2-one hydrochloride 29 (1.3 g, 68%) 
which was used without further purification.  
To a solution of 1-aminopropan-2-one hydrochloride (1.0 g, 9.0 mmol) in DCM (20 ml), was added CaCO3 (5.0 eq) and 
bromoacetyl chloride (2.0 eq). The resulting mixture was refluxed 12 h, then allowed to cool and diluted with water, 
and filtered. Recrystallization (ex THF) gave 30 (0.71 g, 53%); m.p. 77.0˚C; IR υmax/cm-1 3074, 1724, 1643; 1H-NMR 
(300 MHz, CDCl3) δ ppm 2.23 (3H, s, CH3), 3.90 (2H, s, CH2), 4.17 (2H, d, CH2N), 7.19 (1H, br s, NH). 
1-(2-Bromoacetyl)pyrrolidine-2-carboxylic acid methyl ester (18) 
A solution of proline methyl ester (5.0 g, 30 mmol) in water (20 mL) was added to a stirred suspension of CaCO3 in 
CHCl3 at 0 oC, followed by dropwise addition of 2-bromoacetylchloride (9.5 g, 60 mmol) in CHCl3 and stirring 
continued 16 h, then filtered. The filtrate washed with HCl (1M, 20 mL), sodium carbonate (sat., 20 mL) and water 
(20 mL), then dried (MgSO4) and concentrated in vacuo. Recrystallisation (ether) gave 18 (6.62 g, 77 %); 1H-NMR (300 
MHz, CDCl3) δ ppm 1.94 (3H, m), 2.14 (2H, m), 3.62 (4H, m), 3.76 (2H, m), 4.37 (1H, m). 
General procedure E7 
A mixture of the corresponding aldehyde (1.2 eq), ketone (1.0 eq), and KOH (2.4 eq) in absolute ethanol (10 ml) was 
stirred at rt for 4 h, then water was added. The precipitate was collected by filtration and recrystallized (ethanol). 
(E)-3-(4-Fluorophenyl)-1-phenylprop-2-en-1-one (13a) 
General procedure E: acetophenone (0.97 mL, 8.32 mmol), 4-fluorobenzaldehyde (1.07 mL, 9.98 mmol), KOH (1.11 g, 
21 mmol). Yellow solid (1.41 g, 75%); m.p. 87 ˚C (lit.8 52 oC) ; λmax (EtOH/nm) 309; IR υmax/cm-1 1656; 1H-NMR (500 
MHz, CDCl3) δ ppm; 7.14 (2H, dd, J = 6.6 and 8.5 Hz, H-Ar), 7.48-7.55 (3H, m, H-Ar), 7.62 (1H, ddd, J = 1.2, 1.5 and 7.4 
Hz, H-Ar), 7.66 (2H, dd, J = 5.4 and 8.6 Hz, H-Ar), 7.80 (1H, d, J = 15.8 Hz, COCH), 8.03-8.05 (2H, m, H-Ar); 13C NMR 
(125 MHz, CDCl3) δ ppm; 116.2 (d, JCF = 22.0 Hz), 121.8 (d, JCF = 2.2 Hz), 128.5, 128.7, 130.4 (d, JCF = 8.6 Hz), 131.2 (d, 
JCF = 3.1 Hz), 132.9, 138.2, 143.5, 164.1 (d, JCF = 251.3 Hz), 190.3; MS: (ES+) m/z = 227.1 [M+H]+. 
(E)-3-(3-Fluorophenyl)-1-phenylprop-2-en-1-one (13b)  
General procedure E: acetophenone (1.03 g, 8.60 mmol), 3-fluorobenzaldehyde (1.07 mL, 10.20 mmol), NaOH (0.82 
g, 20.60 mmol). Yellow crystals (1.24 g, 64%); m.p. 86-88 ˚C (lit.9 87-89 oC EtOH); λmax (EtOH/nm) 297, 379; IR 
υmax/cm-1 1661, 1594, 1578, 1481, 1444, 1338, 1313, 1267; 1H-NMR (500 MHz, CDCl3) δ ppm; 7.06 (1H, dddd, J = 1.0, 
8.3, 9.3 and 10.8 Hz, H-2), 7.13 (1H, ddd, J = 0.9, 7.6 and 8.4 Hz, H-5), 7.29-7.34 (1H, m, H-4), 7.42-7.45 (2H, m, H-3’ 
and H-5’), 7.52 (1H, ddd, J = 1.3, 2.0 and 7.3 Hz, H-4’), 7.56-7.59 (2H, m, COCHCH and H-6), 7.83 (1H, d, J = 16.0 Hz, 
COCH), 7.95-7.97 (2H, m, H-2’ and H-6’); 13C NMR (125 MHz, CDCl3) δ ppm; 116.3 (d, JCF = 22.2 Hz), 123.0 (d, JCF = 11.3 
Hz), 124.5 (d, JCF = 3.4 Hz), 124.6 (d, JCF = 7.3 Hz), 128.6, 128.7, 129.8 (d, JCF = 2.9 Hz), 131.8 (d, JCF = 8.8 Hz), 132.9, 
137.5, 138.0, 161.0 (d, JCF = 253.1 Hz), 190.5; MS (ES+) m/z = 227.03 [M+H]+.  
44 
 
(E)-3-(2-Fluorophenyl)-1-phenylprop-2-en-1-one (13c) 
General procedure E: acetophenone (1.03 g, 8.60 mmol), 2-fluorobenzaldehyde (1.07 mL, 10.20 mmol), NaOH (0.82 
g, 20.60 mmol). Yellow crystals (1.08 g, 56%); m.p. 49-51 ˚C (lit 47-48 oC EtOH); λmax (EtOH/nm) 302, 345; IR υmax/cm-1 
1659, 1603, 1572, 1482, 1447, 1335, 1317, 1280; 1H-NMR (500 MHz, CDCl3) δ ppm; 7.11-7.14 (1H, m, H-Ar), 7.35-7.42 
(3H, m, H-Ar), 7.51-7.55 (3H, m, CH and H-Ar), 7.61 (1H, dd, J = 7.6 and 7.5 Hz, H-Ar), 7.77 (1H, d, J = 15.8 Hz, COCH), 
8.02-8.04 (2H, m, H-Ar); MS (ES+) m/z = 227.04 [M+H]+. 
(E)-3-(2,4-Difluorophenyl)-1-phenylprop-2-en-1-one (13f) 
General procedure E: acetophenone (0.82 mL, 7.0 mmol), 2,4-difluorobenzaldehyde (1.3 mL, 7.0 mmol), NaOH (350 
mg, 8.80 mmol). Yellow crystals (1.40 g, 80%); m.p. 59-61 ˚C; λmax (EtOH/nm) 311; IR υmax/cm-1 1659, 1604, 1589, 
1497; 1H NMR (500 MHz, CDCl3) δ ppm 7.25 (1H, ddd, J = 2.5, 8.5 and 10.9 Hz, H-3), 7.41 (1H, ddd, J = 2.5, 9.3 and 
11.5 Hz, H-5), 7.58-7.61 (2H, m, H-3’ and H-5’), 7.70 (1H, ddd, J = 1.2, 1.3 and 7.4 Hz, H-4’), 7.78 (1H, d, J = 15.8 Hz, 
COCHCH), 7.98 (1H, d, J = 15.8 Hz, COCH), 8.15-8.17 (2H, m, H-2’ and H-6’), 8.24 (1H, ddd, J = 6.8, 8.9 and 15.5 Hz, H-
6); 13C NMR (125 MHz, DMSO-d6) δ ppm 104.6 (dd, JCF = 26.2 and 26.3 Hz), 112.6 (dd, JCF = 3.5 and 21.7 Hz), 119.2 
(dd, JCF = 3.8 and 11.6 Hz), 123.8 (dd, JCF = 2.3 and 3.7 Hz), 128.6, 128.8, 130.7 (dd, JCF = 3.8 and 10.0 Hz), 133.4, 134.2 
(dd, JCF = 1.4 and 3.7 Hz), 137.2, 161.1 (dd, JCF = 12.5 and 254.5 Hz), 163.1 (dd, JCF = 13.1 and 252.1 Hz), 188.9; MS 
(ES+) m/z = 245.2 [M+H]+; HRMS calcd for C15H10F2O [M+H]+ 245.0772, found 245.0771. 
(E)-1-Phenyl-3-(pyridin-4-yl)prop-2-en-1-one (13g)10 
A mixture of 4-pyridine carboxaldehyde (0.56 g, 5.20 mmol) and (benzoylmethylene) triphenylphosphorane (1.97 g, 
5.20 mmol) in anh. toluene (10 mL) was refluxed for 3.5 h, then allowed to cool and concentrated in vacuo. The 
residue was triturated with petrol until a solid formed, then filtered, washing with 1M HCl (25 mL). The filtrate was 
neutralised with 2.5M NaOH. The resulting precipitate was filtered and dried in vacuo giving 13g as a yellow solid 
(0.85 g, 78%). m.p. 75-77 ˚C (lit. 73-74.5 oC);  λmax (EtOH/nm) 282; IR υmax/cm-1 3058, 3034, 1659, 1593, 1578, 1480, 
1445, 1427; 1H-NMR (300 MHz, CDCl3) δ ppm; 7.41-7.7.56 (5H, m, H-Ar, COCHCH and COCH), 7.63 (2H, d, J = 1.8 Hz, 
H-Ar), 7.95-7.98 (2H, m, H-Ar), 8.64 (2H, d,  J = 4.5 Hz, N-CH-pyridine); MS (ES+) m/z = 210.0 [M+H]+. 
4-(4-Fluorophenyl)-2-mercapto-6-phenylnicotinonitrile (14a)11 
A mixture of (E)-3-(4-fluorophenyl)-1-phenylprop-2-en-1-one (13a) (2.0 g, 8.85 mmol), malononitrile (0.595 g, 8.85 
mmol), sulfur (0.34 g, 10.6 mmol) and morpholine (1.0 mL, 11.5 mmol) in ethanol (25 ml)  was heated to reflux with 
stirring for 2 h, then cooled to 20 oC, acidified with hydrochloric acid, and filtered. Chromatography (silica; 50% ethyl 
acetate, petrol) gave 14a as a yellow solid (0.353g, 68%); m.p. 222.6˚C; λmax (EtOH/nm) 271, 330; IR υmax/cm-1  3066, 
2214; 1H-NMR (300 MHz, CDCl3) δ ppm 7.10-7.23 (3H, m, NH and H-Ar), 7.23-7.37 (3H, m, H-Ar), 7.46-7.59  (3H, m, 
CH-pyridine and H-Ar), 7.83-7.94 (2H, d, J = 6.3 Hz, H-Ar); 13C-NMR (75 MHz, CDCl3) δ ppm 104.5, 115.4; 116.5, 116.8, 
117.8, 127.8, 130.8, 131.2, 132.4, 132.5 134.6; 137.2, 154.2, 159.6; 161.3, 162.8, 166.1; MS (ES+) m/z = 306 [M+H]+; 
Anal. Calcd for C18H10FN2S: C, 70.57; H, 3.62; N, 9.14. Found.C, 70.71; H, 3.58; N, 9.45; HPLC assay system: 87.5% 
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General procedure F11 
A mixture of the required chalcone (1.0 eq.), malononitrile (1.0 eq.), sulfur (1.2 eq.) and morpholine (1.3 eq.) in 
ethanol (25 ml)  was heated to reflux with stirring for 2 h, then cooled to 20 oC, acidified with hydrochloric acid, and 
filtered. The precipitate was purified by chromatography (silica; 50% ethyl acetate, petrol). 
4,6-Diphenyl-2-thioxo-1,2-dihydropyridine-3-carbonitrile, 14d  
General procedure F: (E)-3-phenyl-1-phenylprop-2-en-1-one, 13d (5.0 g, 24 mmol), malononitrile (1.58 g, 24 mmol), 
sulfur (1.0 g, 28.8 mmol) and morpholine (2.7 mL, 31 mmol). Yellow solid (3.52 g, 50%); m.p. 192.4˚C; λmax (EtOH/nm) 
206, 269; IR υmax/cm-1 2215 (CN); 1H-NMR (300 MHz, CDCl3) δ ppm 7.28 (1H, s, NH), 7.41 (3H, m, H-Ar), 7.59 (3H, m, 
H-Ar), 7.66 (3H, m, CH-pyridine, H-Ar), 7.99 (2H, m, H-Ar); 13C-NMR (75 MHz, CDCl3) δ ppm 115.5, 127.8, 128.9, 
129.2, 129.4, 130.5, 131.1, 137.3, 155.3; MS (ES+) m/z =  289.1 [M+H]+; HPLC 88.5%; Anal. Calcd for C18H12N2S: C, 
74.97; H, 4.19; N, 9.71. Found.C, 74.87; H, 4.01; N, 9.57. 
6-(4-Methoxyphenyl)-4-phenyl-2-thioxo-1,2-dihydropyridine-3-carbonitrile, 14i 
General procedure F: (E)-3-phenyl-1-(4-methoxyphenyl)prop-2-en-1-one, 13i  (2.0 g, 8.4 mmol), malononitrile (0.56 
g, 8.4 mmol), sulfur (0.321 g, 10 mmol) and morpholine (0.95 g, 10.9 mmol). Yellow solid (1.47 g, 55%);  λmax 
(EtOH/nm) 303; IR υmax/cm-1 2214 (CN); 1H-NMR (300 MHz, CDCl3) δ ppm 3.83 (3H, s, CH3), 6.90 (2H, m, H-Ar), 7.28 
(2H, m, H-Ar), 7.53 (1H, s, CH-pyridine), 7.62 (3H, m, H-Ar), 7.98 (2H, m, H-Ar).  
2-[3-Cyano-4-(4-fluorophenyl)-6-phenylpyridin-2-ylsulfanyl]acetamide, 20 
To a suspension of 14a (1.0 eq) and sodium acetate trihydrate (1.1 eq) in ethanol (10 ml) was added 
chloroacetamide (1.0 eq). The resulting mixture was heated under reflux for 24 hours. A precipitate formed upon 
cooling which was collected and recrystallised from ethanol to give 20 as pale yellow needles (119 mg, 71%). m.p. 
236.2˚C; λmax (EtOH/nm) 230, 270 and 342; IR υmax/cm-1 1635 (CO), 2210 (CN), 3162 and 3360 (NH); 1H-NMR (300 
MHz, CDCl3) δ ppm 4.06 (2H, s,  CH2), 7.28 (4H, m, Hd, Hd’ and NH2), 7.54 (3H, m, Hb, Hb’ and He), 7.62 (3H, m, CH-
pyridine, Hc and Hc’), 8.10 (2H, d,  J = 7.9 Hz, Ha, Ha’); 13C-NMR (75 MHz, CDCl3) δ ppm 34.4, 116.1, 116.4, 128.2, 
129.2, 131.1, 131.4, 131.5,  153.2, 158.6, 160.0, 162.7, 169.1; MS (ES+) m/z =  364.1 [M+H]+; Anal. Calcd for 
C20H14FN3OS: C, 66.10; H, 3.88; N, 11.56. Found.C, 66.08; H, 3.86; N, 11.54.  
General procedure G: 6 
To a mixture of the required 2-thioxo-1,2-dihydropyridine-3-carbonitrile (1.0 eq) and K2CO3 (1.2 eq) in THF was 
added the required α-halo-compound (1.0 eq). The reaction mixture was heated under reflux for 24 h, allowed to 
cool and diluted with water. The precipitate was collected by filtration and either recrystallization (THF) or 
chromatography (silica; 20-100% EtOAc, petrol) gave the desired 2-pyridyl sulfide. 
2-(2-(3-Cyano-4-(4-fluorophenyl)-6-phenylpyridin-2-ylthio)acetamido)acetic acid (4a)  
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15a (91 mg, 0.19 mmol), was dissolved in TFA (29 μL, 0.38 mmol) and the resulting mixture was stirred at room 
temperature for 30 minutes, then concentrated in vacuo and washed (petrol) to give 4a as a white solid (80 mg, 
99%). Rf = 0.37 (EtOH); m.p. 169-172 ˚C; λmax (EtOH/nm) 270, 342; IR υmax/cm-1 3260, 2215, 1730, 1622; 1H-NMR 
(300 MHz, DMSO-d6) δ ppm 3.80 (2H, d, J = 5.4 Hz, NH-CH2), 4.21 (2H, s, S-CH2),7.43-7.54 (4H, m, H-Ar), 7.82-7.87 
(2H, m, H-Ar), 7.94 (1H, s, CH-pyridine), 8.28-8.30 (2H, m, H-Ar), 8.64 (1H, t, J = 5.4 Hz, NH), 12.62 (1H, s, COOH); MS 
(ES+) m/z = 422.2 [M+H]+; HRMS calcd for C22H16FN3O3S [M+H]+ 422.0976, found 422.0969. 
tert-Butyl 2-(2-(3-cyano-4-(4-fluorophenyl)-6-phenylpyridin-2-ylthio)acetamido)acetate (15a) 
A 1.6M solution of NaOMe was prepared by slowly dissolving sodium metal in MeOH at rt. To 13a (88 mg, 0.39 
mmol),  and 2-cyanothioacetamide (39 mg, 0.39 mmol) was added sodium methoxide (1.6M in MeOH, 0.60 mL, 0.94 
mmol), The resulting solution was heated at 80 oC for 1.5 h, then allowed to cool to rt and concentrated in vacuo. 
The crude material was redissolved in DMF (1 mL/mmol) and tert-butyl 2-(2-bromoacetamido)acetate (149 mg, 0.59 
mmol) was added. The solution was heated at 100 oC for 3-4 h, then cooled, diluted with H2O (20 mL) and extracted 
with EtOAc (3 x 100 mL). Combined organic layers were washed with H2O (3 x 100 mL) and brine (50 mL), dried 
(Na2SO4) and concentrated in vacuo. Chromatography (silica; 0-50% EtOAc/petrol) gave 15a as a white solid (71 mg, 
38%). m.p. 172-174 ˚C; λmax (EtOH/nm) 270, 342; IR υmax/cm-1 3279, 2977, 2214, 1740, 1657; 1H-NMR (500 MHz, 
DMSO) δ ppm 1.39 (9H, s, CH3), 3.77 (2H, d, J = 5.9 Hz, CH2-NH), 4.21 (2H, s, S-CH2), 7.47 (1H, dd, J = 8.3 and 9.1 Hz, 
H-3’ and H-5’), 7.54-7.55 (3H, m, H-2’, H-6’ and H-4’), 7.84 (2H, dd, J = 5.5 and 8.8 Hz, H-3 and H-5), 7.95 (1H, s, CH-
pyridine), 8.29-8.31 (2H, m, H-2 and H-5), 8.65 (1H, t, J = 5.9 Hz, NH); MS (ES+) m/z = 478.2 [M+H]+; HRMS calcd for 
C26H24FN3O3S [M+H]+ 478.1595, found 478.1602. 
tert-Butyl 2-(2-((3-cyano-4,6-dimethylpyridin-2-yl)thio)acetamido)acetate (15k) 
General Procedure G: 2-mercapto-4,6-dimethylnicotinonitrile (110 mg, 0.69 mmol), tert-butyl 2-(2-
bromoacetamido)acetate (210 mg, 0.83 mmol), KOH (39 mg, 0.69 mmol) and DMF (2 mL/mmol). White solid (120 
mg, 52%); m.p. 132-134 ˚C; λmax (EtOH/nm) 266.0, 302.0; IR υmax/cm-1 2218, 1737, 1652; 1H NMR (500 MHz, CDCl3) δ 
ppm 1.44 (9H, s, CH3), 2.47 (3H, s, CH3), 2.59 (3H, s, CH3), 3.92-3.93 (4H, m, NH-CH2 and S-CH2), 6.89 (1H, s, CH-
pyridine), 7.56 (1H, br s, NH); 13C NMR (125 MHz, CDCl3) δ ppm 20.4, 24.8, 28.4, 33.8, 42.9, 82.0, 105.8, 114.7, 121.1, 
152.8, 162.2, 168.9, 168.9; MS (ES+) m/z = 336.1 [M+H]+; HRMS calcd for C16H21N3O3S [M+H]+ 336.1376, found 
336.1377. 
{2-[3-Cyano-4-(4-fluorophenyl)-6-phenylpyridin-2-ylsulfanyl]acetylamino}acetic acid ethyl ester (15l)  
General procedure G: 4-(4-fluorophenyl)-2-mercapto-6-phenylnicotinonitrile 14a (0.30 g, 0.98 mmol), (2-
bromoacetylamino)acetic acid ethyl ester (0.218g, 0.98 mmol), K2CO3 (0.16 g, 1.2 mmol), THF (20 mL), 
chromatography. Yellow solid (0.251 g, 57%). m.p. 171.8˚C; λmax (EtOH/nm) 270, 341; IR υmax/cm-1 3259, 2214, 1743, 
1665; 1H-NMR (300 MHz, CDCl3) δ ppm 1.20 (3H, t,  J = 7.2 Hz, CH3,), 4.00 (2H, d, J = 5.1 Hz, CH2NH), 3.96-4.06 (4H, m, 
CH2), 7.20-7.52 (3H, m, NH and H-Ar), 7.46-7.52 (3H, m, H-Ar), 7.59-7.68 (3H, m, CH-pyridine and H-Ar), 8.08-8.11 
(2H, m, H-Ar); 13C-NMR (75 MHz, CDCl3) δ ppm 14.3, 34.3, 42.1, 61.6, 116.5, 116.8, 116.9, 127.8, 129.5, 130.7, 131.2, 
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129.3, 154.2, 159.7, 162.2, 166.1, 168.2, 169.5; MS (ES+) m/z =  450.1 [M+H]+; Anal. Calcd for C24H20FN3O3S, C, 64.13; 
H, 4.48; N, 9.35. Found.C, 63.89; H, 4.49; N, 9.48. 
1-{2-[3-Cyano-4-(4-fluorophenyl)-6-phenylpyridin-2-ylsulfanyl]acetyl}pyrrolidine-2-carboxylic acid methyl ester 
(19) 
General procedure G: 4-(4-fluorophenyl)-2-mercapto-6-phenylnicotinonitrile 14a (0.30 g, 0.98 mmol), 1-(2-
bromoacetyl)pyrrolidine-2-carboxylic acid methyl ester, 18 (0.281 g, 0.98 mmol), K2CO3 (0.16 g, 1.2 mmol), THF (20 
mL), chromatography. Yellow solid (0.256 g, 55%). m.p. 212.7˚C; λmax (EtOH/nm) 270, 342; IR υmax/cm-1 2922, 2212, 
1734, 1645; 1H-NMR (300 MHz, CDCl3) δ ppm 2.00-2.22 (4H, m, 2 x CH2), 3.67 (3H, s, CH3O), 3.71-3.84 (2H, m, CH2), 
4.19-4.28 (2H, m, CH2), 4.46-4.58 (1H, m, CH), 7.14-7.25 (2H, m, H-Ar), 7.41-7.57 (4H, m, H-Ar and CH-pyridine), 7.57-
7.66 (2H, m, H-Ar), 7.91-8.02 (2H, m, H-Ar); 13C-NMR (75 MHz, CDCl3) δ ppm 25.3, 29.5, 34.3, 47.7, 52.4, 59.8, 116.4, 
116.7, 138.0, 129.2, 130.7, 130.8, 154.0, 172.4; MS (ES+) m/z =  476.1 [M+H]+; Anal. Calcd for C26H22FN3O3S: C, 65.67; 
H, 4.66; N, 8.84. Found.C, 65.68; H, 4.55; N, 8.65.  
[3-Cyano-4-(4-fluorophenyl)-6-phenylpyridin-2-ylsulfanyl]acetic acid methyl ester (21)  
General procedure G:  4-(4-fluorophenyl)-6-phenyl-2-thioxo-1,2-dihydropyridine-3-carbonitrile (0.500 g, 1.6 mmol), 
methyl 2-bromoacetate (0.24 mL, 2.4 mmol), K2CO3 (0.45 g, 0.32 mmol), DMF (40 mL). Yellow solid (0.34 g, 55%). 
m.p. 185.5˚C; λmax (EtOH/nm) 269 and 339; IR υmax/cm-1 1731 (CO), 2212 (CN);  1H-NMR (300 MHz, CDCl3) δ ppm 3.77 
(3H, s, CH3),  4.14 (2H, s, CH2),  7.25 (2H, m, Hd and Hd’), 7.52 (3H, m, Hb, Hb’ and He), 7.63 (3H, m, CH-pyridine, Hc 
and Hc’), 8.08 (2H, m, Ha, Ha’); 13C-NMR (75 MHz, CDCl3) δ ppm 33.1, 52.8, 104.2, 115.4, 116.4, 116.7, 127.8, 129.3, 
130.7, 130.8, 131.1, 132.6, 137.5; MS (ES+) m/z =  379.1 [M+H]+; Anal. Calcd for C21H15FN2O2S: C, 66.65; H, 4.00; N, 
7.40. Found.C, 66.92; H, 3.79; N, 7.42 
 2-[3-Cyano-4-(4-fluorophenyl)-6-phenylpyridin-2-ylsulfanyl]-N-(2-oxopropyl)acetamide (31) 
General procedure G: 14a (0.30 g, 0.98 mmol), 2-bromo-N-(2-oxopropyl)acetamide 30 (0.19 g, 0.98 mmol), K2CO3 
(0.16 g, 1.2 mmol), THF (10 mL), chromatography. Yellow solid (0.137 g, 31%); m.p. 232.1˚C; λmax (EtOH/nm) 270, 
338; IR υmax/cm-1 3280, 2920, 2216, 1732, 1658; 1H-NMR (300 MHz, CDCl3) δ ppm 1.58 (3H, s, CH3), 2.12 (2H, s, CH2), 
4.12 (2H, s, CH2), 7.28 (2H, d, J = 7.9 Hz, H-Ar), 7.30 (1H, br s, NH), 7.21-7.41 (3H, m, H-Ar), 7.50-7.70 (3H, m, CH-
pyridine and H-Ar), 8.05-8.14 (2H, m, H-Ar); 13C-NMR (75 MHz, CDCl3) δ ppm 30.0, 34.3, 50.3, 116.5, 116.8, 116.9, 
127.8, 129.4, 130.7, 130.9, 131.2, 159.6, 168.2; MS (ES+) m/z = 420.1176 [M+H]+; Anal. Calcd for C23H18FN3O2S: C, 
65.86; H, 4.33; N, 10.02. Found.C, 65.84; H, 4.31; N, 10.01. 
General procedure H 
The pyridine t-butyl ester (1.0 eq) was dissolved in trifluoroacetic acid (5 ml). The resulting mixture was stirred at RT 
for 30 minutes. The solvent was removed and the residue was treated with ethyl acetate. The precipitate was 
collected and washed several times with petroleum ether to give the product. 
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2-(2-(3-Cyano-4-(4-fluorophenyl)-6-phenylpyridin-2-ylthio)acetamido)acetic acid (4a)  
General procedure H: 15a (91 mg, 0.19 mmol), was dissolved in TFA (29 μL, 0.38 mmol) gave 4a as a white solid (80 
mg, 99%). Rf = 0.37 (EtOH); m.p. 169-172 ˚C; λmax (EtOH/nm) 270, 342; IR υmax/cm-1 3260, 2215, 1730, 1622; 1H-
NMR (300 MHz, DMSO-d6) δ ppm 3.80 (2H, d, J = 5.4 Hz, NH-CH2), 4.21 (2H, s, S-CH2),7.43-7.54 (4H, m, H-Ar), 7.82-
7.87 (2H, m, H-Ar), 7.94 (1H, s, CH-pyridine), 8.28-8.30 (2H, m, H-Ar), 8.64 (1H, t, J = 5.4 Hz, NH), 12.62 (1H, s, COOH); 
MS (ES+) m/z = 422.2 [M+H]+; HRMS calcd for C22H16FN3O3S [M+H]+ 422.0976, found 422.0969. 
2-(2-(3-Cyano-4-(3-fluorophenyl)-6-phenylpyridin-2-ylthio)acetamido)acetic acid (4b) 
General procedure H: tert-butyl 2-(2-(3-cyano-4-(3-fluorophenyl)-6-phenylpyridin-2-ylthio)acetamido)acetate 15b 
(35 mg, 0.067 mmol), TFA (11 µL, 0.14 mmol). White solid (28 mg, 100%); m.p. 221-224 ˚C; λmax (EtOH/nm) 279.0, 
348.5; IR υmax/cm-1 3241, 2217, 2174, 1735, 1624, 1574, 1525; 1H-NMR (500 MHz, DMSO-d6) δ ppm 3.82 (2H, d,  J = 
5.7 Hz, NH-CH2), 4.22 (2H, s, S-CH2), 7.44-7.48 (1H, m, H-Ar), 7.54-7.58 (3H, m, H-Ar), 7.61-7.71 (3H, m,  H-Ar), 7.99 
(1H, s, CH-pyridine), 8.31-8.33 (2H, m, H-Ar), 8.68 (1H, t, J = 5.7 Hz, NH), 12.67 (1H, s, COOH); MS (ES+) m/z = 422.2 
[M+H]+, 420.1 [M-H]-; HRMS calcd for C22H16FN3O3S [M+H]+ 422.0967, found 422.0967. 
2-(2-((3-Cyano-4-(2-fluorophenyl)-6-phenylpyridin-2-yl)thio)acetamido)acetic acid (4c) 
General procedure H: tert-butyl 2-(2-(3-cyano-4-(2-fluorophenyl)-6-phenylpyridin-2-ylthio)acetamido)acetate 15c 
(18 mg,  0.038 mmol), TFA (6 µL,  0.076 mmol). White solid (16 mg, 99%); m.p. 200-202 ˚C; λmax (EtOH/nm) 340.0, 
270.5; IR υmax/cm-1 2220,1719, 1653, 1573, 1526; 1H-NMR (500 MHz, DMSO-d6) δ ppm 3.82 (2H, d, J = 5.7 Hz, NH-
CH2), 4.23 (2H, s, S-CH2), 7.44-7.51 (2H, m, H-Ar), 7.52-7.55 (3H, m, H-Ar and H-4’), 7.64-7.71 (2H, m, H-Ar), 8.00 (1H, 
s, CH-pyridine), 8.28-8.30 (2H, m, H-Ar), 8.67 (1H, t, J = 5.7 Hz, NH), 12.67 (1H, s, COOH); MS (ES+) m/z = 422.2 
[M+H]+, 420.1 [M-H]-; HRMS calcd for C22H16FN3O3S [M+H]+ 422.0967, found 422.0968. 
[2-(3-Cyano-4,6-diphenylpyridin-2-ylsulfanyl)acetylamino]acetic acid (4d) 
General procedure H: tert-butyl 2-(2-((3-cyano-4,6-diphenylpyridin-2-yl)thio)acetamido)acetate, 15d (0.200 g, 0.44 
mmol), TFA (2 mL). White solid (0.155 g, 88%); m.p. 222.5˚C; λmax (EtOH/nm) 269 and 339; IR υmax/cm-1 1645 (CO), 
1724 (CO), 2214 (CN);  1H-NMR (300 MHz, DMSO-d6) δ ppm 3.80 (2H, d, J = 6.8 Hz, CH2), 4.20 (2H, s, CH2), 7.54 (3H, 
m,  Ha, Ha’ and He’), 7.60 (3H, m, Hd, Hd’ and He), 7.93 (2H, m,  Hb and Hb’), 7.93 (1H, s, CH-pyridine), 8.29 (2H, m, 
Hc and Hc’), 8.64 (1H, t, J = 6.8 Hz, NH), 12.55 (1H, br s, COOH); 13C-NMR (75 MHz, DMSO-d6) δ ppm 34.2, 41.6, 128.1, 
129.2, 130.4, 131.1, 136.2, 137.1 115.9, 116.5, 116.7, 154.7, 158.6, 162.4, 167.6, 171.0; MS (ES+) m/z =  404.1 
[M+H]+; Anal. Calcd for C22H17N3O3S: C, 65.49; H, 4.25; N, 10.42. Found.C, 65.44; H, 3.68; N, 6.23. 
2-(2-((3-Cyano-6-phenyl-4-(4-(trifluoromethyl)phenyl)pyridin-2-yl)thio)acetamido)acetic acid (4e) 
General procedure H: tert-butyl 2-(2-((3-cyano-6-phenyl-4-(4-(trifluoromethyl)phenyl)pyridin-2-
yl)thio)acetamido)acetate 15e (100 mg, 0.19 mmol), TFA (29 µL, 0.38 mmol). White solid (80 mg, 90%); m.p. 243-244 
˚C; λmax (EtOH/nm) 345.0, 268.0; IR υmax/cm-1 3285, 3069, 2214, 1738, 1667; 1H NMR (500 MHz, DMSO-d6) δ ppm 3.82 
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(2H, d, J = 5.7 Hz, NH-CH2), 4.23 (2H, s, S-CH2), 7.54-7.56 (3H, m, H-Ar and H-4’), 7.99-8.01 (5H, m, H-Ar and CH-
pyridine) 8.30-8.32 (2H, m, H-Ar), 8.67 (1H, t, J = 5.7 Hz, NH), COOH not visualised; 13C NMR (125 MHz, DMSO-d6) δ 
ppm 33.8, 41.3, 102.7, 115.4, 116.0, 124.0 (q, JCF = 273.4 Hz), 125.7 (q, JCF = 3.6 Hz), 127.8, 128.9, 129.8, 130.2 (q, JCF 
= 32.2 Hz), 130.9, 136.4, 139.7, 152.7, 158.3, 162.1, 167.1, 171.0; MS (ES+) m/z = 472.2 [M+H]+; HRMS calcd for 
C23H16F3N3O3S [M+H]+ 472.0937, found 472.0932.  
2-(2-((3-Cyano-4-(2,4-difluorophenyl)-6-phenylpyridin-2-yl)thio)acetamido)acetic acid (4f) 
General procedure H: tert-butyl 2-(2-((3-cyano-4-(2,4-difluorophenyl)-6-phenylpyridin-2-yl)thio)acetamido)acetate 
15f (450 mg, 0.91 mmol), TFA (139 µL, 1.82 mmol). White solid (400 mg, 100%); m.p. 226-227 ˚C; λmax (EtOH/nm) 
339.5, 270.5; IR υmax/cm-1 3259, 3079, 2221, 1728, 1619;  1H NMR (500 MHz, DMSO-d6) δ ppm 3.75 (2H, d, J = 5.8 Hz, 
NH-CH2), 4.23 (2H, s, S-CH2), 7.30 (1H, ddd, J = 2.1, 8.4 and 10.6 Hz, H-5), 7.53-7.60 (4H, m, H-Ar, H-4’ and H-3) 7.77 
(1H, ddd, J = 6.6, 8.7 and 15.1 Hz, H-6), 7.99 (1H, s, CH-pyridine), 8.27-8.29 (2H, m, H-Ar), 8.60 (1H, t, J = 5.8 Hz, NH), 
12.62 (1H, s, COOH); 13C NMR (125 MHz, DMSO-d6) δ ppm 33.7, 41.1, 104.1, 104.8 (dd, JCF = 26.8 and 26.9 Hz), 112.4 
(dd, JCF = 3.4 and 21.7 Hz), 115.0, 117.2, 120.1 (dd, JCF = 4.0 and 15.0 Hz)  127.8, 128.9, 131.0, 132.8 (dd, JCF = 3.8 and 
10.3 Hz), 136.3, 148.1, 158.3, 159.1 (dd, JCF = 12.7 and 250.3 Hz), 161.6, 163.4 (dd, JCF = 12.3 and 250.7 Hz), 167.2, 
171.0; MS (ES+) m/z = 440.2 [M+H]+; HRMS calcd for C22H15F2N3O3S [M+H]+ 440.0875, found 440.0874. 
2-(2-((3-Cyano-6-phenyl-[4,4'-bipyridin]-2-yl)thio)acetamido)acetic acid (4g) 
General procedure H: tert-butyl 2-(2-(3-cyano-6-phenyl-4-4’-bipyridin-2-ylthio)acetamido)acetate 15g (80 mg, 0.17 
mmol), TFA (26 µL, 0.34 mmol). White solid (67 mg, 98%); m.p. 268-271 oC; λmax (EtOH/nm) 348.5, 276.5, 249.0; IR 
υmax/cm-1 3267, 2212, 1726, 1665, 1570, 1520; 1H-NMR (500 MHz, DMSO-d6) δ ppm 3.82 (2H, d, J = 5.7 Hz, NH-CH2), 
4.23 (2H, s, S-CH2), 7.54-7.57 (3H, m, H-Ar and H-4’),  7.78 (2H, d, J = 6.1 Hz, CH-pyridine), 8.02 (1H, s, CH-pyridine), 
8.30-8.32 (2H, m, H-Ar), 8.66 (1H, t, J = 5.7 Hz, NH), 8.83 (2H, d J = 6.1 Hz, N-CH-pyridine), 12.64 (1H, s, COOH); 13C 
NMR (125 MHz, DMSO-d6) δ ppm 33.7, 41.1, 102.5, 115.2, 116.0, 123.1, 127.8, 128.9, 131.0, 136.3, 143.1, 150.2, 
151.6, 158.4, 162.2, 167.2, 171.0; MS (ES+) m/z = 405.2 [M+H]+; HRMS calcd for C21H16N4O3S [M+H]+ 405.1016, found 
405.1015. 
{2-[3-Cyano-4-(4-methoxyphenyl)-6-phenylpyridin-2-ylsulfanyl]acetylamino}acetic acid (4h) 
General procedure H: tert-butyl 2-(2-((3-cyano-4-(4-methoxyphenyl)-6-phenylpyridin-2-yl)thio)acetamido)acetate, 
15h (0.200 g, 0.41 mmol), TFA (2 mL). White solid (0.165 g, 93%); m.p. 221.3˚C; λmax (EtOH/nm) 275;  IR υmax/cm-1 
1659 (CO), 1742 (CO), 2214 (CN);  1H-NMR (300 MHz, DMSO-d6) δ ppm 3.80 (2H, d,  J = 6.8 Hz, CH2), 3.85 (3H, s, CH3), 
4.19 (2H, s, CH2), 7.16 (2H, d, J = 9.6 Hz, Ha and Ha’), 7.53 (3H, m, Hd, Hd’ and He), 7.76 (2H, d, J = 9.6 Hz, Hb and 
Hb’), 7.89 (1H, s, CH-pyridine), 8.28 (2H, m,  Hc and Hc’), 8.63 (1H, t, J = 6.8 Hz, NH), 12.55 (1H, br s, COOH); 13C-NMR 
(75 MHz, DMSO-d6) δ ppm 34.2, 41.6, 55.9 114.9, 128.1, 130.6, 131.0, 137.2, 147.6, 103.3 116.0, 116.4, 128.2, 154.3, 
158.4, 161.4, 162.4, 167.7, 171.1; MS (ES+) m/z =  434.1 [M+H]+; Anal. Calcd for C23H19N3O4S: C, 63.73; H, 4.42; N, 
9.69. Found.C, 63.58; H, 4.49; N, 9.61. 
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{2-[3-Cyano-6-(4-methoxy-phenyl)-4-phenyl-pyridin-2-ylsulfanyl]-acetylamino}-acetic acid (4i) 
General procedure G:  14i (0.100 g, 0.31 mmol), tert-butyl 2-(2-bromoacetamido)acetate (0.118 g, 0.47 mmol), KOH 
(0.018 mg, 0.31 mmol), DMF (10 mL). The crude material was used directly in the next step.  
General procedure H: 15i (0.154 g, 0.31 mmol), TFA (2 mL). White solid (0.082 g, 61%); m.p. 224.7˚C; λmax (EtOH/nm) 
272; IR υmax/cm-1 1659 (CO), 1730 (CO), 2214 (CN), 2932 (COOH), 3265 (NH); 1H-NMR (300 MHz, DMSO-d6) δ ppm 
3.84 (2H, d, J = 1.5 Hz, CH2N), 3.85 (3H, s, O-CH3), 4.18 (2H, s, CH2), 7.07 (2H, d, J = 8.7 Hz, Hd and Hd’), 7.59 (3H, m, 
Hb, Hb’ and He), 7.72 (2H, m, Ha and Ha’), 7.85 (1H, s, CH-pyridine), 8.28 (2H, d, J = 8.7 Hz, Hc and Hc’), 8.62 (1H, t, J 
= 1.5 Hz, NH), 12.60 (1H, br s, COOH); 13C-NMR (75 MHz, DMSO-d6) δ ppm 14.4, 55.8, 60.0, 114.8, 128.9, 129.2, 
129.5, 129.9, 130.3, 115.7, 136.3, 154.5, 162.1, 162.2, 167.7, 171.1; MS (ES+) m/z = 434.1 [M+H]+; Anal. Calcd for 
C23H19N3O4S: C, 63.73; H, 4.42; N, 9.69. Found.C, 61.15; H, 4.62; N,6.93. 
 [2-(3-Cyano-6-methyl-4-phenylpyridin-2-ylsulfanyl)acetylamino]acetic acid (4j) 
General procedure G: 6-methyl-4-phenyl-2-thioxo-1,2-dihydropyridine-3-carbonitrile (0.100 g, 0.44 mmol), tert-butyl 
2-(2-bromoacetamido)acetate (0.167 g, 0.66 mmol), KOH (0.024 g, 0.43 mmol), DMF (5 mL). The crude material was 
used directly in the next step.  
General procedure H: 15j (0.100 g, 0.25 mmol), TFA (2 mL). White solid (0.051 g, 60%); m.p. 217.4˚C; λmax (EtOH/nm) 
261; IR υmax/cm-1 1626 (CO), 1715 (CO), 2215 (CN), 3294 (NH); 1H-NMR (300 MHz, DMSO-d6) δ ppm 2.57 (3H, s, CH3), 
3.79 (2H, m, CH2NH), 4.07 (2H, s, CH2), 7.28 (1H, s, CH-pyridine), 7.57 (5H, m,  H-Ar), 8.49 (1H, br s, NH), 12.56 (1H, br 
s, COOH); 13C-NMR (75 MHz, DMSO-d6) δ ppm 23.1, 32.3, 40.0, 114.2, 118.4, 127.1, 127.7, 128.7, 134.4, 152.2, 160.2, 
160.8, 166.2, 169.5; MS (ES+) m/z =  342.1 [M+H]+. 
[2-(3-Cyano-4,6-dimethylpyridin-2-ylsulfanyl)acetylamino]acetic acid (4k) 
General procedure H: tert-butyl 2-(2-((3-cyano-4,6-dimethylpyridin-2-yl)thio)acetamido)acetate 15k (0.050 g, 1.5 
mmol), TFA (10 mL). White solid (0.035 g, 81%); m.p. 219.0˚C; λmax (EtOH/nm) 222, 265 and 304; IR υmax/cm-1 1632 
(CO), 1717 (CO), 2214 (CN); 1H-NMR (300 MHz, DMSO-d6) δ ppm 2.41 (6H, s, CH3), 3.76 (2H, d, J = 4.2Hz, CH2NH), 
4.02 (2H, s, CH2), 7.11 (1H, s, CH-pyridine), 8.45 (1H, t, J = 4.2 Hz, NH), 12.58 (1H, br s, COOH); 13C-NMR (75 MHz, 
DMSO-d6) δ ppm 19.9, 24.5, 33.7, 44.5, 120.9, 115.2, 152.7, 161.8, 167.8, 171.0, 173.6, 193.2; MS (ES+) m/z =  
280.0748 [M+H]+; Anal. Calcd for C12H13N3O3S: C, 51.60; H, 4.69; N, 15.04. Found.C, 47.10; H, 2.83; N, 14.27. 
4-(3-Cyano-4-(4-fluorophenyl)-6-phenylpyridin-2-ylthio)butanoic acid (23a) 
General procedure H: tert-butyl 4-(3-cyano-4-(4-fluorophenyl)-6-phenylpyridin-2-ylthio)butanoate 22a (100 mg, 0.22 
mmol), TFA (34 µL, 0.44 mmol). White solid (64 mg, 72%); m.p. 160-164 ˚C; λmax (EtOH/nm) 272.0, 346.0; IR υmax/cm-1 
2924, 2217, 1711, 1596, 1568, 1525, 1509; 1H-NMR (500 MHz, DMSO-d6) δ ppm 1.95 (2H, quint, J = 7.1 Hz, CH2-CH2-
CH2), 2.38 (2H, t,  J = 7.1 Hz, S-CH2), 3.41 (2H, t, J = 7.1 Hz, CH2-CO), 7.40 (2H, dd, J = 8.8 and 8.9 Hz, H-3 and H-5), 
7.49-7.50 (3H, m, H-Ar), 7.78 (2H, dd, J = 5.4 and 8.8 Hz, H-2 and H-6), 7.89 (1H, s, CH-pyridine), 8.24-8.26 (2H, m, H-
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Ar), 12.12 (1H, s, COOH); MS (ES+) m/z = 393.2 [M+H]+; HRMS calcd for C22H17FN2O2S [M+H]+ 393.1068, found 
393.1069.  
5-(3-Cyano-4-(4-fluorophenyl)-6-phenylpyridin-2-ylthio)pentanoic acid (23b) 
General procedure H: tert-butyl 5-(3-cyano-4-(4-fluorophenyl)-6-phenylpyridin-2-ylthio)pentanoate 22b (120 mg, 
0.26 mmol), TFA (40 µL, 0.52 mmol). White solid (58 mg, 54%); m.p. 205-206 ˚C; λmax (EtOH/nm) 270.0, 345.5; IR 
υmax/cm-1 2898, 2210, 1695; 1H-NMR (500 MHz, DMSO-d6) δ ppm 1.69-1.83 (4H, m, CH2-CH2-CH2-CH2), 2.30 (2H, t, J = 
7.4 Hz, S-CH2), 3.42 (2H, t,  J = 7.0 Hz, CH2-CO), 7.44 (2H, dd, J = 8.7 and 8.8 Hz, H-Ar), 7.55-7.57 (3H, m, H-Ar), 7.84 
(2H, dd, J = 5.5 and 8.8 Hz, H-Ar and H-4’), 7.91 (1H, s, CH-pyridine), 8.27-8.30 (2H, m, H-Ar), 12.05 (1H, s, COOH); 13C 
NMR (125 MHz, DMSO-d6) δ ppm 23.8, 28.3, 29.6, 33.2, 103.1, 115.7, 115.8 (d, JCF = 21.8 Hz), 116.0, 127.5, 129.0, 
130.8, 131.2 (d, JCF = 8.9 Hz), 132.1 (d, JCF = 2.7 Hz), 136.7, 153.2, 157.9, 162.7, 163.2 (d, JCF = 248.3 Hz), 174.3; MS 
(ES+) m/z = 405.2 [M-H]-; HRMS calcd for C23H19FN2O2S [M-H]- 405.41362, found 405.40444. 
General Procedure I 
To the relevant chalcone 13 (1 eq.) and 2-cyanothioacetamide (1 eq.) was added a freshly prepared solution of 
NaOMe (1.6M in MeOH, 2.4 eq.). The resulting solution was heated at 80 oC for 1.5 h, then cooled to RT and 
concentrated in vacuo. The crude material was redissolved in DMF (1 mL/mmol) and the relevant bromoacetamide 
or bromoalkyl (1.5 eq.) was added. The solution was heated at 100 oC for 3-4 h, then cooled and diluted with H2O (20 
mL) and the product extracted into EtOAc (3 x 100 mL). Combined organic layers were washed with H2O (3 x 100 mL 
and brine (50 mL) dried over Na2SO4 and concentrated in vacuo. Chromatography gave the products. 
tert-Butyl 2-(2-(3-cyano-4-(3-fluorophenyl)-6-phenylpyridin-2-ylthio)acetamido)acetate (15b) 
General Procedure I: 13b (88 mg, 0.39 mmol), 8.5% w/v sodium methoxide in MeOH (0.60 mL, 0.94 mmol), 2-
cyanothioacetamide (39 mg, 0.39 mmol) followed by tert-butyl 2-(2-bromoacetamido)acetate (149 mg, 0.59 mmol). 
White solid (86 mg, 46%); m.p. 173-174 ˚C; λmax (EtOH/nm) 270.0, 339.5; IR υmax/cm-1 2980, 2932, 2218, 1724, 1649, 
1570, 1526, 1483, 1437, 1366; 1H-NMR (500 MHz, CDCl3) δ ppm 1.31 (9H, s, CH3), 3.84 (2H, d, J = 5.1 Hz, NH-CH2), 
4.03 (2H, s,  S-CH2), 7.07 (1H, br s, NH), 7.17-7.20 (1H, m, H-Ar), 7.26 (1H, ddd, J = 2.2, 2.3 and 9.1 Hz, H-Ar), 7.36-7.38 
(1H, ddd, J = 1.0, 2.2 and 7.7 Hz, H-Ar), 7.43-7.49 (4H, m, H-Ar), 7.53 (1H, s, CH-pyridine), 7.99-8.01 (2H, m, H-Ar); MS 
(ES+) m/z = 478.1 [M+H]+. 
tert-Butyl 2-(2-(3-cyano-4-(2-fluorophenyl)-6-phenylpyridin-2-ylthio)acetamido)acetate (15c) 
General Procedure I: 13c (54 mg, 0.23 mmol), 8.5% w/v sodium methoxide in MeOH (0.35 mL, 0.55 mmol), 2-
cyanothioacetamide (35 mg, 0.23 mmol) followed by tert-butyl 2-(2-bromoacetamido)acetate (88 mg, 0.35 mmol). 
White solid (22 mg, 20%); m.p. 164-168 ˚C; λmax (EtOH/nm) 270.0, 341.5; IR υmax/cm-1 2972, 2216, 1730, 1653, 1616, 
1573, 1525, 1485; 1H-NMR (500 MHz, CDCl3) δ ppm 1.31 (9H, s, CH3), 3.84 (2H, d, J = 5.1 Hz, NH-CH2), 4.03 (2H, s, S-
CH2), 7.09 (1H, br s, NH), 7.20-7.27 (2H, m, H-Ar), 7.40-7.49 (5H, m, H-Ar), 7.56 (1H, s, CH-pyridine), 7.98-8.00 (2H, m, 
H-Ar); MS (ES+) m/z = 478.1 [M+H]+; HRMS calcd for C26H24FN3O3S [M+H]+ 478.1595, found 478.1590. 
52 
 
tert-Butyl 2-(2-((3-cyano-6-phenyl-4-(4-(trifluoromethyl)phenyl)pyridin-2-yl)thio)acetamido)acetate (15e) 
General Procedure I: 13e (320 mg, 1.14 mmol), 8.5% w/v sodium methoxide in MeOH (1.75 mL, 2.74 mmol), 2-
cyanothioacetamide (170 mg, 1.71 mmol)  and tert-butyl 2-(2-bromoacetamido)acetate (860 mg, 3.42 mmol). White 
solid (170 mg, 28%); m.p. 203-205 ˚C; λmax (EtOH/nm) 269.0, 340.5; IR υmax/cm-1 3294, 2982, 2212, 1743, 1660, 1572, 
1525; 1H NMR (500 MHz, CDCl3) δ ppm 1.30 (9H, s, CH3), 3.83 (2H, d, J = 5.1 Hz, NH-CH2), 4.03 (2H, s, S-CH2), 7.03 (1H, 
t, J = 5.1 Hz, NH), 7.43-7.45 (3H, m, H-Ar), 7.53 (1H, s,  CH-pyridine), 7.67 (2H, d, J = 8.2 Hz, H-Ar), 7.75 (2H, d, J = 8.2 
Hz, H-Ar), 7.98-8.00 (2H, m, H-Ar); 13C-NMR (125 MHz, CDCl3) δ ppm 28.0, 34.0, 42.3, 82.3, 103.9, 114.9, 116.5, 126.2 
(q, JCF = 3.9 Hz), 127.5, 128.9, 129.2, 131.1, 136.5, 139.4, 153.3, 159.5, 162.0, 167.8, 168.4, C-F3, C-CF3 and quaternary 
carbons are not visualised; MS (ES+) m/z = 528.3 [M+H]+; HRMS calcd for C27H24F3N3O3S [M+H]+ 528.1563, found 
528.1560. 
tert-Butyl 2-(2-((3-cyano-4-(2,4-difluorophenyl)-6-phenylpyridin-2-yl)thio)acetamido)acetate (15f) 
General Procedure I: (E)-3-(2,4-difluorophenyl)-1-phenylprop-2-en-1-one 13f (590 mg, 2.43 mmol), 8.5% w/v sodium 
methoxide in MeOH (3.70 mL, 5.83 mmol), 2-cyanothioacetamide (370 mg, 3.65 mmol) and tert-butyl 2-(2-
bromoacetamido)acetate (1.83 g, 7.29 mmol). White solid (490 mg, 41%); m.p. 156-158 ˚C; λmax (EtOH/nm) 274.0, 
328.0, 380.5; IR υmax/cm-1 3326, 2973, 2924, 2218, 1729, 1655, 1618; 1H NMR (500 MHz, CDCl3) δ ppm 1.30 (9H, s, 
CH3), 3.83 (2H, d, J = 5.5 Hz, NH-CH2), 4.02 (2H, s, S-CH2), 6.94-7.02 (2H, m, H-Ar), 7.05 (1H, t, J = 5.5 Hz, NH), 7.40-
7.46 (4H, m, H-5 and H-Ar), 7.51 (1H, d, J = 1.5 Hz, H-Ar,), 7.97-7.98 (2H, m, H-Ar); 13C NMR (125 MHz, CDCl3) δ ppm 
27.9, 33.9, 42.3, 82.3, 105.2 (dd, JCF = 25.4 and 25.5 Hz), 105.3, 112.4 (dd, JCF = 3.9 and 21.8 Hz), 114.7, 117.6 (d, JCF = 
1.9 Hz), 120.0 (dd, JCF = 3.9 and 14.6 Hz), 127.5, 129.2, 131.0, 131.7 (dd, JCF = 3.8 and 10.0 Hz), 136.5, 148.5, 159.3, 
159.7 (dd, JCF = 12.3 and 253.5 Hz), 161.5, 164.2 (dd, JCF = 11.9 and 253.6 Hz), 167.9, 168.4; MS (ES+) m/z = 496.3 
[M+H]+; HRMS calcd for C26H23F2N3O3S [M+H]+ 496.1501, found 496.1498. 
tert-Butyl 2-(2-(3-cyano-6-phenyl-4-4’-bipyridin-2-ylthio)acetamido)acetate (15g) 
General Procedure I: 13g (140 mg, 0.67 mmol), 8.5% w/v sodium methoxide in MeOH (1.0 mL, 1.68 mmol), 2-
cyanothioacetamide (67 mg, 0.67 mmol) followed by tert-butyl 2-(2-bromoacetamido)acetate (0.25 g, 1.01 mmol). 
White solid (114 mg, 39%); m.p. 166-168 ˚C; λmax (EtOH/nm) 221.0, 249.0, 276.5, 347.5; IR υmax/cm-1 2938, 2863, 
2212, 1665; 1H-NMR (500 MHz, CDCl3) δ ppm 1.40 (9H, s, CH3), 3.94 (2H, d, J = 5.2 Hz, NH-CH2), 4.15 (2H, s, S-CH2), 
7.03 (1H, br s, NH), 7.56-7.57 (3H, m, H-Ar), 7.65 (1H, s, CH-pyridine), 7.90 (2H, d, J = 4.6 Hz, H-2 and H-6), 8.10 (2H, 
dd, J = 2.5 and 6.1 Hz, H-Ar), 8.95 (2H, d, J = 4.6 Hz, H-3 and H-5); 13C-NMR (125 MHz, CDCl3) δ ppm 28.0, 34.0, 42.3, 
82.5, 103.2, 114.3, 115.8, 121.2, 124.5, 127.7, 129.4, 131.6, 136.1, 146.7, 150.1 , 160.2, 162.7, 167.4, 168.5; MS (ES+) 
m/z = 461.3 [M+H]+; HRMS calcd for C25H24N4O3S [M+H]+ 461.1642, found 461.1636. 
tert-Butyl 4-(3-cyano-4-(4-fluorophenyl)-6-phenylpyridin-2-ylthio)butanoate (22a) 
General Procedure I: 13a (75 mg, 0.33 mmol), 8.5% w/v sodium methoxide in MeOH (0.50 mL, 0.80 mmol), 2-
cyanothioacetamide (33 mg, 0.33 mmol) followed by tert-butyl bromobutyrate (112 mg, 0.50 mmol). White solid (50 
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mg, 34%); m.p. 104-105 ˚C; λmax (EtOH/nm) 271.0; IR υmax/cm-1 2978, 2930, 2212, 1721, 1603, 1570; 1H-NMR (500 
MHz, CDCl3) δ ppm 1.46 (9H, s, CH3), 2.15 (2H, quint, J = 7.3 Hz, CH2-CH2-CH2), 2.48 (2H, t, J = 7.3 Hz, S-CH2), 3.48 (2H, 
t, J = 7.3 Hz, CH2-CO), 7.24 (2H, dd, J = 8.4 and 8.6 Hz, H-3 and H-5), 7.51-7.55 (4H, m, CH-pyridine, H-3’, H-4’ and H-
5’), 7.61-7.66 (2H, m, H-2 and H-6), 8.09-8.11 (2H, m, H-2’ and H-6’); MS (ES+) m/z = 449.1 [M+H]+. 
tert-Butyl 5-(3-cyano-4-(4-fluorophenyl)-6-phenylpyridin-2-ylthio)pentanoate (22b) 
General Procedure I: 13a (118 mg, 0.52 mmol), 8.5% w/v sodium methoxide in MeOH (0.80 mL, 1.25 mmol), 2-
cyanothioacetamide (52 mg, 0.52 mmol) followed by tert-butyl bromovalerate (185 mg, 0.78 mmol). White solid 
(140 mg, 58%); m.p. 120-121˚C; λmax (EtOH/nm) 272.0, 347.5; IR υmax/cm-1 2984, 2936, 2214, 1707, 1595, 1566; 1H-
NMR (300 MHz, CDCl3) δ ppm 1.44 (9H, s, CH3), 1.80-1.92 (4H, m, CH2-CH2-CH2-CH2), 2.30 (2H, t, J = 7.3 Hz, S-CH2), 
3.43 (2H, t,  J = 6.9 Hz, CH2-CO), 7.25 (2H, dd, J = 8.4 and 8.6 Hz, H-3 and H-5), 7.50 (1H, s, CH-pyridine), 7.51-7.56 
(3H, m, H-3’, H-4’ and H-5’), 7.61-7.65 (2H, m, H-2 and H-6), 8.09-8.11 (2H, m, H-2’ and H-6’); 13C-NMR (125 MHz, 
CDCl3) δ ppm 24.4, 28.1, 28.7, 30.3, 35.1, 80.3, 103.7, 115.4, 115.8, 116.2 (d, JCF = 23.0 Hz), 127.3, 129.0, 130.4 (d, JCF 
= 8.7 Hz), 130.7, 132.3 (d, JCF = 3.4 Hz), 137.4, 153.4, 158.6, 164.0 (d, JCF = 254.6 Hz), 164.3, 172.7; MS (ES+) m/z = 
463.1 [M+H]+; HRMS calcd for C27H27FN2O2S [M+H]+ 463.1850, found 463.1848. 
2-((3-Cyano-4-(4-fluorophenyl)-6-phenylpyridin-2-yl)thio)-N-(2-oxopropyl)acetamide (31) 
General Procedure I: 4-fluorochalcone 13a (15 mg, 0.067 mmol), 8.5% w/v sodium methoxide in MeOH (0.10 mL, 
0.16 mmol), 2-cyanothioacetamide (7 mg, 0.067 mmol) and 2-bromo-N-(2-oxopropyl)acetamide 30 (20 mg, 0.10 
mmol). White solid (10 mg, 36%); m.p. 231-233 ˚C; λmax (EtOH/nm) 270.0, 338.0; IR υmax/cm-1 3281, 2920, 2216, 1732, 
1659; 1H NMR (500 MHz, CDCl3) δ ppm 2.02 (3H, s, CH3), 4.03 (2H, s, S-CH2), 4.04 (2H, d, J = 5.9 Hz, NH-CH2), 7.16-
7.20 (2H, m, H-Ar), 7.26 (1H, br s, NH), 7.44-7.45 (3H, m, H-Ar), 7.52 (1H, s, CH-pyridine), 7.56-7.59 (2H, m, H-Ar), 
7.99-8.00 (2H, m, H-Ar); MS (ES+) m/z = 420.3 [M+H]+; HRMS calcd for C23H18FN3O2S [M+H]+ 420.1177, found 
420.1180. 
2-((3-Cyano-6-phenyl-[4,4'-bipyridin]-2-yl)thio)-N-(2-oxopropyl)acetamide (32) 
General Procedure I: 4-pyridylchalcone (48 mg, 0.23 mmol), 8.5% w/v sodium methoxide in MeOH (0.35 mL, 0.56 
mmol), 2-cyanothioacetamide (46 mg, 0.23 mmol) and 2-bromo-N-(2-oxopropyl)acetamide 30 (67 mg, 0.35 mmol). 
Purification via column chromatography (silica; 0-15% MeOH/DCM). White solid (72 mg, 78%); m.p. 238-240 ˚C; λmax 
(EtOH/nm) 345.0, 277.0, 249.0; IR υmax/cm-1 2913, 2213, 1730, 1657, 1570, 1517; 1H NMR (500 MHz, DMSO-d6) δ 
ppm 2.03 (3H, s, CH3), 3.98 (2H, d, J = 5.5 Hz, NH-CH2), 4.25 (2H, s, S-CH2), 7.55-7.56 (3H, m, H-Ar and H-4’), 7.78 (2H, 
d, J = 6.9 Hz, CH-pyridine), 8.03 (1H, s, CH-pyridine), 8.30-8.32 (2H, m, H-Ar), 8.61 (1H, t, J = 5.5 Hz, NH), 8.83 (2H, d, J 
= 6.9 Hz, N-CH-pyridine); 13C NMR (125 MHz, DMSO-d6) δ ppm 26.9, 33.7, 49.5, 102.5, 115.2, 116.0, 123.1, 127.8, 
128.9, 131.0, 136.3, 143.1, 150.2, 151.6, 158.4, 162.2, 167.2, 204.3; MS (ES+) m/z = 403.3 [M+H]+; HRMS calcd for 
C22H18N4O2S [M+H]+ 403.1223, found 403.1218. 
tert-Butyl 2-(2-hydroxyethylamino)acetate (24) 
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To a solution of ethanolamine (3.0 mL, 49.7 mmol) in THF (0.5 mL/mmol) was added tert- butyl bromoacetate (2 mL, 
13.5 mmol) dropwise. The resulting solution was stirred at RT for 72 h. The mixture was concentrated in vacuo and 
the residue redissolved in DCM (50 mL). The organic phase was washed with an aqueous solution of saturated 
NaHCO3 (50 mL) and brine (50 mL), then dried over Na2SO4 and concentrated in vacuo to give 24 as a yellow oil (1.96 
g, 82%). IR υmax/cm-1 3399, 2970, 1730, 1638; 1H-NMR (300 MHz, CDCl3) δ ppm 1.49 (9H, s, CH3), 2.82 (2H, t, J = 5.0 
Hz, CH2-NH), 3.36 (2H, s, CH2-CO), 3.65 (2H, t, J = 5.0 Hz, CH2-OH), NH and OH not visualised; MS (ES+) m/z = 176.2 
[M+H]+. 
tert-Butyl 2-((tert-butoxycarbonyl)(2-((3-cyano-4-(4-fluorophenyl)-6-phenylpyridin-2-yl)thio)ethyl)amino)acetate 
(27) 
To a solution of tert-butyl 2-(2-hydroxyethylamino)acetate 24 (0.53 g, 3.03 mmol) in DCM (3 mL/mmol) was added 
Boc anhydride (0.80 g, 3.64 mmol), Et3N (0.51 mL, 3.64 mmol) and DMAP (10 mol%). The resulting solution was 
stirred at RT for 3 h. The mixture was diluted with water (15 mL) and the product extracted with DCM (2 x 15 mL). 
Combined organic layers were dried over Na2SO4 and concentrated in vacuo. The resulting solid was redissolved in 
DCM (3 mL/mmol). Mesyl chloride (0.28 mL, 3.64 mmol) and triethylamine (0.63 mL, 4.55 mmol) were added at 0 oC. 
The resulting solution was warmed to RT and stirred for 16 h. The reaction mixture was quenched with an aqueous 
solution of NaHCO3 and extracted with EtOAc (3 x 50 mL). Combined organic layers were washed with brine, dried 
over Na2SO4 and concentrated in vacuo. The resulting oil was redissolved in DMF (4 mL) and 4-(4-fluorophenyl)-6-
phenyl-2-thioxo-1,2-dihydropyridine-3-carbonitrile 14a (90 mg, 0.29 mmol) and KOH (17 mg, 0.32 mmol) were 
added. The resulting solution was heated to 100 oC for 3 h, cooled, diluted with water and extracted with DCM (3 x 
20 mL). Combined organic layers were washed with brine, dried over Na2SO4 and concentrated in vacuo. Purification 
via column chromatography (silica; 0-50% EtOAc/petrol) gave 27 as a white solid (20 mg, 12%). m.p. 152-154 ˚C; λmax 
(EtOH/nm) 338.0, 270.0; IR υmax/cm-1 3282, 2926, 2215, 1653, 1526, 1508; 1H NMR (500 MHz, CDCl3) δ ppm 1.25 (9H, 
s, CH3), 1.34 (9H, s, CH3), 3.38 (2H, t, J = 7.0 Hz, S-CH2),  3.57 (2H, t, J = 7.0 Hz, S-CH2-CH2), 4.59 (2H, s, NH-CH2), 7.17-
7.20 (2H, m, dd, J = 8.6 and 8.7 Hz, H-Ar), 7.39-7.42 (3H, m, H-Ar), 7.57-7.80 (3H, m, H-Ar and CH-pyridine), 8.02-8.09 
(2H, m, H-Ar); MS (ES+) m/z = 564.7 [M+H]+. 
2-((2-((3-Cyano-4-(4-fluorophenyl)-6-phenylpyridin-2-yl)thio)ethyl)amino)acetic acid (28) 
General procedure H: tert-butyl 2-((tert-butoxycarbonyl)(2-((3-cyano-4-(4-fluorophenyl)-6-phenylpyridin-2-
yl)thio)ethyl)amino)acetate 27 (15 mg, 0.027 mmol), TFA (5 µL, 0.054 mmol). White solid (10 mg, 91%); m.p. 193-194 
˚C; λmax (EtOH/nm) 339.0, 269.0; IR υmax/cm-1 3285, 3073, 2926, 2215, 1653, 1508; 1H NMR (500 MHz, MeOD) δ ppm 
3.17 (2H, t, J = 7.1 Hz, CH2), 3.31 (2H, s, CH2), 3.63 (2H, t,  J = 7.1 Hz, CH2),  7.45-7.51 (2H, m, H-Ar), 7.54-7.62 (3H, m,  
H-Ar), 7.83-7.88 (2H, m, H-Ar), 7.97 (1H, s, CH-pyridine), 8.30-8.39 (2H, m, H-Ar); MS (ES+) m/z = 408.3 [M+H]+; HRMS 
calcd for C22H18FN3O2S [M-H]- 406.1031, found 406.1026. 
2-(3-Cyano-4-(4-fluorophenyl)-6-phenylpyridin-2-ylthio)-N-(2-(4 methoxybenzylamino)-2-oxoethyl)acetamide, 16 
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To a solution of 2-(2-(3-cyano-4-(4-fluorophenyl)-6-phenylpyridin-2-ylthio)acetamido)acetic acid 4a (180 mg, 0.43 
mmol) in DMF (20 mL) was added HBTU (200 mg, 0.52 mmol), DIPEA (50 µL, 0.52 mmol) and p-methoxybenzylamine 
(0.56 mL, 4.3 mmol). The resulting mixture was heated at 60 oC for 4.5 h. The mixture was cooled and water (10 mL) 
added, which resulted in precipitation of the product. Filtration gave 16 as a white solid (110 mg, 47%). m.p. 216-220 
˚C; λmax (EtOH/nm) 269.5, 339.0; IR υmax/cm-1 3281, 3069, 2212, 1632, 1547, 1508; 1H-NMR (300 MHz, DMSO-d6) δ 
ppm 3.71 (3H, s, O-CH3), 3.77 (2H, d,  J = 3.9 Hz, NH-CH2-CO), 4.17 (2H, d, J = 3.9 Hz, NH-CH2-Ar), 4.21 (2H, s, S-CH2), 
6.84 (2H, d, J = 8.9 Hz, H-Ar),  7.14 (2H, d, J = 8.9 Hz, H-Ar), 7.43-7.53 (5H, m, H-Ar), 7.80-7.83 (2H, m, H-Ar), 7.93 (1H, 
s, CH-pyridine), 8.21-8.30 (3H, m, NH and H-Ar), 8.63 (1H, t, J = 5.9 Hz, NH); MS (ES+) m/z = 541.6 [M+H]+; HRMS 
calcd for C30H25FN4O3S [M+H]+ 541.1704, found 541.1700. 
N-(2-Amino-2-oxoethyl)-2-((3-cyano-4-(4-fluorophenyl)-6-phenylpyridin-2-yl)thio)acetamide, 17 
General procedure H: 2-((3-cyano-4-(4-fluorophenyl)-6-phenylpyridin-2-yl)thio)-N-(2-((4- methoxybenzyl)amino)-2-
oxoethyl)acetamide 16 (50 mg, 0.093 mmol),TFA (5 mL/mmol) gave 17 as a white solid (11 mg, 52%). m.p. 231-232 
˚C; λmax (EtOH/nm) 338.0, 269.5; IR υmax/cm-1 3285, 3073, 2926, 2215, 1653, 1508; 1H NMR (500 MHz, DMSO-d6) δ 
ppm 3.57 (2H, d, J = 5.5 Hz, NH-CH2), 4.09 (2H, s, S-CH2),  7.24 (1H, s, NH2), 7.35 (2H, dd, J = 8.6 and 8.7 Hz, H-Ar), 
7.42-7.43 (3H, m, H-Ar and H-4’), 7.72 (2H, dd, J = 5.4 and 8.6 Hz, H-Ar), 7.83 (1H, s, CH-pyridine), 8.17-8.19 (2H, m, 
H-Ar), 8.40 (1H, t, J = 5.5 Hz, NH); MS (ES+) m/z = 421.3 [M+H]+; HRMS calcd for C22H17FN4O2S [M+H]+ 421.1129, 
found 421.1130. 
General procedure J 
A mixture of 2-amino-6-chloro-pyrimidine-3-carbonitrile 33 (1.0 eq), and the corresponding aniline (1.0 eq) in DMF (2 
ml) was heated to 100 oC for 24 hours, then allowed to cool to rt, poured into water (20 mL) water and extracted 
with dichloromethane (3 x 20 mL). The combined organic layers were washed with water (3 x 20 mL)and brine (20 
mL),dried (Na2SO4) and concentrated in vacuo. Recrystallization (ethanol) gave the product. 
4-Amino-2-(2-tolylamino)pyrimidine-5-carbonitrile (5a)12,13 
General procedure J: 4-amino-2-chloropyrimidine-5-carbonitrile (0.200 g, 1.29 mmol), o-toluidine (0.089 mL, 1.29 
mmol) and DMF (2 mL) gave 5a as a white solid (0.145 g, 50%); m.p. 186.7˚C; λmax (EtOH/nm) 260 and 302; IR 
υmax/cm-1 2208  (CN); 3163  (NH); 1H-NMR (300 MHz, DMSO-d6) δ ppm 2.17 (3H, s, CH3), 7.09 (6H, m, NH2 and H-Ar), 
8.26 (1H, s, H-6), 9.00 (s, 1H, NH); 13C-NMR (75 MHz, DMSO-d6) δ ppm 18.2, 80.4, 117.2, 125.6, 126.3, 126.7, 130.6, 
133.6, 137.5, 161.8, 162.4, 163.6; MS (ES+) m/z =  226.1 [M+H]+. 
4-Amino-2-(3-methoxyphenylamino)pyrimidine-5-carbonitrile (5b) 
General procedure J: 4-amino-2-chloropyrimidine-5-carbonitrile (0.200 g, 1.29 mmol), 3-methoxyaniline (0.100 mL, 
1.29 mmol) and DMF (2 mL). Yellow solid (0.121 g, 39%); m.p. 196.0˚C; λmax (EtOH/nm) 313; IR υmax/cm-1 2214 (CN); 
3435  (NH); 1H-NMR (300 MHz, DMSO-d6) δ ppm 3.72 (3H, s, O-CH3), 6.56 (1H, d, J = 7.8 Hz, Hc), 7.15 (1H, t, J = 7.8 
Hz, Hb), 7.30 (1H, d, J = 7.8 Hz, Ha), 7.36-7.48 (3H, m, Hd and NH2), 8.34 (1H, s,  H-6), 9.64 (1H, s, NH); 13C-NMR (75 
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MHz, DMSO-d6) δ ppm 55.5, 80.9, 106.6, 108.4, 113.0, 117.0, 129.5, 141.1, 160.0, 160.6, 162.2, 163.4; MS (ES+) m/z 
=  242.1 [M+H]+; C12H11N5O requires C, 59.74; H, 4.60; N, 29.03; found C, 59.80; H, 4.40; N, 28.99 
4-Amino-2-(4-fluorophenylamino)pyrimidine-5-carbonitrile (5c) 
General procedure J: 4-amino-2-chloropyrimidine-5-carbonitrile (0.200 g, 1.29 mmol), 4-fluoroaniline (0.123 mL, 1.29 
mmol) and DMF (2 mL). Yellow solid (0.129 g, 44%); m.p. 264.6˚C; λmax (EtOH/nm) 310; IR υmax/cm-1 2214 (CN); 3329 
(NH);  1H-NMR (300 MHz, DMSO-d6) δ ppm 7.10 (2H, t, J = 8.4 Hz, Ha and Hd), 7.48 (2H, br s, NH2), 7.76 (2H, br s,  Hb 
and Hc), 8.35 (1H, s, H-6), 9.73 (1H, s, NH); 13C-NMR (75 MHz, DMSO-d6) δ ppm 80.9, 115.0, 115.5, 117.0, 122.2, 
122.4, 136.4, 156.6, 160.6, 162.2, 163.5; MS (ES+) m/z = 230.1 [M+H]+; C11H8FN5 requires C, 57.64; H, 3.52; N, 30.55; 
found C, 57.81; H, 3.42; N, 30.35 
General procedure K: 
Methyl pyrrole-2-carboxylate (1.01 g, 8.04 mmol) was added to a stirred solution of aluminium trichloride (1.54 g, 
16.1 mmol) and the benzoylchloride derivative (3.35 g, 16.1 mmol) in DCM (20 mL) at 0 oC, and the resulting mixture 
was stirred for 4h at rt. The reaction was quenched by careful addition of water, diluted by addition of an equal 
amount of EtOAc and water, and extracted with EtOAc (3 x). The combined organic layers were washed with NaHCO3 
(sat., aq.), water and brine before being dried (Na2SO4), and concentrated in vacuo. Chromatography (SiO2; 40-80% 
EtOAc, petroleum ether) and precipitation (EtOAc/MeOH/petroleum ether) gave 35a as a yellow solid (1.24 g, 52%) 
Methyl 4-(2,3-dichlorobenzoyl)-1H-pyrrole-2-carboxylate (35a) 
General procedure K: methyl pyrrole-2-carboxylate (1.01 g, 8.04 mmol), aluminium trichloride (1.54 g, 16.1 mmol), 
2,3-dichlorobenzoylchloride derivative (3.35 g, 16.1 mmol) in DCM (20 mL) at 0 oC, gave 35a as a yellow solid (1.24 g, 
52%); mp 189.9-190.7 °C. max (EtOH/nm) 285. IR υmax/cm-1 3285, 3113, 2953, 1687, 1656. 1H NMR (300 MHz, DMSO-
d6) H 3.80 (3H, s, OCH3), 7.02 (1H, s, pyrrole-CH), 7.44-7.50 (3H, m, pyrrole-CH, ClCCHCHCH, ClCCHCHCH), 7.79 (1H, 
dd, J = 1.5, 7.5 Hz, ClCCHCHCH), 12.87 (1H, br s, pyrrole-NH). 13C NMR (75 MHz, DMSO-d6) C 51.6, 115.1, 124.3, 
124.8, 126.9, 127.5, 128.6, 130.4, 131.5, 132.3, 141.3, 160.3, 187.2. MS (ES+) m/z = 299.48 [M+H]+ 
Methyl 4-(2,4-dichlorobenzoyl)-1H-pyrrole-2-carboxylate (35b) 
General procedure K: methyl pyrrole-2-carboxylate (3.0 g, 24 mmol), aluminium chloride (5.52 g, 60 mmol) and 2,4-
dichlorobenzoylchloride (10.1 g, 48 mmol) 35b was obtained as a yellow solid (4.54 g, 64%). mp 173-174 °C, max 
(EtOH/nm) 284. IR υmax/cm-1 3190, 3114, 1705, 1628, 1582, 1555, 1481, 1447, 1393. 1H NMR (300 MHz, DMSO-d6) H 
3.79 (s, 3H, OCH3), 7.02 (s, 1H, PyrH), 7.46 (s, 1H, PyrH), 7.48-7.57 (m, 2H, 2 x ArH), 7.74 (app. d, 1H, J = 1.2 Hz, ArH), 
12.84 (s, 1H, NH). 13C NMR (75 MHz, DMSO-d6) C 51.0, 114.7, 123.9, 124.7, 127.0, 129.1, 129.6, 130.4, 134.6, 137.7, 
159.9, 186.7. HRMS (ES+) calcd for [M+NH4]+, 315.0298, found, 315.0296 (35Cl). Anal. calcd for C13H9Cl2NO3: C, 
52.37%, H, 3.04%, N, 4.70%. Found: C, 52.25%, H, 3.09%, N, 4.71% 
Methyl 4-(2-(trifluoromethyl)benzoyl)-1H-pyrrole-2-carboxylate (35c) 
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General procedure K: methyl pyrrole-2-carboxylate (3.0 g, 24 mmol), aluminium chloride (5.8 g, 60 mmol) and 2-
trifluoromethylbenzoylchloride (10.0 g, 48 mmol) 35c was obtained as a yellow solid (1.43 g, 20%). mp 141-142 °C, 
max (EtOH/nm) 279, 232. IR υmax/cm-1 3273, 1707, 1640, 1553, 1439, 1385, 1308, 1274.; 1H NMR (300 MHz, DMSO-
d6) H 3.78 (s, 3H, OCH3), 6.98 (s, 1H, =CH), 7.39 (s, 1H, =CH), 7.58 (d, 1H, J = 6.6 Hz, ArH), 7.66-7.81 (m, 2H, 2 x ArH), 
7.86 (d, 1H, J = 7.5 Hz, ArH), 12.83 (s, 1H, NH). 13C NMR (75 MHz, DMSO-d6) C 50.8, 114.5, 119.8 (q, JC-F = 272 Hz, 
CF3), 123.8, 125.1, 125.7 (q, JC-F = 31 Hz, CCF3), 126.1 (q, JC-F = 4.7 Hz, ArH), 127.6, 129.2, 129.6, 131.8, 138.6, 160.0, 
188.3. HRMS (ES+) calcd for C14H10F3NO3 [M+H]+, 298.0686, found, 298.0688. Anal. calcd for C14H10F3NO3 requires C, 
56.57%, H, 3.39%, N, 4.71%. Found: C, 56.64%, H, 3.59%, N, 4.89% 
4-Benzoyl-1H-pyrrole-2-carboxylate (35d) 
General procedure K: methyl pyrrole-2-carboxylate (3.0 g, 24 mmol), aluminium chloride (5.52 g, 60 mmol) and 
benzoylchloride (6.7 g, 48 mmol) 35d  was obtained as a yellow solid (1.83 g, 90%); mp 148-149 °C,max (EtOH/nm) 
285 and 238. IR max (cm-1): 3293, 1715, 1620, 1596, 1555, 1446, 1384. 1H NMR (300 MHz, DMSO-d6) H ppm 3.81 (s, 
3H, OCH3), 7.15 (s, 1H, =CH), 7.48-7.67 (m, 4H, 3 x ArH and =CH), 7.73-7.83 (m, 2H, 2 x ArH), 12.76 (s, 1H, NH). 13C 
NMR (75 MHz, DMSO-d6) C ppm 30.1, 115.5, 123.2, 124.2, 128.0, 128.7, 131.3, 138.6, 160.1, 188.6. HRMS (ES+) calcd 
for C13H11NO3 [M+H]+, 230.0812, found, 230.0811. Anal. calcd for C13H11NO3: C, 68.11%, H, 4.84%, N, 6.11%. Found: C, 
68.33%, H, 4.78%, N, 6.21% 
1-(4-(2,3-Dichlorobenzoyl)-1H-pyrrol-2-yl)ethanone (39) 
General procedure K: 2-acetyl pyrrole (600 mg, 5.40 mmol), 2,3-dichlorobenzoyl chloride (2.30 g, 11.0 mmol) and 
aluminium chloride (1.32 g, 13.7 mmol) in DCM (10 mL). Chromatography (silica gel, 3:2 EtOAc/petrol) gave 39 as a 
pale pink solid (850 mg, 56%); Rf = 0.65 (2:3 EtOAc/petrol); mp: 144-146 ˚C; max (EtOH/nm) 290; IR (cm-1) 3348 (N-H), 
1655 (C=O), 1519 (C=O); 1H NMR (500 MHz, DMSO-d6) δ 3.23 (3H, s, CH3), 7.23 (1H, d, J = 1.4 Hz, pyrrole-H), 7.32-
7.34 (2H, m, ArH and pyrrole-H), 7.37 (1H, dd, J = 7.7 and 7.8 Hz, ArH), 7.68 (1H, dd, J = 1.7 and 7.8 Hz, ArH), 12.5 (1H, 
s br, NH); 13C NMR (125 MHz, DMSO-d6) δ 25.8 (CH3), 116.5, 124.8, 126.9, 127.5, 128.6, 131.4, 131.5, 132.3, 133.6, 
141.4, 187.4 (C=O), 188.4 (C=O); HRMS calcd. for C13H1035Cl2NO2 [M+H]+ 282.0083, found 282.0083. 
(Z)-3-(4-(2,3-Dichlorobenzoyl)-1H-pyrrol-2-yl)-3-hydroxy-1-(pyridin-4-yl)prop-2-en-1-one (44) 
General procedure K: 43 (200 mg, 0.71 mmol), aluminium chloride (400 mg, 2.50 mmol) and 2,3-dichlorobenzoyl 
chloride (135 mg, 1.40 mmol) in DCM (10 mL). Chromatography (silica, 4:1 EtOAc/petrol) gave 44 as a pale yellow 
solid (150 mg, 55 %); mp: 243-245 ˚C; λmax (EtOH/nm) 358, 294; IR (cm-1) 3125, 1619, 1598; 1H NMR (500 MHz, 
DMSO-d6) δ ppm 7.36 (1H, s, CHCO), 7.49-7.54 (2H, m, 2 × ArH), 7.64 (1H, s, pyrrole-H), 7.82 (1H, dd, J = 1.5 and 7.0 
Hz, ArH), 7.84 (1H, s, pyrrole-H), 7.99 (2H, d, J = 6.0 Hz, 2 × pyridyl-H), 8.79 (2H, d, J = 6.0 Hz, 2 × pyridyl-H), 12.95 
(1H, s br, NH), 15.90 (1H, s br, OH); 13C NMR (125 MHz, DMSO-d6) δ ppm 95.2, 117.2, 120.1, 125.7, 127.1, 127.6, 
128.7, 131.6, 131.8, 132.4, 132.5, 140.5, 141.3, 150.5, 173.4, 182.9, 187.4; HRMS calcd. for C19H1335Cl2N2O3 [M+H]+ 
387.0298, found 387.0296. 
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General procedure L: 
Lithium hydroxide (6.4 g, 268 mmol) was added to a stirred solution of the appropriate methyl pyrrole-2-carboxylate 
(2.0 g, 6.7 mmol) in THF (50 mL) and H2O (80 mL). The resulting mixture was stirred at 65 °C for 20 h, then HCl (1M) 
was added to pH 7, and extracted with EtOAc (3 x 10 mL). The combined organics were washed with H2O (50 mL) and 
brine (50 mL), dried (Na2SO4), and concentrated in vacuo. Chromatography (SiO2; 50-80% EtOAc/petroleum ether) 
and precipitation (EtOAc/MeOH/petroleum ether) gave the product. 
4-(2,3-Dichlorobenzoyl)-1H-pyrrole-2-carboxylic acid (36a) 
General procedure L: Lithium hydroxide (6.4 g, 268 mmol), 35a (2.0 g, 6.7 mmol) in THF (50 mL) and H2O (80 mL). 
gave 36a as a slightly pink solid (88%); mp 249-250 °C, λmax (EtOH/nm) 285, 238. IR υmax/cm-1 3300 (OH), 1672 (CO), 
1638, 1550, 1443, 1384. 1H NMR (300 MHz, DMSO-d6) H 6.97 (app. t, 1H, J = 2.0 Hz, PyrH), 7.34-7.40 (m, 1H, PyrH), 
7.40-7.52 (m, 2H, 2 x ArH), 7.76 (dd, 1H, J = 7.2 and 2.4 Hz, ArH), 12.66 (s, 1H, NH), 12.90 (br s, 1H, COOH). 13C NMR 
(75 MHz, DMSO-d6) C 114.3, 124.4, 125.3, 126.5, 127.3, 128.1, 129.2, 131.0, 132.1, 141.3, 160.8, 186.7. HRMS (ES+) 
calcd for C12H735Cl2NO3 [M+NH4]+, 301.0141, found, 301.0139. Anal. calcd for C12H7Cl2NO3: C, 50.73%, H, 2.48%, N, 
4.93%. Found: C, 50.59%, H, 2.26%, N, 4.78%. 
4-(2,4-Dichlorobenzoyl)-1H-pyrrole-2-carboxylic acid (36b) 
General procedure L:  35b (1.0 g, 3.35 mmol) gave 36b as slightly pink solid (785 mg, 82%); mp 213-214 °C, max 
(EtOH/nm) 284, 233. IR υmax/cm-1 3299 (NH), 1674(CO), 1641, 1584, 1553, 1499, 1439, 1385, 1279, 1223, 1101, 880, 
861, 756 (Cl). 1H NMR (300 MHz, DMSO-d6) H 3.42 (OH), 6.97 (s, 1H, PyrH), 7.38 (s, 1H, PyrH), 7.46-7.57 (m, 2H, 2 x 
ArH), 7.74 (s, 1H, ArH), 12.64 (s, 1H, NH). 13C NMR (75 MHz, DMSO-d6) C 114.2, 124.6, 125.4, 127.0, 129.07, 129.13, 
129.6, 130.4, 134.5, 137.9, 160.9, 186.8. HRMS (ES+) calcd for C12H735Cl2NO3 [M+H]+, 282.9798, found, 282.9797 
(35Cl). Anal. calcd for C12H735Cl2NO3: C, 50.73%, H, 2.48%, N, 4.93%. Found: C, 50.88%, H, 2.33%, N, 4.79% 
4-(2-(Trifluoromethyl)benzoyl)-1H-pyrrole-2-carboxylic acid (36c) 
General procedure L:  35c (1.0 g, 3.36 mmol) gave 36c as a slightly pink solid (762 mg, 80%); mp 221-222 °C, max 
(EtOH/nm) 279, 232. IR υmax/cm-1 3317 (NH), 1639 (CO), 1557, 1443, 1388, 1313, 1281, 1227. 1H NMR (300 MHz, 
DMSO-d6) H 6.93 (app. t, 1H, J = 1.8 Hz, =CH), 7.26-7.36 (m, 1H, =CH), 7.57 (d, 1H, J = 6.9 Hz, ArH), 7.66-7.81 (m, 2H, 
2 x ArH), 7.86 (d, 1H, J = 6.6 Hz, ArH), 12.63 (s, 1H, NH), 12.90 (br s, 1H, COOH). 13C NMR (75 MHz, DMSO-d6) C 
114.0, 123.1 (q, JC-F = 272 Hz, CF3), 124.7, 124.8, 125.4 (q, JC-F = 31.4 Hz, CCF3), 125.8 (q, JC-F = 4.6 Hz, ArH), 127.4, 
128.5, 129.3, 131.5, 138.4, 160.6, 188.1. HRMS (ES+) calcd for C13H8F3NO3 [M+H]+, 284.0529, found, 284.0527. 
4-Benzoyl-1H-pyrrole-2-carboxylic acid (36d) 
General procedure L:  35d (1.0 g, 3.36 mmol) gave 36d was obtained as a slightly pink solid (811 mg, 86%); mp 225-
226 °C, max (EtOH/nm) 285, 237. IR υmax/cm-1 3333, 1667, 1624, 1549, 1426, 1382. 1H NMR (300 MHz, DMSO-d6)H 
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ppm 7.11 (s, 1H, =CH), 7.44-7.67 (m, 4H, 3 x ArH and =CH), 7.72-7.84 (m, 2H, 2 x ArH), 12.55 (s, 1H, NH). 13C NMR (75 
MHz, DMSO-d6) C ppm 115.1, 124.1, 124.6, 128.1, 128.4, 131.4, 138.8, 161.1, 188.8. HRMS (ES+) calcd for C12H9NO3 
[M+H]+, 216.0655, found, 216.0655. Anal. calcd for C12H9NO3: C, 66.97%, H, 4.22%, N, 6.51%. Found: C, 66.81%, H, 
4.17%, N, 6.33%. 
4-(2,3-Dichlorobenzoyl)-1-methyl -1H-pyrrole-2-carboxylic acid (36e) 
To a solution of 35a (100 mg, 0.34 mmol) in DMF (3 mL) was added sodium hydride (12 mg, 0.51 mmol) with stirring 
at 0 oC, followed by methyl iodide (72 mg, 0.51 mmol). The mixture was allowed to warm to rt and stirring continued 
18h, then evaporated. Precipitation from EtOAc, petrol gave the ester. The crude material was treated according to 
General Procedure L to give 36e (97 mg, 72%). 1H NMR (300 MHz, DMSO-d6)H ppm 3.90 (s, 3H, CH3) 7.03 (d, J = 1.5 
Hz, 1H, PrH), 7.40-7.51 (m, 2H, PrH and ArH), 7.58-7.62 (m, 1H, ArH), 7.75-7.85 (m, 1H, ArH). 13C NMR (75 MHz, 
DMSO-d6) C ppm 36.6, 116.8, 121.8, 125.1, 126.5, 127.3, 128.1, 131.0, 132.0, 134.9, 141.2, 160.9, 186.3.  
General procedure M:  
A solution of carbonyldiimidazole (2.0 eq.) and the required carboxylic acid (1.0 eq.) in THF (5 mL/mmol) was heated 
to 80 oC for 4 h. The appropriate amine (2.5 eq.) was added and the mixture heated at 50 °C for 3 h then at RT for 18 
h. The product was extracted into EtOAc (50 mL/mmol), washed with water (50 mL/mmol), brine (50 mL/mmol) and 
dried over Na2SO4. The solvent was removed under vacuum and the crude product purified as specified. 
4-(2,3-Dichlorobenzoyl)-N-(4-fluorobenzyl)-1H-pyrrole-2-carboxamide (6a) 
General procedure M: CDI (55 mg, 0.34 mmol) and 36a (100 mg, 0.35 mmol), THF (3 mL), 4-fluorobenzylamine (70 
mg, 0.56 mmol). Chromatography (SiO2; 30% EtOAc, petrol) gave 6a as a white solid (60 mg, 44%); mp 222-223 °C, 
max (EtOH/nm) 288, 237. IR υmax/cm-1 3364 (OH), 3172 (NH), 3119 (NH), 2922, 2851, 2372, 1616 (CO), 1568, 1505, 
1391, 1288, 1223, 1150 (CF), 851, 797, 744, 696 (Cl). HPLC (Method A): 99.7% Rt = 18.6 min. 1H NMR (300 MHz, 
DMSO-d6) H 4.40 (s, 2H, CH2), 7.10-7.24 (m, 3H, 2 x ArH and =CH), 7.27-7.37 (m, 3H, 2 x ArH and =CH), 7.40-7.52 (m, 
2H, 2 x ArH), 7.77 (dd, 1H, J = 7.5 and 1.8 Hz, ArH), 8.90 (app. t, 1H, J = 5.7 Hz, NH), 12.46 (s, 1H, NH). 13C NMR (75 
MHz, DMSO-d6) C 41.1 (CH2), 110.2 (=CH), 114.6 (d, JC-F = 21 Hz, 2 x ArH), 124.1 (C), 126.5 (ArH), 127.3 (C), 128.0 (C-
Cl), 128.1 (=CH and ArH), 128.9 (d, JC-F = 8 Hz, 2 x ArH), 130.9 (ArH), 132.0 (C, Ar), 135.3 (CH2C), 141.6 (C-Cl), 159.5 
(CON), 160.9 (d, JC-F = 245 Hz, C-F), 187.0 (CO). HRMS (ES+) calcd for C19H1335Cl2FN2O2 [M+NH4]+, 408.0676, found, 
408.0672. Anal. calcd for C19H13Cl2FN2O2: C, 58.33%, H, 3.35%, N, 7.16%. Found: C, 58.33%, H, 3.45%, N, 7.18%. 
4-(2,4-Dichlorobenzoyl)-N,N-dimethyl-1H-pyrrole-2-carboxamide (6b) 
General procedure M: CDI (114 mg, 0.7 mmol), 36b (100 mg, 0.35 mmol),THF (4 mL), dimethylamine (2M in THF; 
0.44 mL, 0.88 mmol). Chromatography (SiO2; 5-10% MeOH/EtOAc) and precipitation (EtOAc/MeOH/petroleum 
ether) gave 6b as a white solid (80 mg, 73%); mp 208-209 °C, λmax (EtOH/nm) 287. IR υmax/cm-1 3151, 1640, 1586, 
1553, 1484, 1377, 1341. 1H NMR (300 MHz, DMSO-d6) H 3.07 (br s, 3H, CH3), 3.17 (br s, 3H, CH3), 6.90 (s, 1H, PyrH), 
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7.21 (s, 1H, PyrH), 7.47-7.56 (m, 2H, 2 x ArH), 7.74 (s, 1H, ArH), 12.29 (s, 1H, NH). 13C NMR (75 MHz, DMSO-d6) C ppm 
36.7, 111.2, 124.1, 126.9, 127.0, 127.9, 129.0, 129.6, 130.5, 134.4, 138.0, 160.9, 186.8. HRMS (ES+) calcd for 
C14H1235Cl2N2O2 [M+H]+, 311.0349, found, 311.0345. Anal. calcd for C14H12Cl2N2O2 requires C, 54.04%, H, 3.89%, N, 
9.00%. Found: C, 53.94%, H, 3.68%, N, 8.98% 
4-(2,4-Dichlorobenzoyl)-N-phenethyl-1H-pyrrole-2-carboxamide (6c) 
General procedure M: CDI (114 mg, 0.7 mmol), 36b (100 mg, 0.35 mmol), THF (4 mL), phenylethylamine (107 mg, 
0.88 mmol). Chromatography (SiO2; 50% EtOAc, petrol) and precipitation (EtOAc/MeOH/petroleum ether) gave 6c as 
a white solid (80 mg, 59%); mp 226-227 °C, max (EtOH/nm) 288, 239. IR υmax/cm-1 3356 (NH), 1643 (CO), 1602, 1570, 
1533, 1493, 1288. 1H NMR (300 MHz, DMSO-d6) H 2.81 (t, 2H, J = 7.1 Hz, CH2), 3.40-3.51 (m, 2H, CH2), 7.15 (s, 1H, 
PyrH), 7.15-7.34 (m, 6H, PyrH and 5 x ArH), 7.45-7.59 (m, 2H, 2 x ArH), 7.75 (s, 1H, ArH), 8.35-8.46 (m, 1H, NH), 12.35 
(s, 1H, NH). 13C NMR (75 MHz, DMSO-d6) C ppm 34.8, 39.8, 109.8, 124.2, 125.6, 126.9, 127.7, 127.9, 128.1, 128.4, 
129.0, 129.5, 130.4, 134.3, 138.2, 139.1, 159.5, 186.9. HRMS (ES+) calcd for C20H1635Cl2N2O2 [M+H]+, 387.0662, found, 
387.0666. C20H16Cl2N2O2 requires C, 62.03%, H, 4.16%, N, 7.23%. Found: C, 61.88%, H, 3.98%, N, 7.13% 
N-Methyl-4-(2-(trifluoromethyl)benzoyl)-1H-pyrrole-2-carboxamide (6d)  
General procedure M: CDI (113 mg, 0.7 mmol), 36c (100 mg, 0.35 mmol), THF (4 mL), methylamine (2M in THF, 0.44 
mL, 0.88 mmol). Chromatography (SiO2; 40-95% EtOAc, petrol) and precipitation (EtOAc/MeOH/petroleum ether) 
gave 6d as a white solid (71 mg, 68%); mp 223-224 °C, max (EtOH/nm) 284, 235. IR υmax/cm-1 3381 (NH), 3178 (NH), 
3119, 1621 (CO), 1574, 1535, 1487, 1394, 1314, 1288, 1240. 1H NMR (300 MHz, DMSO-d6) H 2.72 (d, 3H, J = 4.5 Hz, 
CH3), 7.10 (s, 1H, =CH), 7.14 (s, 1H, =CH), 7.56 (d, 1H, J = 6.9 Hz, ArH), 7.67-7.81 (m, 2H, 2 x ArH), 7.85 (d, 1H, J = 8.1 
Hz, ArH), 8.28 (app. d, 1H, J = 4.5 Hz, NH), 12.34 (s, 1H, NH). 13C NMR (75 MHz, DMSO-d6) C 24.8, 109.3, 123.2 (q, JC-F 
= 272 Hz, CF3), 124.4, 125.4 (q, JC-F = 32 Hz, CCF3), 125.6 (q, JC-F = 4.7 Hz, ArH), 127.1, 127.4, 128.0, 129.1, 131.4, 
138.7, 159.8, 188.2. HRMS (ES+) calcd for C14H11F3N2O2 [M+H]+, 297.0845, found, 297.0843. 
4-Benzoyl-N-pyridin-3-ylmethyl-1H-pyrrole-2-carboxamide (6e) 
General procedure M: CDI (113 mg, 0.7 mmol), 36d (75 mg, 0.35 mmol), THF (4 mL), 3-pyridylmethylamine (61 mg, 
0.56 mmol) 6e was obtained as a white solid (104 mg, 73%); mp 214-215 °C, max (C2H5OH/nm) 289 and 242. IR 
υmax/cm-1 3340, 3181, 3055, 1668), 1532, 1423. 1H-NMR (300 MHz, DMSO-d6) δ ppm 4.47 (d, 2H, J = 5.7 Hz, CH2), 
7.30-7.40 (m, 2H, ArH and =CH), 7.43 (s, 1H, =CH), 7.47-7.66 (m, 3H, 3 x ArH), 7.67-7.83 (m, 3H, 3 x ArH), 8.46 (d, 1H, 
J = 3.9 Hz, ArH), 8.55 (br s, 1H, ArH), 8.93 (app. t, 1H, J = 5.6 Hz, NH), 12.35 (s, 1H, NH). 13C NMR (75 MHz, DMSO-d6) 
C ppm 39.6, 111.1, 122.9, 123.8, 127.1, 127.3, 128.0, 131.1, 134.6, 134.7, 139.0, 147.7, 148.5, 159.9, 188.9. HRMS 
(ES+) calcd for C18H15N3O2 [M+H]+, 306.1237, found, 306.1233. Anal. calcd for C18H15N3O2: C, 70.81%, H, 4.95%, N, 
13.76%. Found: C, 70.20%, H, 4.78%, N, 13.41%. 
4-(2,3-Dichlorobenzoyl)-N-methyl-1H-pyrrole-2-carboxamide (6f) 
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General procedure M: CDI (55 mg, 0.34 mmol) and 36a (100 mg, 0.35 mmol), THF (3 mL), methylamine (2M in THF, 
0.44 mL, 0.88 mmol) 6f was obtained as a white solid (72 mg, 69%); mp 254-255 °C, max (C2H5OH/nm) 287 and 235. 
IR υmax/cm-1 3362, 3187, 3130, 1619, 1580, 1537, 1491. 1H-NMR (300 MHz, DMSO-d6) δ ppm 2.73 (app. d, 3H, J = 3.6 
Hz, CH3), 7.11 (s, 1H, =CH), 7.24 (s, 1H, =CH), 7.40-7.52 (m, 2H, 2 x ArH), 7.77 (dd, 1H, J = 7.5 and 1.2 Hz, ArH), 8.29 
(app. d, 1H, J = 3.3 Hz, NH), 12.39 (s, 1H, NH). 13C NMR (75 MHz, DMSO-d6) C ppm 24.8, 109.4, 123.8, 126.2, 127.0, 
127.5, 127.8, 128.2, 130.6, 131.7, 141.3, 159.7, 186.7. HRMS (ES+) calcd for C13H1035Cl2N2O2 [M+H]+, 297.0192, found, 
297.0194. Anal. calcd for C13H10Cl2N2O2: C, 52.55%, H, 3.39%, N, 9.43%. Found: C, 52.25%, H, 3.10%, N, 9.20%. 
4-(2,3-Dichlorobenzoyl)-N,N-dimethyl-1H-pyrrole-2-carboxamide (6g) 
General procedure M: CDI (55 mg, 0.34 mmol) and 36a (100 mg, 0.35 mmol), THF (3 mL), dimethylamine (2M in THF, 
0.44 mL, 0.88 mmol) 6g was obtained as a slightly brown solid (105 mg, 96%); mp 223-224 °C, max (C2H5OH/nm) 286 
and 233. IR υmax/cm-1 3200, 3117, 2922, 2851, 1647, 1599, 1541, 1505, 1406. 1H-NMR (300 MHz, DMSO-d6) δ ppm 
3.04 (br s, 3H, CH3), 3.02 (br s, 3H, CH3), 6.92 (s, 1H, =CH), 7.21 (dd, 1H, J = 3.3 and 1.2 Hz, =CH), 7.41-7.52 (m, 2H, 2 x 
ArH), 7.77 (dd, 1H, J = 6.9 and 1.2 Hz, ArH), 12.32 (s, 1H, NH). 13C NMR (75 MHz, DMSO-d6) C ppm 36.7, 36.8, 111.2, 
123.9, 126.5, 127.1, 127.3, 128.0, 130.9, 132.0, 141.4, 160.9, 186.7. HRMS (ES+) calcd for C14H1235Cl2N2O2 [M+H]+, 
311.0349, found, 311.0347 (35Cl). 
4-(2,3-Dichlorobenzoyl)-N-(pyridin-4-ylmethyl)-1H-pyrrole-2-carboxamide (6h) 
General procedure M: CDI (114 mg, 0.7 mmol), 36a (100 mg, 0.35 mmol),THF (4 mL), 4-pyridylmethylamine (61 mg, 
0.56 mmol) 6h was obtained as a white solid (128 mg, 97%); mp 244-245 °C, max (C2H5OH/nm) 285 and 236. IR 
υmax/cm-1 3337, 3121, 3057, 2920, 2850, 1618, 1564, 1527, 1491, 1410. 1H-NMR (300 MHz, DMSO-d6) δ ppm 3.59 (d, 
2H, J = 5.7 Hz, CH2), 6.39 (s, 1H, =CH), 6.42 (d, 2H, J = 5.7 Hz, 2 x ArH), 6.46 (s, 1H, =CH), 6.54-6.66 (m, 2H, 2 x ArH), 
6.91 (dd, 1H, J = 7.5 and 2.1 Hz, ArH), 7.64 (d, 2H, J = 7.5 Hz, ArH), 8.12 (app. t, 1H, J = 5.9 Hz, NH), 11.63 (s, 1H, NH). 
13C NMR (75 MHz, DMSO-d6) C ppm 40.9, 110.4, 121.8, 124.1, 126.5, 127.3, 127.9, 128.1, 130.8, 132.0, 141.5, 148.0, 
149.1, 159.8, 186.9. HRMS (ES+) calcd for C18H1335Cl2N2O2 [M+H]+, 374.0458, found, 374.0459. 
4-(2,3-Dichlorobenzoyl)-N-(pyridin-3-ylmethyl)-1H-pyrrole-2-carboxamide (6i) 
General procedure M: CDI (114 mg, 0.7 mmol), 36a (100 mg, 0.35 mmol),THF (4 mL), 3-pyridylmethylamine (61 mg, 
0.56 mmol) 6i was obtained as a white solid (79 mg, 60%); mp 178-179 °C, max (C2H5OH/nm) 287 and 237. IR 
υmax/cm-1 3435, 3168, 1624, 1575, 1541, 1489, 1392, 1293. 1H-NMR (300 MHz, DMSO-d6) δ ppm 4.47 (d, 2H, J = 2.7 
Hz, CH2), 7.20 (s, 1H, =CH), 7.30 (s, 1H, =CH), 7.32-7.39 (m, 1H, ArH), 7.40-7.52 (m, 2H, 2 x ArH), 7.69 (d, 1H, J = 7.8 
Hz, ArH), 7.76 (dd, 1H, J = 7.5 and 1.8 Hz, ArH), 8.45 (d, 1H, J = 4.8 Hz, ArH), 8.52 (s, 1H, ArH), 8.93 (app. t, 1H, J = 5.7 
Hz, NH), 12.45 (s, 1H, NH). 13C NMR (75 MHz, DMSO-d6) C ppm 41.2, 110.3, 123.0, 124.1, 126.5, 127.3, 128.0, 128.1, 
130.9, 132.0, 134.5, 134.7, 141.5, 147.7, 148.5, 159.7, 187.0. HRMS (ES+) calcd for C18H1335Cl2N2O2 [M+H]+, 374.0458, 
found, 374.0456. 
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4-(2,3-Dichlorobenzoyl)-N-(pyridin-2-ylmethyl)-1H-pyrrole-2-carboxamide (6j) 
General procedure M: CDI (114 mg, 0.7 mmol), 36a (100 mg, 0.35 mmol),THF (4 mL), 2-pyridylmethylamine (61 mg, 
0.56 mmol) 6j was obtained as a white solid (111 mg, 84%); mp 228-229 °C, max (C2H5OH/nm) 286 and 236. IR 
(Diamond ATR) υmax/cm-1 3372, 3165, 3121, 1621, 1570, 1526, 1494, 1291, 1211, 904, 745, 698. HPLC (Method A): 
99.9% Rt = 10.9 min; (Method B): 99.8% Rt = 14.0 min. 1H-NMR (300 MHz, DMSO-d6) δ ppm 4.52 (d, 2H, J = 5.7 Hz, 
CH2), 7.20-7.35 (m, 4H, 2 x =CH and 2 x ArH), 7.40-7.54 (m, 2H, 2 x ArH), 7.70-7.82 (m, 2H, 2 x ArH), 8.50 (d, 1H, J = 
3.9 Hz, ArH), 8.96 (app. t, 1H, J = 5.4 Hz, NH), 12.44 (s, 1H, NH). 13C NMR (75 MHz, DMSO-d6) C ppm 43.9 (CH2), 110.4 
(=CH), 120.7 (ArH), 121.6 (ArH), 124.1 (C), 126.5 (ArH), 127.3 (C), 128.0 (ArH), 128.1 (=CH), 128.2 (ArH), 130.8 (ArH), 
132.0 (C, Ar), 136.2 (ArH), 141.6 (C-Cl), 148.4 (ArH), 158.3 (C, Ar), 159.7 (CON), 186.9 (CO). HRMS (ES+) calcd for 
C18H1335Cl2N2O2 [M+H]+, 374.0458, found, 374.0459 (35Cl). Anal. calcd for C18H13Cl2N2O2 C, 57.77%, H, 3.50%, N, 
11.23%. Found: C, 57.75%, H, 3.23%, N, 11.20%. 
N-Benzyl-4-(2,3-dichlorobenzoyl)-1H-pyrrole-2-carboxamide (6k) 
General procedure M: CDI (114 mg, 0.7 mmol), 36a (100 mg, 0.35 mmol),THF (4 mL), benzylamine (60 mg, 0.56 
mmol), 6k was obtained as a white solid (62 mg, 46%); mp 223-224 °C, max (C2H5OH/nm) 286 and 237. IR υmax/cm-1 
3347, 3161, 3123, 2922, 1620, 1570, 1533, 1491, 1410. 1H-NMR (300 MHz, DMSO-d6) δ ppm 4.43 (d, 2H, J = 6.0 Hz, 
CH2), 7.17-7.37 (m, 7H, 2 x =CH and 5 x ArH), 7.40-7.51 (m, 2H, 2 x ArH), 7.76 (dd, 1H, J = 7.5 and 2.1 Hz, ArH), 8.88 
(app. t, 1H, J = 6.0 Hz, NH), 12.43 (s, 1H, NH). 13C NMR (75 MHz, DMSO-d6) C ppm 42.1, 110.4, 124.4, 126.6, 126.7, 
127.2, 127.5, 128.1, 128.2, 128.3, 128.5, 131.1, 132.2, 139.4, 141.9, 159.8, 187.2. HRMS (ES+) calcd for 
C19H1435Cl2N2O2 [M+H]+, 373.0505, found, 373.0502. 
4-(2,3-Dichlorobenzoyl)-N-phenethyl-1H-pyrrole-2-carboxamide (6l) 
General procedure M: CDI (114 mg, 0.7 mmol), 36a (100 mg, 0.35 mmol),THF (4 mL), phenethylamine (68 mg, 0.56 
mmol), 6l was obtained as a white solid (56 mg, 41%); mp 232-233 °C, max (C2H5OH/nm) 288 and 236. IR υmax/cm-1 
3404, 3332, 3125, 2924, 2854, 1655, 1618, 1572, 1533, 1492, 1433, 1392, 1288, 1242, 1192, 1141, 747, 696. 1H-NMR 
(300 MHz, DMSO-d6) δ ppm 2.80 (t, 2H, J = 7.4 Hz, CH2), 3.44 (app. q, 2H, J = 6.7 Hz, NHCH2), 7.13 (s, 1H, =CH), 7.15-
7.33 (m, 6H, =CH and 5 x ArH), 7.39-7.52 (m, 2H, 2 x ArH), 7.77 (dd, 1H, J = 7.8 and 1.8 Hz, ArH), 8.42 (app. t, 1H, J = 
5.6 Hz, NH), 12.37 (s, 1H, NH). 13C NMR (75 MHz, DMSO-d6) C ppm 34.8, 39.8, 109.8, 124.0, 125.6, 126.5, 127.3, 
127.8, 127.9, 128.0, 128.2, 128.4, 130.8, 132.0, 139.1, 141.6, 159.5, 186.9. HRMS (ES+) calcd for C20H1635Cl2N2O2 
[M+H]+, 387.0662, found, 387.0662. 
4-(2,3-Dichlorobenzoyl)-1-methyl-N-(pyridin-3-ylmethyl)-1H-pyrrole-2-carboxamide (6m) 
General procedure M: CDI (88 mg, 0.54 mmol), 36e (80 mg, 0.27 mmol),THF (4 mL), 3-pyridylmethylamine (73 mg, 
0.68 mmol), 6m was obtained as a white solid (63 mg, 61%); mp 183-184 °C, max (C2H5OH/nm) 284 and 240. IR 
υmax/cm-1 3106, 1641, 1518, 1281. 1H-NMR (300 MHz, DMSO-d6) δ ppm 3.86 (s, 3H, CH3), 4.41 (d, 2H, J = 5.7 Hz, CH2), 
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7.24 (s, 1H, =CH), 7.35 (dd, 1H, J = 7.2 and 5.1 Hz, ArH), 7.39-7.57 (m, 3H, =CH and 2 x ArH), 7.69 (d, 1H, J = 7.8 Hz, 
ArH), 7.77 (d, 1H, J = 7.5 Hz, ArH), 8.45 (d, 1H, J = 4.5 Hz, ArH), 8.52 (s, 1H, ArH), 8.91 (app. t, 1H, J = 5.3 Hz, NH). 13C 
NMR (75 MHz, DMSO-d6) δC ppm 36.5, 112.5, 121.5, 122.9, 126.4, 127.3, 127.5, 128.0, 130.8, 132.0, 133.8, 134.55, 
134.62, 141.4, 147.6, 148.5, 160.3, 186.3. HRMS (ES+) calcd for C19H1535Cl2N3O2 [M+H]+, 388.0614, found, 388.0611. 
Anal. calcd for C19H15Cl2N3O2: C, 58.78%, H, 3.89%, N, 10.82%. Found: C, 58.49%, H, 3.71%, N, 10.41% 
4-(2,3-Dichlorobenzoyl)-N-methyl-N-(pyridin-3-ylmethyl)-1H-pyrrole-2-carboxamide (6n) 
General procedure M: CDI (114 mg, 0.7 mmol), 36a (100 mg, 0.35 mmol),THF (4 mL), N-methyl-1-(pyridin-3-
yl)methanamine (68 mg, 0.56 mmol), 6n was obtained as a white solid (68 mg, 50%); mp 175-176 °C, max 
(C2H5OH/nm) 286 and 235. IR υmax/cm-1 3225, 3061, 1649, 1597, 1548, 1481, 1449, 1410. 1H-NMR (300 MHz, DMSO-
d6) δ ppm 3.21 (br s, 3H, CH3), 4.74 (br s, 2H, CH2), 7.25 (s, 1H, =CH), 7.32-7.51 (m, 3H, 2 x ArH and =CH), 7.68 (d, 1H, J 
= 7.5 Hz, ArH), 7.75 (dd, 1H, J = 7.2 and 2.1 Hz, ArH), 8.50 (dd, 1H, J = 4.7 and 1.7 Hz, ArH), 8.52 (s, 1H, ArH), 12.43 (s, 
1H, NH). 13C NMR (75 MHz, DMSO-d6) C ppm 35.6, 49.4, 111.5, 123.2, 124.0, 126.5, 126.6, 127.3, 128.0, 128.3, 
130.9, 132.0, 132.6, 134.6, 141.3, 148.1, 148.4, 161.3, 186.7. HRMS (ES+) calcd for C19H1535Cl2N3O2 [M+H]+, 388.0614, 
found, 388.0613. Anal. calcd for C19H15Cl2N3O2: C, 58.78%, H, 3.89%, N, 10.82%. Found: C, 58.77%, H, 4.01%, N, 
10.61% 
(4-(2,3-Dichlorobenzoyl)-1H-pyrrol-2-yl)(3,4-dihydro-2,6-naphthyridin-2(1H)-yl)methanone (6o) 
General procedure M: 36a (50 mg, 0.18 mmol), CDI (60 mg, 0.35 mmol), 1,2,3,4-tetrahydro-2,6-naphthyridine (60  
mg, 0.45 mmol) in THF (3 mL). Chromatography (KP-NH silica, 1:9 MeOH/EtOAc) gave 6o as a white solid (40 mg, 
55%); mp: 225-227 ˚C; λmax (EtOH/nm) 287; IR (cm-1) 3202, 1604, 1551; 1H NMR (500 MHz, DMSO-d6) δ ppm 2.95 (2H, 
s, NCH2CH2), 3.95 (2H, s, NCH2CH2), 4.90 (2H, s, NCH2), 7.04 (1H, s, pyrrole-H), 7.27 (1H, s, pyrrole-H), 7.32 (1H, d, J = 
5.1 Hz, pyridyl-H), 7.46-7.51 (2H, m, 2 × ArH), 7.79 (1H, dd, J = 2.0 and 7.4 Hz, ArH), 8.37 (1H, d, J = 5.1 Hz, pyridyl-H), 
8.43 (1H, s, pyridyl-H), 12.45 (1H, s br, NH); 13C NMR (125 MHz, DMSO-d6) δ ppm 121.3, 124.2, 127.0, 127.6, 128.5, 
130.5, 131.4, 132.3, 141.6, 142.0, 147.0, 161.3 (C=O), 187.2 (C=O); HRMS calcd. for C20H1635Cl2N3O2 [M+H]+ 400.0614, 
found 400.0618. 
 (4-(2,3-Dichlorobenzoyl)-1H-pyrrol-2-yl)(isoindolin-2-yl)methanone (6p) 
General procedure M: 36a (50 mg, 0.18 mmol), CDI (60 mg, 0.35 mmol), isoindoline (55  mg, 0.05 mL, 0.45 mmol) in 
THF (3 mL). Chromatography (silica gel, 1:1 EtOAc/petrol) gave 6p as a white solid (54 mg, 78%); mp: 290-292 ˚C; λmax 
(EtOH/nm) 285; IR (cm-1) 3191, 1606, 1585; 1H NMR (500 MHz, DMSO-d6) δ 4.89 (2H, s, NCH2), 5.19 (2H, s, NCH2), 
7.22-7.23 (1H, m, pyrrole-H), 7.26 (1H, s br, pyrrole-H), 7.33-7.35 (2H, m, 2 × ArH), 7.41-7.45 (2H, m, 2 × ArH), 7.47-
7.52 (2H, m, 2 × ArH), 7.80 (1H, dd, J = 2.0 and 7.4 Hz, ArH), 12.47 (1H, s br, NH); 13C NMR (125 MHz, DMSO-d6) δ 
53.0, 53.3, 111.8, 122.8, 123.1, 124.8, 127.0, 127.4, 127.6, 127.8, 128.6, 129.7, 131.4, 132.3, 135.2, 137.1, 141.5, 
159.2, 187.3; HRMS calcd. for C20H1535Cl2N2O2 [M+H]+ 385.0505, found 385.0505. 
(4-(2,3-Dichlorobenzoyl)-1H-pyrrol-2-yl)(3,4-dihydroisoquinolin-2(1H)-yl)methanone (6q) 
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General procedure M: 36a (50 mg, 0.18 mmol), CDI (60 mg, 0.35 mmol), 1,2,3,4-tetrahydroisoquinoline (60 mg, 0.06 
mL, 0.45 mmol) in THF (3 mL). Chromatography (silica gel, 1:1 EtOAc/petrol) gave 6q as a white solid (65 mg, 91%); 
mp: 192-194 ˚C; λmax (EtOH/nm) 286; IR (cm-1) 3202, 1604, 1548; 1H NMR (500 MHz, DMSO-d6) δ ppm 2.93 (2H, s, 
NCH2CH2), 3.91 (2H, s, NCH2CH2), 4.84 (2H, s, NCH2), 7.01 (1H, s, pyrrole-H), 7.20-7.28 (5H, m, pyrrole-H, 4 × ArH), 
7.47-7.49 (2H, m, 2 × ArH), 7.79 (1H, dd, J = 2.4 and 7.1 Hz, ArH), 12.38 (1H, s br, NH); 13C NMR (125 MHz, DMSO-d6) 
δ ppm 124.2, 126.2, 126.4, 126.6, 127.0, 127.2, 127.6, 128.3, 128.5, 129.3, 131.4, 132.3, 133.3, 134.8, 141.6, 187.3 
(C=O); HRMS calcd. for C21H1735Cl2N2O2 [M+H]+ 399.0662, found 399.0662. 
 (4-(2,3-Dichlorobenzoyl)-1H-pyrrol-2-yl)(1H-pyrrolo[3,4-c]pyridin-2(3H)-yl)methanone (6r) 
General procedure M: 36a (55 mg, 0.2 mmol), CDI (65 mg, 0.4 mmol), 2,3-dihydro-1H-pyrrolo[3,4-c]pyridine 
hydrochloride (60 mg, 0.5 mmol) in THF (3 mL). Chromatography (KP-NH silica, 1:9 MeOH/EtOAc) gave 6r as a white 
solid (43 mg, 56%); mp: 258-260 ˚C; λmax (EtOH/nm) 286; IR (cm-1) 3181, 1633, 1577; 1H NMR (500 MHz, DMSO-d6) δ 
ppm 4.94 (2H, d, J = 10.2 Hz, NCH2), 5.18 (2H, d, J = 7.8 Hz, NCH2), 7.22 (1H, s, pyrrole-H), 7.24 (1H, s, pyrrole-H), 7.31 
(1H, dd, J = 1.6 and 7.6 Hz, ArH), 7.35 (1H, dd, J = 7.6 and 7.7 Hz, ArH), 7.41-7.43 (1H, m, pyridyl-H), 7.60 (1H, dd, J = 
1.6 and 7.7 Hz, ArH), 8.40 (1H, d, J = 5.0 Hz, pyridyl-H), 8.53 (1H, s, pyridyl-H), 13.24 (1H, s br, pyrrole-NH); 13C NMR 
(125 MHz, DMSO-d6) δ ppm 51.4, 52.7, 111.9, 118.5, 124.9, 127.6, 128.5, 129.8, 131.4, 131.9, 132.2, 141.5, 144.6, 
148.0, 159.2, 187.3; HRMS calcd. for C19H1435Cl2N3O2 [M+H]+ 386.0458, found 386.0460. 
 (E)-1-(4-(2,3-Dichlorobenzoyl)-1H-pyrrol-2-yl)-3-(pyridin-4-yl)prop-2-en-1-one (40) 
A mixture 39 (200 mg, 0.70 mmol) and 4-pyridine carboxaldehyde (75 mg, 0.07 mL, 0.70 mmol) in EtOH (1 mL) was 
cooled to 0 oC, potassium hydroxide (40%, 285 mg in 0.7 mL H2O) was added dropwise and the resulting solution 
stirred at rt for 18 h. Upon addition of H2O (40 mL) a precipitate formed which was collected by filtration. 
Recrystallisation (EtOH) gave 40 as a beige solid (245 mg, 95%); mp: 262-265 ˚C; λmax (EtOH/nm) 324, 286, 219; IR 
(cm-1) 3225, 1649, 1588; 1H NMR (500 MHz, DMSO-d6) δ 7.49-7.52 (2H, m, 2 × ArH), 7.59 (1H, s, pyrrole-H), 7.68 (1H, 
d, J = 16.0 Hz, alkene-H), 7.82 (1H, dd, J = 2.4 and 7.0 Hz, ArH), 7.87 (2H, d, J = 6.0 Hz, 2 × pyridyl-H), 7.92 (1H, s, 
pyrrole-H), 8.07 (1H, d, J = 16.0 Hz, alkene-H), 8.67 (2H, d, J = 6.0 Hz, 2 × pyridyl-H), 12.92 (1H, s, NH); 13C NMR (125 
MHz, DMSO-d6) δ 117.8, 122.6, 125.3, 126.5, 127.1, 127.6, 128.7, 131.6, 132.4, 132.8, 134.4, 139.5. 141.4, 141.7, 
149.5, 150.3, 178.6, 187.5; HRMS calcd. for C19H1135Cl2N2O2 [M-H]- 369.0203, found 369.0201. 
1-(4-(2,3-Dichlorobenzoyl)-1H-pyrrol-2-yl)-3-(pyridin-4-yl)propan-1-one (41) 
To ammonium chloride (205 mg, 3.85 mmol), in ethanol (0.30 mL) and water (0.30 mL) was added 40 (75 mg, 0.20 
mmol) followed by indium powder (35 mg, 0.30 mmol). The mixture was heated at reflux for 8 h, cooled to RT and 
diluted with H2O (10 mL). The solid was extracted into EtOAc (2 × 25 mL), washed with brine (25 mL) and dried 
(Na2SO4) and evaporated. Chromatography(C18 silica, 70% MeCN, 0.1% formic acid, water) gave 41 as an off-white 
solid (20 mg, 27%); mp: 249-251 ˚C; λmax (EtOH/nm) 294, 237; IR (cm-1) 1640, 1551; 1H NMR (500 MHz, DMSO-d6) δ 
2.93 (2H, t, J = 7.5 Hz, CH2CH2), 3.26 (2H, t, J = 7.5 Hz, CH2CH2), 7.31 (2H, d, J = 6.0 Hz, 2 × pyridyl-H), 7.42 (1H, s, 
pyrrole-H), 7.44 (1H, dd, J = 1.7 and 7.7 Hz, ArH), 7.46 (1H, s br, pyrrole-H), 7.49 (1H, dd, J = 7.7 and 7.9 Hz, ArH), 7.79 
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(1H, dd, J = 1.7 and 7.9 Hz, ArH), 8.45 (2H, d, J = 6.0 Hz, 2 × pyridyl-H), 12.66 (1H, s br, NH); 13C NMR (125 MHz, 
CD3OD) δ 30.4, 38.7, 117.3, 125.8, 126.8, 127.9, 129.2, 129.9, 132.6, 132.8, 134.7, 134.8, 142.9, 149.7, 153.6, 190.3, 
191.0; HRMS calcd. for C19H1535Cl2N2O2 [M+H]+ 373.0505, found 373.0509. 
 (E)-(4-(2,3-Dichlorobenzoyl)-1H-pyrrol-2-yl)(2-(pyridin-4-yl)cyclopropyl)methanone (42) 
A solution of (E)-1-(4-(2,3-dichlorobenzoyl)-1H-pyrrol-2-yl)-3-(pyridine-4-yl)prop-2-en-1-one 40 (100 mg, 0.26 mmol) 
in DMSO (1 mL) was added to a mixture of trimethylsulfoxonium iodide (70 mg, 0.32 mmol) and potassium tert-
butoxide (35 mg, 0.32 mmol). The resulting solution was stirred at rt for 24 h then further trimethylsulfoxonium 
iodide (70 mg, 0.32 mmol) and potassium tert-butoxide (35 mg, 0.32 mmol) was added, and stirring continued for a 
further 24 h until complete by LCMS. The mixture was treated with brine (10 mL) and the product extracted with 
EtOAc (2 × 10 mL), washed with water (10 mL), brine (10 mL), dried(Na2SO4) and evaporated. HPLC (C18 silica 1:1 
0.1% Formic acid, MeCN) gave 42 as a white solid (30 mg, 24%); mp: 125-127 ˚C; λmax (EtOH/nm) 293, 234; IR (cm-1) 
3119, 1636, 1548; 1H NMR (500 MHz, CD3OD) δ ppm 1.41 (1H, ddd, J = 4.2, 6.4 and 8.4 Hz, CH2), 1.63 (1H, ddd, J = 
4.2, 5.4 and 9.2 Hz, CH2), 2.44 (1H, ddd, J = 4.2, 6.4 and 9.2 Hz, cyclopropane-CH), 2.87 (1H, ddd, J = 4.2, 5.4 and 8.4 
Hz, cyclopropane-CH), 7.10 (2H, d, J = 6.2 Hz, 2 × pyridyl-H), 7.18 (1H, dd,  J = 1.6 and 7.6 Hz, ArH), 7.23 (1H, dd, J = 
7.6 and 7.8 Hz, ArH), 7.27 (1H, d, J = 1.5 Hz, pyrrole-H), 7.31 (1H, d, J = 1.5 Hz, pyrrole-H), 7.50 (1H, dd, J = 1.6 and 7.8 
Hz, ArH), 8.22 (2H, d, J = 6.2 Hz, 2 × pyridyl-H); 13C NMR (125 MHz, CD3OD) δ ppm 19.9, 28.3, 30.0, 117.8, 123.0, 
127.0, 128.0, 129.2, 132.7, 132.8, 134.8, 142.9, 150.0, 152.9, 189.4, 190.4; HRMS calcd. for C20H1535Cl2N2O2 [M+H]+ 
385.0505, found 385.0506. 
1-(Pyridin-4-yl)-3-(1H-pyrrol-2-yl)propane-1,3-dione (43) 
To a stirred solution of potassium tert-butoxide (370 mg, 3.3 mmol) in THF (5 mL) was added 2-acetyl pyrrole (165 
mg, 1.5 mmol) followed by ethyl isonicotinate (500 mg, 3.3 mmol). The resulting mixture was stirred at RT for 6 h. 
The mixture was acidified to pH 4 with aq. HCl (1.0 M) and water (50 mL) added, upon which the product 
precipitated. The product was collected by filtration and recrystallised from EtOH to give 43 as a yellow solid (230 
mg, 33%); mp: 190-191 ˚C; λmax (EtOH/nm) 359, 283; IR (cm-1) 3044, 1595; 1H NMR (500 MHz, DMSO-d6) δ 6.34 (1H, s, 
pyrrole-H), 7.17 (1H, s, CHCO), 7.27 (1H, s, pyrrole-H), 7.41 (1H, s, pyrrole-H), 7.94 (2H, d, J = 6.0 Hz, 2 × pyridyl-H), 
8.78 (2H, d, J = 6.0 Hz, 2 × pyridyl-H), 12.18 (1H, br s, NH), 16.30 (1H, br s, OH); 13C NMR (125 MHz, DMSO-d6) δ 94.9, 
111.0, 117.7, 119.9, 127.3, 129.9, 141.0, 150.5, 172.2, 182.1; HRMS calcd. for C12H11N2O2 [M+H]+ 215.0815, found 
215.0817. 
Kinase Selectivity for 6h 
Kinase selectivity screening was conducted by Millipore. 
Kinase %inhibition @ 10 uM 
Abl(h) 8 
Aurora-A(h) 11 
CDK2/cyclinA(h) 5 
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c-RAF(h) -27 
cSRC(h) 0 
DAPK1(h) -6 
EGFR(h) -14 
GSK3α(h) 14 
IKKα(h) -14 
IR(h) -4 
IRAK4(h) 7 
JAK3(h) -5 
JNK1α1(h) 27 
MAPK1(h) 45 
MAPKAP-K2(h) 11 
MEK1(h) -9 
PKBβ(h) 4 
PKCα(h) -6 
SAPK2a(h) 76 
SGK(h) 5 
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X-ray Crystallography 
Table S1.  Crystal data and structure refinement for irh34 (12a). 
 
Identification code  irh34 
CCDC reference 1410001 
Chemical formula (moiety) C11H13N3O2S2 
Chemical formula (total) C11H13N3O2S2 
Formula weight  283.36 
Temperature  120(2) K 
Radiation, wavelength  synchrotron, 0.6946 Å 
Crystal system, space group  monoclinic, P21/n 
Unit cell parameters a = 7.826(3) Å  = 90° 
 b = 9.969(4) Å  = 98.843(4)° 
 c = 16.338(6) Å  = 90° 
Cell volume 1259.5(8) Å3 
Z 4 
Calculated density  1.494 g/cm3 
Absorption coefficient  0.344 mm1 
F(000) 592 
Crystal colour and size colourless, 0.040  0.040  0.010 mm3 
Reflections for cell refinement 959 ( range 2.3 to 28.5°) 
Data collection method Bruker APEX2 CCD diffractometer 
 thin-slice  scans 
 range for data collection 3.3 to 29.7° 
Index ranges h 11 to 11, k 14 to 14, l 22 to 22 
Completeness to  = 24.6° 99.2 %  
Reflections collected 12427 
Independent reflections 3627 (Rint = 0.0336) 
Reflections with F2>2 2752 
Absorption correction multi-scan 
Min. and max. transmission 0.983 and 0.996 
Structure solution direct methods 
Refinement method Full-matrix least-squares on F2 
Weighting parameters a, b 0.0717, 0.4971 
Data / restraints / parameters 3627 / 0 / 171 
Final R indices [F2>2] R1 = 0.0449, wR2 = 0.1180 
R indices (all data) R1 = 0.0643, wR2 = 0.1295 
Goodness-of-fit on F2 1.034 
Largest and mean shift/su 0.001 and 0.000 
Largest diff. peak and hole 0.48 and 0.50 e Å3 
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Table S2.  Atomic coordinates and equivalent isotropic displacement parameters (Å2) for irh34.   
Ueq is defined as one third of the trace of the orthogonalized Uij tensor. 
 
      x      y      z      Ueq 
 
S1 0.45275(6) 0.22259(5) 0.61587(3) 0.02745(13) 
S2 0.30115(7) 0.53007(5) 0.58625(3) 0.03477(15) 
O1 0.58167(18) 0.12389(15) 0.60562(9) 0.0329(3) 
O2 0.50063(19) 0.33638(15) 0.66871(9) 0.0347(3) 
N1 0.3157(2) 0.14337(19) 0.30508(11) 0.0324(4) 
N2 0.2995(2) 0.14560(17) 0.65177(11) 0.0301(4) 
N3 0.0974(3) 0.7440(2) 0.50956(14) 0.0483(5) 
C1 0.3714(2) 0.28568(19) 0.51623(12) 0.0266(4) 
C2 0.3757(2) 0.19692(19) 0.45052(12) 0.0271(4) 
C3 0.3048(2) 0.2314(2) 0.36934(12) 0.0276(4) 
C4 0.2301(3) 0.3586(2) 0.35621(13) 0.0313(4) 
C5 0.2293(3) 0.4478(2) 0.42095(13) 0.0313(4) 
C6 0.2988(2) 0.4141(2) 0.50191(12) 0.0287(4) 
C7 0.1571(3) 0.2202(2) 0.68066(17) 0.0434(5) 
C8 0.0229(3) 0.1145(3) 0.68861(16) 0.0423(5) 
C9 0.0617(4)  0.0015(3) 0.6380(3) 0.0702(10) 
C10 0.2360(3) 0.0155(2) 0.61470(16) 0.0402(5) 
C11 0.1779(3) 0.6545(2) 0.53731(14) 0.0363(5) 
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Table S3.   Bond lengths [Å] and angles [°] for irh34. 
 
S1–O1  1.4374(16) S1–O2  1.4399(16) 
S1–N2  1.6086(17) S1–C1  1.770(2) 
S2–C6  1.797(2) S2–C11  1.694(2) 
N1–H1A  0.86(3) N1–H1B  0.91(3) 
N1–C3  1.381(3) N2–C7  1.477(3) 
N2–C10  1.485(3) N3–C11  1.145(3) 
C1–C2  1.396(3) C1–C6  1.405(3) 
C2–H2  0.950 C2–C3  1.400(3) 
C3–C4  1.399(3) C4–H4  0.950 
C4–C5  1.383(3) C5–H5  0.950 
C5–C6  1.392(3) C7–H7A  0.990 
C7–H7B  0.990 C7–C8  1.507(3) 
C8–H8A  0.990 C8–H8B  0.990 
C8–C9  1.480(4) C9–H9A  0.990 
C9–H9B  0.990 C9–C10  1.482(3) 
C10–H10A  0.990 C10–H10B  0.990 
 
O1–S1–O2 119.11(9) O1–S1–N2 106.97(9) 
O1–S1–C1 107.21(9) O2–S1–N2 107.29(9) 
O2–S1–C1 107.17(9) N2–S1–C1 108.78(9) 
C6–S2–C11 99.85(10) H1A–N1–H1B 118(3) 
H1A–N1–C3 112.8(19) H1B–N1–C3 110.9(17) 
S1–N2–C7 121.21(15) S1–N2–C10 119.32(14) 
C7–N2–C10 110.40(17) S1–C1–C2 115.75(14) 
S1–C1–C6 123.77(15) C2–C1–C6 120.42(18) 
C1–C2–H2 119.3 C1–C2–C3 121.35(18) 
H2–C2–C3 119.3 N1–C3–C2 120.17(19) 
N1–C3–C4 122.19(18) C2–C3–C4 117.60(18) 
C3–C4–H4 119.4 C3–C4–C5 121.11(19) 
H4–C4–C5 119.4 C4–C5–H5 119.2 
C4–C5–C6 121.65(19) H5–C5–C6 119.2 
S2–C6–C1 120.14(15) S2–C6–C5 122.00(16) 
C1–C6–C5 117.85(18) N2–C7–H7A 110.9 
N2–C7–H7B 110.9 N2–C7–C8 104.23(19) 
H7A–C7–H7B 108.9 H7A–C7–C8 110.9 
H7B–C7–C8 110.9 C7–C8–H8A 110.3 
C7–C8–H8B 110.3 C7–C8–C9 107.03(19) 
H8A–C8–H8B 108.6 H8A–C8–C9 110.3 
H8B–C8–C9 110.3 C8–C9–H9A 109.8 
C8–C9–H9B 109.8 C8–C9–C10 109.3(2) 
H9A–C9–H9B 108.3 H9A–C9–C10 109.8 
H9B–C9–C10 109.8 N2–C10–C9 105.00(19) 
N2–C10–H10A 110.7 N2–C10–H10B 110.7 
C9–C10–H10A 110.7 C9–C10–H10B 110.7 
H10A–C10–H10B 108.8 S2–C11–N3 174.9(2) 
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Table S4.  Torsion angles [°] for irh34. 
 
O1–S1–N2–C7 171.32(17) O1–S1–N2–C10  44.80(18) 
O2–S1–N2–C7 42.44(19) O2–S1–N2–C10  173.68(16) 
C1–S1–N2–C7  73.18(19) C1–S1–N2–C10 70.69(18) 
O1–S1–C1–C2 29.00(17) O1–S1–C1–C6  153.84(16) 
O2–S1–C1–C2 157.96(15) O2–S1–C1–C6  24.88(19) 
N2–S1–C1–C2  86.35(16) N2–S1–C1–C6 90.82(18) 
S1–C1–C2–C3 175.70(14) C6–C1–C2–C3  1.6(3) 
C1–C2–C3–N1 177.92(18) C1–C2–C3–C4 0.4(3) 
N1–C3–C4–C5  176.34(19) C2–C3–C4–C5 1.1(3) 
C3–C4–C5–C6  1.5(3) C4–C5–C6–S2 179.10(16) 
C4–C5–C6–C1 0.3(3) S1–C1–C6–S2 5.4(2) 
S1–C1–C6–C5  175.86(15) C2–C1–C6–S2  177.61(14) 
C2–C1–C6–C5 1.2(3) C11–S2–C6–C1  172.97(16) 
C11–S2–C6–C5 8.29(19) S1–N2–C7–C8 166.45(16) 
C10–N2–C7–C8 19.7(3) N2–C7–C8–C9  19.5(3) 
C7–C8–C9–C10 12.8(4) C8–C9–C10–N2  0.7(4) 
S1–N2–C10–C9  159.6(2) C7–N2–C10–C9  12.1(3) 
 
 
 
Table S5.   Anisotropic displacement parameters (Å2) for irh34.  The anisotropic displacement factor exponent takes 
the form: 22[h2a*2U11 + ...+ 2hka*b*U12] 
 
      U11      U22      U33      U23      U13      U12 
 
S1 0.0243(2)  0.0263(2) 0.0300(2)  0.00216(17)  0.00146(17)   0.00299(17) 
S2 0.0385(3)  0.0260(3) 0.0381(3)   0.00274(19) 0.0004(2)   0.00121(19) 
O1 0.0262(7)  0.0331(7) 0.0378(8)  0.0058(6) 0.0001(6)  0.0018(6) 
O2 0.0345(8)  0.0305(8) 0.0355(8)   0.0018(6)  0.0061(6)   0.0051(6) 
N1 0.0348(9)  0.0311(9) 0.0300(9)  0.0012(7) 0.0005(7)  0.0015(7) 
N2 0.0286(8)  0.0277(8) 0.0343(9)  0.0004(7) 0.0059(7)   0.0040(6) 
N3 0.0579(14)  0.0351(10) 0.0518(13)  0.0006(9) 0.0084(10)  0.0077(9) 
C1 0.0235(8)  0.0259(9) 0.0292(9)  0.0033(7) 0.0002(7)   0.0040(7) 
C2 0.0241(9)  0.0244(9) 0.0321(10)  0.0036(7) 0.0019(7)   0.0020(7) 
C3 0.0239(9)  0.0296(10) 0.0291(9)  0.0011(7) 0.0034(7)   0.0042(7) 
C4 0.0308(10)  0.0310(10) 0.0309(10)  0.0042(8) 0.0014(8)   0.0006(8) 
C5 0.0307(10)  0.0251(9) 0.0372(11)  0.0050(7) 0.0023(8)  0.0005(7) 
C6 0.0258(9)  0.0250(9) 0.0346(10)  0.0001(7) 0.0032(7)   0.0035(7) 
C7 0.0390(12)  0.0391(12) 0.0555(14)   0.0104(10) 0.0185(11)   0.0042(9) 
C8 0.0373(12)  0.0462(13) 0.0454(13)  0.0002(10) 0.0132(10)   0.0029(10) 
C9 0.0514(17)  0.0477(16) 0.123(3)   0.0266(17) 0.0494(19)   0.0202(13) 
C10 0.0398(12)  0.0319(11) 0.0519(13)   0.0072(9) 0.0164(10)   0.0112(9) 
C11 0.0383(11)  0.0282(10) 0.0429(12)   0.0022(8) 0.0072(9)   0.0026(8) 
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Table S6.   Hydrogen coordinates and isotropic displacement parameters (Å2) for irh34. 
 
      x       y       z       U 
 
H1A 0.237(4) 0.157(3) 0.2631(18) 0.047(8) 
H1B 0.334(3) 0.058(3) 0.3243(17) 0.044(7) 
H2 0.4279 0.1114 0.4611 0.033 
H4 0.1791 0.3842 0.3019 0.038 
H5 0.1802 0.5343 0.4099 0.038 
H7A 0.1104 0.2897 0.6400 0.052 
H7B 0.1968 0.2637 0.7347 0.052 
H8A 0.0282 0.0876 0.7473 0.051 
H8B  0.0944 0.1495 0.6683 0.051 
H9A  0.0258  0.0077 0.5875 0.084 
H9B 0.0575  0.0855 0.6700 0.084 
H10A 0.2295 0.0176 0.5537 0.048 
H10B 0.3134  0.0587 0.6372 0.048 
  
 
 
 
 
Table S7.  Hydrogen bonds for irh34 [Å and °]. 
 
D–H...A d(D–H) d(H...A) d(D...A) <(DHA) 
 
N1–H1A...O2a 0.86(3) 2.22(3) 3.065(3) 168(3) 
N1–H1B...O1b 0.91(3) 2.19(3) 3.084(3) 166(2) 
 
Symmetry operations for equivalent atoms 
a   x1/2,y+1/2,z1/2      b   x+1,y,z+1        
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Table S8.  Crystal data and structure refinement for irh33 (3a). 
 
Identification code  irh33 
CCDC reference 1410003 
Chemical formula (moiety) C11H13N3O2S2 
Chemical formula (total) C11H13N3O2S2 
Formula weight  283.36 
Temperature  120(2) K 
Radiation, wavelength  synchrotron, 0.6946 Å 
Crystal system, space group  triclinic, P1 
Unit cell parameters a = 6.3088(11) Å  = 92.623(2)° 
 b = 9.4321(16) Å  = 106.331(2)° 
 c = 11.166(2) Å  = 105.543(2)° 
Cell volume 609.02(18) Å3 
Z 2 
Calculated density  1.545 g/cm3 
Absorption coefficient  0.356 mm1 
F(000) 296 
Crystal colour and size colourless, 0.100  0.060  0.040 mm3 
Reflections for cell refinement 956 ( range 3.2 to 29.7°) 
Data collection method Bruker APEX2 CCD diffractometer 
 thin-slice  scans 
 range for data collection 3.1 to 29.7° 
Index ranges h 8 to 8, k 13 to 13, l 15 to 15 
Completeness to  = 24.6° 95.1 %  
Reflections collected 5928 
Independent reflections 3259 (Rint = 0.0154) 
Reflections with F2>2 2992 
Absorption correction multi-scan 
Min. and max. transmission 0.905 and 0.985 
Structure solution direct methods 
Refinement method Full-matrix least-squares on F2 
Weighting parameters a, b 0.0614, 0.2169 
Data / restraints / parameters 3259 / 0 / 171 
Final R indices [F2>2] R1 = 0.0350, wR2 = 0.0964 
R indices (all data) R1 = 0.0374, wR2 = 0.0989 
Goodness-of-fit on F2 1.061 
Largest and mean shift/su 0.001 and 0.000 
Largest diff. peak and hole 0.47 and 0.37 e Å3 
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Table S9.  Atomic coordinates and equivalent isotropic displacement parameters (Å2) for irh33.   
Ueq is defined as one third of the trace of the orthogonalized Uij tensor. 
 
      x      y      z      Ueq 
 
S1 1.26080(5) 0.76007(3) 0.82726(3) 0.01752(10) 
S2 0.71598(5) 0.17379(3) 0.72181(3) 0.01532(10) 
O1 0.58683(18) 0.08027(11) 0.79114(9) 0.0215(2) 
O2 0.92256(17) 0.14878(11) 0.70740(9) 0.0210(2) 
N1 0.95529(19) 0.80431(12) 0.93174(10) 0.0166(2) 
N2 1.2484(2) 1.01893(12) 0.93190(11) 0.0184(2) 
N3 0.54162(19) 0.15819(13) 0.58099(10) 0.0185(2) 
C1 1.1430(2) 0.87383(13) 0.90441(11) 0.0155(2) 
C2 1.0334(2) 0.60795(13) 0.82872(11) 0.0155(2) 
C3 0.9865(2) 0.46098(13) 0.77987(11) 0.0165(2) 
C4 0.7895(2) 0.35855(13) 0.79122(11) 0.0154(2) 
C5 0.6441(2) 0.40232(14) 0.85089(12) 0.0172(2) 
C6 0.6944(2) 0.54971(14) 0.89994(12) 0.0175(2) 
C7 0.8898(2) 0.65449(13) 0.88922(11) 0.0150(2) 
C8 0.3007(2) 0.16057(18) 0.56295(14) 0.0271(3) 
C9 0.2750(3) 0.2817(2) 0.47955(17) 0.0346(4) 
C10 0.4228(3) 0.26626(19) 0.39552(15) 0.0297(3) 
C11 0.6329(2) 0.23542(17) 0.48523(13) 0.0231(3) 
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Table S10.   Bond lengths [Å] and angles [°] for irh33. 
 
S1–C1  1.7744(12) S1–C2  1.7405(13) 
S2–O1  1.4399(10) S2–O2  1.4350(10) 
S2–N3  1.6197(12) S2–C4  1.7589(13) 
N1–C1  1.3157(16) N1–C7  1.3815(15) 
N2–H2A  0.82(2) N2–H2B  0.85(2) 
N2–C1  1.3299(17) N3–C8  1.4823(18) 
N3–C11  1.4826(17) C2–C3  1.3881(16) 
C2–C7  1.4140(16) C3–H3  0.950 
C3–C4  1.3964(17) C4–C5  1.4061(17) 
C5–H5  0.950 C5–C6  1.3890(17) 
C6–H6  0.950 C6–C7  1.3969(17) 
C8–H8A  0.990 C8–H8B  0.990 
C8–C9  1.520(2) C9–H9A  0.990 
C9–H9B  0.990 C9–C10  1.525(2) 
C10–H10A  0.990 C10–H10B  0.990 
C10–C11  1.527(2) C11–H11A  0.990 
C11–H11B  0.990  
 
C1–S1–C2 88.63(6) O1–S2–O2 120.23(6) 
O1–S2–N3 106.50(6) O1–S2–C4 107.91(6) 
O2–S2–N3 106.39(6) O2–S2–C4 107.34(6) 
N3–S2–C4 107.95(6) C1–N1–C7 110.37(10) 
H2A–N2–H2B 122(2) H2A–N2–C1 119.2(14) 
H2B–N2–C1 118.3(15) S2–N3–C8 119.93(9) 
S2–N3–C11 118.53(9) C8–N3–C11 110.42(11) 
S1–C1–N1 115.66(9) S1–C1–N2 119.28(10) 
N1–C1–N2 125.05(12) S1–C2–C3 128.51(9) 
S1–C2–C7 109.51(9) C3–C2–C7 121.98(11) 
C2–C3–H3 121.1 C2–C3–C4 117.78(11) 
H3–C3–C4 121.1 S2–C4–C3 118.79(9) 
S2–C4–C5 119.90(9) C3–C4–C5 121.23(11) 
C4–C5–H5 119.9 C4–C5–C6 120.23(11) 
H5–C5–C6 119.9 C5–C6–H6 120.2 
C5–C6–C7 119.65(11) H6–C6–C7 120.2 
N1–C7–C2 115.81(11) N1–C7–C6 125.05(11) 
C2–C7–C6 119.13(11) N3–C8–H8A 111.0 
N3–C8–H8B 111.0 N3–C8–C9 103.62(12) 
H8A–C8–H8B 109.0 H8A–C8–C9 111.0 
H8B–C8–C9 111.0 C8–C9–H9A 111.2 
C8–C9–H9B 111.2 C8–C9–C10 102.67(13) 
H9A–C9–H9B 109.1 H9A–C9–C10 111.2 
H9B–C9–C10 111.2 C9–C10–H10A 111.1 
C9–C10–H10B 111.1 C9–C10–C11 103.52(12) 
H10A–C10–H10B 109.0 H10A–C10–C11 111.1 
H10B–C10–C11 111.1 N3–C11–C10 103.93(11) 
N3–C11–H11A 111.0 N3–C11–H11B 111.0 
C10–C11–H11A 111.0 C10–C11–H11B 111.0 
H11A–C11–H11B 109.0  
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Table S11.  Torsion angles [°] for irh33. 
 
O1–S2–N3–C8 43.50(12) O1–S2–N3–C11  176.03(10) 
O2–S2–N3–C8 172.89(10) O2–S2–N3–C11  46.64(11) 
C4–S2–N3–C8  72.16(12) C4–S2–N3–C11 68.31(11) 
C7–N1–C1–S1  1.58(14) C7–N1–C1–N2 179.50(12) 
C2–S1–C1–N1 1.62(10) C2–S1–C1–N2  179.40(11) 
C1–S1–C2–C3 178.50(12) C1–S1–C2–C7  1.12(9) 
S1–C2–C3–C4  179.06(10) C7–C2–C3–C4 0.51(18) 
C2–C3–C4–S2 176.17(9) C2–C3–C4–C5  0.44(18) 
O1–S2–C4–C3 153.40(10) O1–S2–C4–C5  29.95(12) 
O2–S2–C4–C3 22.45(12) O2–S2–C4–C5  160.89(10) 
N3–S2–C4–C3  91.87(11) N3–S2–C4–C5 84.79(11) 
S2–C4–C5–C6  176.52(10) C3–C4–C5–C6 0.06(19) 
C4–C5–C6–C7 0.28(19) C1–N1–C7–C2 0.66(15) 
C1–N1–C7–C6  178.19(12) C5–C6–C7–N1 178.60(12) 
C5–C6–C7–C2  0.21(18) S1–C2–C7–N1 0.53(14) 
S1–C2–C7–C6 179.46(9) C3–C2–C7–N1  179.11(11) 
C3–C2–C7–C6  0.19(19) S2–N3–C8–C9 126.45(12) 
C11–N3–C8–C9  16.92(15) N3–C8–C9–C10 34.68(16) 
C8–C9–C10–C11  39.86(16) S2–N3–C11–C10  151.76(10) 
C8–N3–C11–C10  7.81(15) C9–C10–C11–N3 29.39(16) 
 
 
 
 
Table S12.   Anisotropic displacement parameters (Å2) for irh33.  The anisotropic displacement factor exponent takes 
the form: 22[h2a*2U11 + ...+ 2hka*b*U12] 
 
      U11      U22      U33      U23      U13      U12 
 
S1 0.01638(16)  0.01554(16) 0.02077(17)   0.00111(11) 0.00896(12)  0.00200(11) 
S2 0.01746(16)  0.01347(16) 0.01568(16)  0.00091(10) 0.00729(11)  0.00341(11) 
O1 0.0283(5)  0.0164(4) 0.0218(5)  0.0040(3) 0.0136(4)  0.0031(4) 
O2 0.0204(5)  0.0203(5) 0.0249(5)  0.0010(4) 0.0091(4)  0.0082(4) 
N1 0.0183(5)  0.0143(5) 0.0183(5)  0.0011(4) 0.0082(4)  0.0040(4) 
N2 0.0196(5)  0.0147(5) 0.0224(5)  0.0014(4) 0.0102(4)  0.0037(4) 
N3 0.0167(5)  0.0213(5) 0.0156(5)   0.0001(4) 0.0058(4)  0.0021(4) 
C1 0.0161(5)  0.0167(5) 0.0140(5)  0.0006(4) 0.0048(4)  0.0055(4) 
C2 0.0150(5)  0.0153(5) 0.0153(5)  0.0010(4) 0.0056(4)  0.0022(4) 
C3 0.0162(6)  0.0170(6) 0.0165(6)   0.0004(4) 0.0059(4)  0.0045(5) 
C4 0.0175(5)  0.0143(5) 0.0143(5)  0.0008(4) 0.0058(4)  0.0037(4) 
C5 0.0190(6)  0.0157(5) 0.0176(5)  0.0017(4) 0.0086(4)  0.0030(4) 
C6 0.0195(6)  0.0172(6) 0.0181(6)  0.0015(4) 0.0098(4)  0.0050(5) 
C7 0.0166(5)  0.0153(5) 0.0134(5)  0.0015(4) 0.0051(4)  0.0046(4) 
C8 0.0161(6)  0.0354(8) 0.0269(7)  0.0014(6) 0.0063(5)  0.0036(5) 
C9 0.0300(8)  0.0432(9) 0.0343(8)  0.0062(7) 0.0086(6)  0.0179(7) 
C10 0.0329(8)  0.0332(8) 0.0212(7)  0.0047(5) 0.0049(6)  0.0103(6) 
C11 0.0245(6)  0.0277(7) 0.0172(6)  0.0034(5) 0.0093(5)  0.0048(5) 
77 
 
Table S13.   Hydrogen coordinates and isotropic displacement parameters (Å2) for irh33. 
 
      x       y       z       U 
 
H2A 1.361(4) 1.055(2) 0.908(2) 0.029(5) 
H2B 1.185(4) 1.073(3) 0.964(2) 0.037(6) 
H3 1.0851 0.4311 0.7400 0.020 
H5 0.5110 0.3308 0.8577 0.021 
H6 0.5965 0.5791 0.9406 0.021 
H8A 0.2769 0.1849 0.6445 0.033 
H8B 0.1893 0.0636 0.5212 0.033 
H9A 0.3336 0.3809 0.5301 0.042 
H9B 0.1118 0.2649 0.4293 0.042 
H10A 0.4688 0.3588 0.3586 0.036 
H10B 0.3392 0.1831 0.3267 0.036 
H11A 0.6957 0.1716 0.4406 0.028 
H11B 0.7559 0.3290 0.5244 0.028 
  
 
 
 
 
Table S14.  Hydrogen bonds for irh33 [Å and °]. 
 
D–H...A d(D–H) d(H...A) d(D...A) <(DHA) 
 
N2–H2A...O1a 0.82(2) 2.16(2) 2.9448(15) 159(2) 
N2–H2B...N1b 0.85(2) 2.11(2) 2.9608(16) 172(2) 
 
Symmetry operations for equivalent atoms 
a   x+1,y+1,z      b   x+2,y+2,z+2        
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Table S15.  Crystal data and structure refinement for irh32 (3i). 
 
Identification code  irh32 
CCDC reference 1410004 
Chemical formula (moiety) C10H13N3O2S2 
Chemical formula (total) C10H13N3O2S2 
Formula weight  271.35 
Temperature  150(2) K 
Radiation, wavelength  MoK, 0.71073 Å 
Crystal system, space group  orthorhombic, Pca21 
Unit cell parameters a = 14.3612(3) Å  = 90° 
 b = 9.07325(14) Å  = 90° 
 c = 18.9809(4) Å  = 90° 
Cell volume 2473.26(8) Å3 
Z 8 
Calculated density  1.457 g/cm3 
Absorption coefficient  0.424 mm1 
F(000) 1136 
Crystal colour and size colourless, 0.200  0.100  0.100 mm3 
Reflections for cell refinement 6930 ( range 3.0 to 29.6°) 
Data collection method Oxford Diffraction Gemini A Ultra diffractometer 
 thin-slice  scans 
 range for data collection 3.0 to 29.6° 
Index ranges h 14 to 19, k 12 to 11, l 20 to 25 
Completeness to  = 25.2° 99.8 %  
Reflections collected 11183 
Independent reflections 5361 (Rint = 0.0237) 
Reflections with F2>2 4330 
Absorption correction multi-scan 
Min. and max. transmission 0.920 and 0.960 
Structure solution direct methods 
Refinement method Full-matrix least-squares on F2 
Weighting parameters a, b 0.0501,  
Data / restraints / parameters 5361 / 1 / 327 
Final R indices [F2>2] R1 = 0.0319, wR2 = 0.0764 
R indices (all data) R1 = 0.0432, wR2 = 0.0790 
Goodness-of-fit on F2 0.964 
Absolute structure parameter 0.40(4) 
Largest and mean shift/su 0.001 and 0.000 
Largest diff. peak and hole 0.38 and 0.39 e Å3 
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Table S16.  Atomic coordinates and equivalent isotropic displacement parameters (Å2) for irh32.   
Ueq is defined as one third of the trace of the orthogonalized Uij tensor. 
 
      x      y      z      Ueq 
 
S1 0.27921(6) 0.01637(9) 0.19391(5) 0.0214(2) 
S2 0.06800(6) 0.01041(8) 0.43813(5) 0.01748(19) 
O1 0.03330(17)  0.1245(2) 0.40849(14) 0.0243(6) 
O2 0.09346(19) 0.0121(2) 0.51156(13) 0.0245(6) 
N1 0.3895(2) 0.1910(3) 0.26541(15) 0.0196(6) 
N2 0.4384(2) 0.1442(3) 0.15061(17) 0.0252(7) 
N3  0.0120(2) 0.1342(3) 0.42809(17) 0.0195(6) 
C1 0.3793(2) 0.1281(3) 0.20342(19) 0.0185(7) 
C2 0.2480(2) 0.0606(3) 0.28081(19) 0.0179(7) 
C3 0.1724(2) 0.0127(3) 0.3184(2) 0.0171(8) 
C4 0.1650(2) 0.0621(3) 0.38776(19) 0.0180(7) 
C5 0.2310(2) 0.1556(3) 0.41747(19) 0.0216(7) 
C6 0.3069(2) 0.2022(3) 0.37883(18) 0.0210(7) 
C7 0.3167(2) 0.1543(3) 0.30941(18) 0.0166(7) 
C8  0.0438(2) 0.1655(3) 0.35604(17) 0.0212(7) 
C9  0.1386(2) 0.2409(3) 0.3574(2) 0.0252(7) 
C10  0.1353(2) 0.3953(3) 0.3869(2) 0.0260(7) 
S3 0.70877(6) 0.51415(9) 0.24353(5) 0.0221(2) 
S4 0.92127(6) 0.49211(8)  0.00048(5) 0.0185(2) 
O3 0.88497(17) 0.4912(2)  0.07063(14) 0.0261(6) 
O4 0.95704(18) 0.6280(2) 0.02740(14) 0.0259(6) 
N4 0.5566(2) 0.3766(4) 0.29375(18) 0.0285(7) 
N5 0.61468(19) 0.2999(3) 0.18474(16) 0.0201(6) 
N6 1.0033(2) 0.3732(3) 0.00170(17) 0.0198(6) 
C11 0.6179(2) 0.3836(3) 0.2410(2) 0.0191(7) 
C12 0.7450(2) 0.4505(3) 0.16152(18) 0.0163(7) 
C13 0.8175(2) 0.5012(3) 0.1199(2) 0.0194(8) 
C14 0.8307(2) 0.4335(3) 0.05510(19) 0.0175(7) 
C15 0.7743(2) 0.3169(3) 0.0326(2) 0.0205(7) 
C16 0.7022(2) 0.2683(3) 0.07430(19) 0.0206(7) 
C17 0.6858(2) 0.3360(3) 0.13921(18) 0.0179(7) 
C18 1.0790(3) 0.3723(4) 0.0535(2) 0.0370(10) 
C19 1.0834(3) 0.2378(4) 0.0980(2) 0.0459(12) 
C20 1.0053(4) 0.2283(5) 0.1518(3) 0.0586(13) 
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Table S17.   Bond lengths [Å] and angles [°] for irh32. 
 
S1–C1  1.768(3) S1–C2  1.756(4) 
S2–O1  1.437(2) S2–O2  1.441(3) 
S2–N3  1.618(3) S2–C4  1.753(3) 
N1–C1  1.316(4) N1–C7  1.379(4) 
N2–H2A  0.93(4) N2–H2B  0.75(4) 
N2–C1  1.322(5) N3–H3  0.79(4) 
N3–C8  1.469(4) C2–C3  1.369(5) 
C2–C7  1.412(4) C3–H3A  0.950 
C3–C4  1.396(5) C4–C5  1.391(5) 
C5–H5  0.950 C5–C6  1.381(5) 
C6–H6A  0.950 C6–C7  1.395(5) 
C8–H8A  0.990 C8–H8B  0.990 
C8–C9  1.524(4) C9–H9A  0.990 
C9–H9B  0.990 C9–C10  1.509(4) 
C10–H10A  0.980 C10–H10B  0.980 
C10–H10C  0.980 S3–C11  1.763(3) 
S3–C12  1.740(4) S4–O3  1.430(3) 
S4–O4  1.436(2) S4–N6  1.598(3) 
S4–C14  1.757(3) N4–H4A  0.94(4) 
N4–H4B  0.87(4) N4–C11  1.335(5) 
N5–C11  1.311(4) N5–C17  1.378(4) 
N6–H6  0.86(3) N6–C18  1.466(5) 
C12–C13  1.385(5) C12–C17  1.408(4) 
C13–H13  0.950 C13–C14  1.389(5) 
C14–C15  1.400(4) C15–H15  0.950 
C15–C16  1.376(5) C16–H16  0.950 
C16–C17  1.397(5) C18–H18A  0.990 
C18–H18B  0.990 C18–C19  1.485(6) 
C19–H19A  0.990 C19–H19B  0.990 
C19–C20  1.519(7) C20–H20A  0.980 
C20–H20B  0.980 C20–H20C  0.980 
 
C1–S1–C2 88.91(16) O1–S2–O2 118.43(15) 
O1–S2–N3 107.38(16) O1–S2–C4 106.85(16) 
O2–S2–N3 106.66(16) O2–S2–C4 108.84(17) 
N3–S2–C4 108.34(15) C1–N1–C7 110.7(3) 
H2A–N2–H2B 122(4) H2A–N2–C1 119(3) 
H2B–N2–C1 119(3) S2–N3–H3 108(3) 
S2–N3–C8 117.7(2) H3–N3–C8 116(3) 
S1–C1–N1 115.5(3) S1–C1–N2 120.5(3) 
N1–C1–N2 124.0(3) S1–C2–C3 128.2(3) 
S1–C2–C7 108.7(2) C3–C2–C7 123.1(3) 
C2–C3–H3A 121.6 C2–C3–C4 116.7(3) 
H3A–C3–C4 121.6 S2–C4–C3 119.3(2) 
S2–C4–C5 118.9(3) C3–C4–C5 121.8(3) 
C4–C5–H5 119.7 C4–C5–C6 120.6(3) 
H5–C5–C6 119.7 C5–C6–H6A 120.5 
C5–C6–C7 119.1(3) H6A–C6–C7 120.5 
N1–C7–C2 116.3(3) N1–C7–C6 125.0(3) 
C2–C7–C6 118.7(3) N3–C8–H8A 109.6 
N3–C8–H8B 109.6 N3–C8–C9 110.4(3) 
H8A–C8–H8B 108.1 H8A–C8–C9 109.6 
H8B–C8–C9 109.6 C8–C9–H9A 108.9 
C8–C9–H9B 108.9 C8–C9–C10 113.3(3) 
H9A–C9–H9B 107.7 H9A–C9–C10 108.9 
H9B–C9–C10 108.9 C9–C10–H10A 109.5 
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C9–C10–H10B 109.5 C9–C10–H10C 109.5 
H10A–C10–H10B 109.5 H10A–C10–H10C 109.5 
H10B–C10–H10C 109.5 C11–S3–C12 88.52(16) 
O3–S4–O4 118.60(15) O3–S4–N6 106.78(16) 
O3–S4–C14 106.71(16) O4–S4–N6 107.85(16) 
O4–S4–C14 107.65(16) N6–S4–C14 109.00(15) 
H4A–N4–H4B 124(4) H4A–N4–C11 119(3) 
H4B–N4–C11 117(3) C11–N5–C17 110.3(3) 
S4–N6–H6 108(2) S4–N6–C18 124.6(2) 
H6–N6–C18 124(2) S3–C11–N4 120.0(3) 
S3–C11–N5 116.0(3) N4–C11–N5 124.0(3) 
S3–C12–C13 128.6(3) S3–C12–C17 109.5(2) 
C13–C12–C17 121.9(3) C12–C13–H13 121.3 
C12–C13–C14 117.4(3) H13–C13–C14 121.3 
S4–C14–C13 120.0(2) S4–C14–C15 118.3(3) 
C13–C14–C15 121.8(3) C14–C15–H15 119.9 
C14–C15–C16 120.1(3) H15–C15–C16 119.9 
C15–C16–H16 120.2 C15–C16–C17 119.6(3) 
H16–C16–C17 120.2 N5–C17–C12 115.8(3) 
N5–C17–C16 125.0(3) C12–C17–C16 119.2(3) 
N6–C18–H18A 108.6 N6–C18–H18B 108.6 
N6–C18–C19 114.7(3) H18A–C18–H18B 107.6 
H18A–C18–C19 108.6 H18B–C18–C19 108.6 
C18–C19–H19A 108.9 C18–C19–H19B 108.9 
C18–C19–C20 113.4(4) H19A–C19–H19B 107.7 
H19A–C19–C20 108.9 H19B–C19–C20 108.9 
C19–C20–H20A 109.5 C19–C20–H20B 109.5 
C19–C20–H20C 109.5 H20A–C20–H20B 109.5 
H20A–C20–H20C 109.5 H20B–C20–H20C 109.5 
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Table S18.  Torsion angles [°] for irh32. 
 
O1–S2–N3–C8  58.1(3) O2–S2–N3–C8 174.0(2) 
C4–S2–N3–C8 56.9(3) C7–N1–C1–S1  0.5(3) 
C7–N1–C1–N2 179.7(3) C2–S1–C1–N1 0.8(2) 
C2–S1–C1–N2  179.4(3) C1–S1–C2–C3  178.8(3) 
C1–S1–C2–C7  0.7(2) S1–C2–C3–C4 178.4(2) 
C7–C2–C3–C4 0.6(5) C2–C3–C4–S2 177.8(2) 
C2–C3–C4–C5 0.1(5) O1–S2–C4–C3 24.6(3) 
O1–S2–C4–C5  157.6(3) O2–S2–C4–C3 153.6(2) 
O2–S2–C4–C5  28.7(3) N3–S2–C4–C3  90.8(3) 
N3–S2–C4–C5 87.0(3) S2–C4–C5–C6  178.1(2) 
C3–C4–C5–C6  0.4(5) C4–C5–C6–C7 0.1(5) 
C1–N1–C7–C2  0.1(4) C1–N1–C7–C6 179.6(3) 
C5–C6–C7–N1  179.2(3) C5–C6–C7–C2 0.5(4) 
S1–C2–C7–N1 0.7(3) S1–C2–C7–C6  179.1(2) 
C3–C2–C7–N1 178.9(3) C3–C2–C7–C6  0.9(5) 
S2–N3–C8–C9 160.5(2) N3–C8–C9–C10 68.7(4) 
O3–S4–N6–C18 158.0(3) O4–S4–N6–C18 29.6(3) 
C14–S4–N6–C18  87.0(3) C17–N5–C11–S3  0.2(3) 
C17–N5–C11–N4 178.4(3) C12–S3–C11–N4  178.4(3) 
C12–S3–C11–N5 0.2(3) C11–S3–C12–C13 177.7(3) 
C11–S3–C12–C17  0.2(2) S3–C12–C13–C14  178.3(2) 
C17–C12–C13–C14  0.7(5) C12–C13–C14–S4 180.0(2) 
C12–C13–C14–C15  1.0(5) O3–S4–C14–C13  139.9(3) 
O3–S4–C14–C15 41.0(3) O4–S4–C14–C13  11.6(3) 
O4–S4–C14–C15 169.3(2) N6–S4–C14–C13 105.1(3) 
N6–S4–C14–C15  74.0(3) S4–C14–C15–C16  179.6(2) 
C13–C14–C15–C16 1.4(5) C14–C15–C16–C17 0.0(5) 
C11–N5–C17–C12 0.0(4) C11–N5–C17–C16  179.8(3) 
C15–C16–C17–N5 178.3(3) C15–C16–C17–C12  1.6(5) 
S3–C12–C17–N5 0.1(3) S3–C12–C17–C16 180.0(2) 
C13–C12–C17–N5  177.9(3) C13–C12–C17–C16 2.0(5) 
S4–N6–C18–C19 119.1(3) N6–C18–C19–C20  71.7(5) 
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Table S19.   Anisotropic displacement parameters (Å2) for irh32.  The anisotropic displacement factor exponent takes 
the form: 22[h2a*2U11 + ...+ 2hka*b*U12] 
 
      U11      U22      U33      U23      U13      U12 
 
S1 0.0226(4)  0.0284(4) 0.0130(5)   0.0035(4) 0.0012(3)   0.0059(3) 
S2 0.0220(4)  0.0165(4) 0.0139(5)  0.0003(4) 0.0037(3)   0.0005(3) 
O1 0.0332(14)  0.0187(10) 0.0211(16)  0.0005(10) 0.0076(11)   0.0040(9) 
O2 0.0332(13)  0.0263(12) 0.0141(14)  0.0024(10) 0.0024(11)  0.0032(10) 
N1 0.0214(14)  0.0232(13) 0.0141(15)   0.0012(12) 0.0003(12)   0.0013(12) 
N2 0.0288(16)  0.0348(17) 0.0121(17)   0.0028(14) 0.0018(15)   0.0072(14) 
N3 0.0219(14)  0.0188(12) 0.0177(16)   0.0055(12)  0.0010(13)  0.0008(11) 
C1 0.0214(16)  0.0193(14) 0.0150(19)  0.0033(14) 0.0004(15)   0.0016(12) 
C2 0.0214(16)  0.0182(14) 0.0140(18)   0.0013(14) 0.0001(14)  0.0028(13) 
C3 0.0184(17)  0.0167(15) 0.016(2)   0.0013(13) 0.0007(12)   0.0012(12) 
C4 0.0178(15)  0.0180(14) 0.0182(18)  0.0017(14) 0.0026(14)  0.0014(12) 
C5 0.0252(17)  0.0255(14) 0.0141(18)   0.0040(13) 0.0019(15)   0.0004(13) 
C6 0.0243(17)  0.0228(14) 0.0160(18)   0.0058(14)  0.0007(15)   0.0039(13) 
C7 0.0183(17)  0.0153(13) 0.0161(18)  0.0012(13)  0.0007(14)  0.0003(12) 
C8 0.0279(17)  0.0236(15) 0.0120(17)   0.0008(14)  0.0010(14)   0.0002(13) 
C9 0.0241(16)  0.0285(16) 0.0231(19)   0.0016(15)  0.0056(16)   0.0022(14) 
C10 0.0252(17)  0.0255(15) 0.027(2)   0.0009(15)  0.0017(16)  0.0034(14) 
S3 0.0242(4)  0.0277(4) 0.0144(5)   0.0048(4) 0.0025(4)   0.0061(3) 
S4 0.0227(4)  0.0174(4) 0.0156(5)  0.0009(3) 0.0039(4)   0.0003(3) 
O3 0.0275(13)  0.0371(13) 0.0138(14)  0.0020(10) 0.0047(11)  0.0050(10) 
O4 0.0366(15)  0.0174(10) 0.0236(16)   0.0032(10) 0.0122(12)   0.0058(10) 
N4 0.0298(17)  0.0398(17) 0.0158(18)   0.0053(14) 0.0083(15)   0.0144(15) 
N5 0.0215(14)  0.0232(12) 0.0157(16)  0.0002(12) 0.0021(12)   0.0036(11) 
N6 0.0191(14)  0.0184(12) 0.0219(17)   0.0079(12)  0.0015(13)   0.0033(11) 
C11 0.0202(17)  0.0229(14) 0.0142(18)  0.0040(15)  0.0010(16)  0.0001(12) 
C12 0.0196(15)  0.0187(14) 0.0106(17)  0.0001(13)  0.0031(14)  0.0033(12) 
C13 0.0231(19)  0.0160(16) 0.019(2)  0.0003(13)  0.0022(14)   0.0026(12) 
C14 0.0205(16)  0.0169(14) 0.0153(19)  0.0022(13) 0.0045(14)  0.0017(12) 
C15 0.0251(17)  0.0196(14) 0.0168(18)   0.0032(13) 0.0009(15)  0.0025(13) 
C16 0.0214(15)  0.0205(14) 0.0200(18)   0.0026(13)  0.0025(15)   0.0040(13) 
C17 0.0196(16)  0.0179(14) 0.0161(18)  0.0013(13) 0.0005(15)  0.0001(12) 
C18 0.035(2)  0.0339(19) 0.042(3)   0.0041(18)  0.0134(19)   0.0023(16) 
C19 0.055(3)  0.036(2) 0.046(3)   0.0012(19)  0.023(2)  0.004(2) 
C20 0.072(3)  0.051(2) 0.053(3)  0.015(2)  0.012(3)   0.015(2) 
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Table S20.   Hydrogen coordinates and isotropic displacement parameters (Å2) for irh32. 
 
      x       y       z       U 
 
H2A 0.493(3) 0.198(4) 0.158(2) 0.030 
H2B 0.426(3) 0.114(4) 0.115(2) 0.030 
H3 0.002(3) 0.203(4) 0.451(2) 0.023 
H3A 0.1273  0.0511 0.2982 0.020 
H5 0.2237 0.1878 0.4648 0.026 
H6A 0.3519 0.2660 0.3993 0.025 
H8A  0.0482 0.0723 0.3291 0.025 
H8B 0.0019 0.2300 0.3321 0.025 
H9A  0.1637 0.2447 0.3089 0.030 
H9B  0.1819 0.1810 0.3862 0.030 
H10A  0.1976 0.4390 0.3851 0.039 
H10B  0.0922 0.4552 0.3589 0.039 
H10C  0.1139 0.3920 0.4359 0.039 
H4A 0.506(3) 0.310(4) 0.290(2) 0.034 
H4B 0.566(3) 0.436(4) 0.329(2) 0.034 
H6 0.986(2) 0.297(4)  0.0227(19) 0.024 
H13 0.8567 0.5793 0.1352 0.023 
H15 0.7857 0.2712  0.0116 0.025 
H16 0.6638 0.1892 0.0591 0.025 
H18A 1.0718 0.4591 0.0846 0.044 
H18B 1.1389 0.3830 0.0282 0.044 
H19A 1.1439 0.2360 0.1230 0.055 
H19B 1.0808 0.1499 0.0671 0.055 
H20A 1.0165 0.1446 0.1833 0.088 
H20B 0.9458 0.2146 0.1274 0.088 
H20C 1.0033 0.3195 0.1794 0.088 
  
 
 
 
 
Table S21.  Hydrogen bonds for irh32 [Å and °]. 
 
D–H...A d(D–H) d(H...A) d(D...A) <(DHA) 
 
N2–H2A...N5 0.93(4) 2.04(4) 2.970(4) 173(4) 
N2–H2B...O2a 0.75(4) 2.19(4) 2.935(4) 173(4) 
N3–H3...O4b 0.79(4) 2.19(4) 2.973(4) 172(4) 
N4–H4A...N1 0.94(4) 2.05(5) 2.981(4) 168(4) 
N4–H4B...O3c 0.87(4) 2.09(4) 2.900(4) 154(4) 
N6–H6...O1d 0.86(3) 2.06(4) 2.915(4) 170(3) 
 
Symmetry operations for equivalent atoms 
a   x+1/2,y,z1/2      b   x+1,y+1,z+1/2      c   x+3/2,y,z+1/2        
d   x+1,y,z1/2        
 
 
 
 
